
<html lang="en"     class="pb-page"  data-request-id="dba63538-d989-4ee2-a6e0-11e295c45851"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2021.64.issue-9;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.1c00242;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold" /></meta><meta name="dc.Creator" content="Chaodong  Xiong" /></meta><meta name="dc.Creator" content="Lina  Zhou" /></meta><meta name="dc.Creator" content="Jing  Tan" /></meta><meta name="dc.Creator" content="Shanshan  Song" /></meta><meta name="dc.Creator" content="Xubin  Bao" /></meta><meta name="dc.Creator" content="Ning  Zhang" /></meta><meta name="dc.Creator" content="Huaqian  Ding" /></meta><meta name="dc.Creator" content="Jiannan  Zhao" /></meta><meta name="dc.Creator" content="Jin-xue  He" /></meta><meta name="dc.Creator" content="Ze-Hong  Miao" /></meta><meta name="dc.Creator" content="Ao  Zhang" /></meta><meta name="dc.Description" content="The ubiquitin-like protein NEDD8 is a critical signaling molecule implicated in the functional maintenance and homeostasis of cells. Dysregulation of this process is involved in a variety of human ..." /></meta><meta name="Description" content="The ubiquitin-like protein NEDD8 is a critical signaling molecule implicated in the functional maintenance and homeostasis of cells. Dysregulation of this process is involved in a variety of human ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 15, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00242" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00242" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00242" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00242" /></link>
        
    
    

<title>Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00242" /></meta><meta property="og:title" content="Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0018.jpeg" /></meta><meta property="og:description" content="The ubiquitin-like protein NEDD8 is a critical signaling molecule implicated in the functional maintenance and homeostasis of cells. Dysregulation of this process is involved in a variety of human diseases, including cancer. Therefore, NEDD8-activating enzyme E1 (NAE), the only activation enzyme of the neddylation pathway, has been an emergent anticancer target. In view of the single-agent modest response of the clinical NAE inhibitor, pevonedistat (compound 1, MLN4924), efforts on development of new inhibitors with both high potency and better safety profiles are urgently needed. Here, we report a structural hopping strategy by optimizing the central deazapurine framework and the solvent interaction region of compound 1, leading to compound 26 bearing a pyrimidotriazole scaffold. Compound 26 not only has compatible potency in the biochemical and cell assays but also possesses improved pharmacokinetic (PK) properties than compound 1. In vivo, compound 26 showed significant antitumor efficacy and good safety in xenograft models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00242"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00242">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00242&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00242&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00242&amp;href=/doi/10.1021/acs.jmedchem.1c00242" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 6161-6178</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00206" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00246" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chaodong Xiong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chaodong Xiong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chaodong++Xiong">Chaodong Xiong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lina Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lina Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lina++Zhou">Lina Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jing Tan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Tan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Tan">Jing Tan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shanshan Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shanshan Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shanshan++Song">Shanshan Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xubin Bao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xubin Bao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xubin++Bao">Xubin Bao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ning Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ning Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ning++Zhang">Ning Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huaqian Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huaqian Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huaqian++Ding">Huaqian Ding</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiannan Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiannan Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China</div><div class="loa-info-affiliations-info">School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiannan++Zhao">Jiannan Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jin-xue He</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jin-xue He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e18b888f999484be8984a192888c8ccf8082cf828f"><span class="__cf_email__" data-cfemail="90faf9fee8e5f5cff8f5d0e3f9fdfdbef1f3bef3fe">[email protected]</span></a>. Phone: +86-21-50801068.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jin-xue++He">Jin-xue He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ze-Hong Miao</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ze-Hong Miao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#f2889a9f9b939db2819b9f9fdc9391dc919c"><span class="__cf_email__" data-cfemail="a6dccecbcfc7c9e6d5cfcbcb88c7c588c5c8">[email protected]</span></a>. Phone: +86-21-50806072.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ze-Hong++Miao">Ze-Hong Miao</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ao Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ao Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div><div class="loa-info-affiliations-info">Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China</div><div class="loa-info-affiliations-info">State Key Laboratory of Esophageal Cancer Prevention and Treatment, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#ef8e80d9d6ded695878e8188af9c859b9ac18a8b9ac18c81"><span class="__cf_email__" data-cfemail="274648111e161e5d4f46494067544d535209424352094449">[email protected]</span></a>. Phone: +86-21-34204020.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ao++Zhang">Ao Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7205-9202" title="Orcid link">http://orcid.org/0000-0001-7205-9202</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00242&amp;href=/doi/10.1021%2Facs.jmedchem.1c00242" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 6161–6178</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 15, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 February 2021</li><li><span class="item_label"><b>Published</b> online</span>15 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00242" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00242</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6161%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChaodong%2BXiong%252C%2BLina%2BZhou%252C%2BJing%2BTan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D9%26contentID%3Dacs.jmedchem.1c00242%26title%3DDevelopment%2Bof%2BPotent%2BNEDD8-Activating%2BEnzyme%2BInhibitors%2BBearing%2Ba%2BPyrimidotriazole%2BScaffold%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6178%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00242"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1099</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00242" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chaodong&quot;,&quot;last_name&quot;:&quot;Xiong&quot;},{&quot;first_name&quot;:&quot;Lina&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Shanshan&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Xubin&quot;,&quot;last_name&quot;:&quot;Bao&quot;},{&quot;first_name&quot;:&quot;Ning&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Huaqian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Jiannan&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Jin-xue&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Ze-Hong&quot;,&quot;last_name&quot;:&quot;Miao&quot;},{&quot;first_name&quot;:&quot;Ao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6161-6178&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00242&quot;},&quot;abstract&quot;:&quot;The ubiquitin-like protein NEDD8 is a critical signaling molecule implicated in the functional maintenance and homeostasis of cells. Dysregulation of this process is involved in a variety of human diseases, including cancer. Therefore, NEDD8-activating enzyme E1 (NAE), the only activation enzyme of the neddylation pathway, has been an emergent anticancer target. In view of the single-agent modest response of the clinical NAE inhibitor, pevonedistat (compound 1, MLN4924), efforts on development of new inhibitors with both high potency and better safety profiles are urgently needed. Here, we report a structural hopping strategy by optimizing the central deazapurine framework and the solvent interaction region of compound 1, leading to compound 26 bearing a pyrimidotriazole scaffold. Compound 26 not only has compatible potency in the biochemical and cell assays but also possesses improved pharmacokinetic (PK) properties than compound 1. In vivo, compound 26 showed significant antitumor efficacy and good safety i&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00242&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00242" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00242&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00242" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00242&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00242" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00242&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00242&amp;href=/doi/10.1021/acs.jmedchem.1c00242" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00242" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00242" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00242%26sid%3Dliteratum%253Aachs%26pmid%3D33857374%26genre%3Darticle%26aulast%3DXiong%26date%3D2021%26atitle%3DDevelopment%2Bof%2BPotent%2BNEDD8-Activating%2BEnzyme%2BInhibitors%2BBearing%2Ba%2BPyrimidotriazole%2BScaffold%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D9%26spage%3D6161%26epage%3D6178%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/jmcmar.2021.64.issue-9/20210513/jmcmar.2021.64.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The ubiquitin-like protein NEDD8 is a critical signaling molecule implicated in the functional maintenance and homeostasis of cells. Dysregulation of this process is involved in a variety of human diseases, including cancer. Therefore, NEDD8-activating enzyme E1 (NAE), the only activation enzyme of the neddylation pathway, has been an emergent anticancer target. In view of the single-agent modest response of the clinical NAE inhibitor, pevonedistat (compound <b>1</b>, MLN4924), efforts on development of new inhibitors with both high potency and better safety profiles are urgently needed. Here, we report a structural hopping strategy by optimizing the central deazapurine framework and the solvent interaction region of compound <b>1</b>, leading to compound <b>26</b> bearing a pyrimidotriazole scaffold. Compound <b>26</b> not only has compatible potency in the biochemical and cell assays but also possesses improved pharmacokinetic (PK) properties than compound <b>1</b>. In vivo, compound <b>26</b> showed significant antitumor efficacy and good safety in xenograft models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The ubiquitin (Ub)-proteasome system (UPS) modulates the homeostasis of a broad range of intracellular proteins that possess essential cell functions, including survival, proliferation, apoptosis, and differentiation.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> The UPS pathway is executed by iterative covalent linking of the small protein ubiquitin to the substrate protein through a cascade of three different enzymes (E1, E2, and E3) to initiate the proteasomal degradation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is reported that the ubiquitylation pathway is involved in the degradation of more than 80% of intracellular proteins and dysregulation of UPS can cause many diseases, including cancer, diabetes, and neurodegenerative diseases.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Unfortunately, though the UPS pathway has been extensively exploited as drug targets, drugs targeting the three enzymes (E1, E2, and E3) remain premature with critical challenge.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Bortezomib,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> a drug targeting the downstream kinase 26S proteasome also caused many toxic side effects due to its poor selectivity in substrate degradation.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">In addition to the ubiquitin proteins, ubiquitin-like (Ubl) proteins,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> such as neural precursor cell-expressed developmentally downregulated 8 (NEDD8) and many others, have also been found as homologous pathways involved in the conjugation and turnover of many functional proteins. Like ubiquitylation, NEDD8-engagement of proteins (neddylation)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> is also a post-translational modification and catalyzed by three key enzymes successively, including the NEDD8-activating enzyme E1 (NAE; a heterodimer of AppBp1 and UBA3), the conjugating enzyme E2 (UBC12 and UBE2F), and the substrate-recruiting E3 ligase (e.g<i>.,</i> RBX1/2 or DCN1). The culminating evidence indicated that the neddylation pathway is involved in the modulation of many biological mechanisms and dysregulation of this process can lead to tumorigenesis.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17">(10−17)</a> Meanwhile, overactive neddylation has been reported in a variety of malignancies.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> Because NAE is involved in the first step of the neddylation pathway and is the only activation enzyme of this process, it has been proposed as an emergent target for the development of anticancer drugs. Many strategies have been exploited either to target the different binding domains of NAE<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> or to disrupt its protein–protein interactions with E2 or other coenzymes,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> but most of them are in a premature state.</div><div class="NLM_p">Because NEDD8 protein forms a NEDD8-adenosine 5′-monophosphate (AMP) intermediate under the catalysis of NAE during the initial activation process, structurally similar AMP mimics generally have capacity of binding with NAE in high potency.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compounds <b>1–3</b><a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27−29)</a> are the representatives of this class with compound <b>1</b> showing the optimal combination with both high potency and selectivity against NAE. This compound exhibits good antitumor efficacy in a variety of tumor xenograft models, including hematologic malignancies<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> and several solid tumors.<a onclick="showRef(event, 'ref19 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref19 ref33 ref34 ref35 ref36">(19,33−36)</a> Intriguingly, the reported phase I clinical results showed that the single-agent of compound <b>1</b> (pevonedistat) only exhibited an overall response rate (ORR) of 17% in acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In addition, compound <b>1</b> has been used in combination with azacitidine in phase Ib and showed higher responses (ORR was 50%) in patients with AML.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In a phase II clinical trial, the combination showed promising activity and acceptable toxicity in patients with higher-risk MDS as well.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Currently, more single-agent trials for various tumors are carried out and a few phase III trials in combination with chemotherapies are also initiated (<a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>).</div><div class="NLM_p">The exact reason for the relatively modest ORR in the reported clinical 1 trials with the single-agent of compound <b>1</b> is unknown, but more investigations with structurally different inhibitors in various tumor types are needed. In this regard, we recently conducted a structural modification of the clinical compound <b>1</b> by structural hopping on the central deazapurine bicyclic framework (shown in red in the X-ray crystal structure, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), followed by further optimization of the solvent interaction region (shown in blue in the X-ray crystal structure, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), leading to a new compound <b>26</b> bearing a pyrimidotriazole scaffold (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). This new compound showed comparable potency to that of compound <b>1</b>, but with improved overall PK properties. Herein, we report the design, synthesis, and pharmacological evaluation of this compound.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Represented AMP mimics as NAE inhibitors. Scaffold hopping refers to the search for active compounds containing different core structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure-Based Drug Design</h3><div class="NLM_p last">The cocrystal structure<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> of the compound <b>1</b>—NEDD8—NAE complex (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GZN">3GZN</a>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) showed that the ribose 3′-OH of compound <b>1</b> forms a H-bonding with the residues of Asp100 and Lys124 in the NAE enzyme. One of the sulfamate oxygens forms a H-bonding with the backbone amide NH of Gly79, and the sulfamoyl group forms a covalent adduct with the carbonyl moiety of Gly76 at the end of the NEDD8 protein. Meanwhile, the N1 and N6 on the deazapurine ring form a H-bonding with the backbone amide NH of Ile148 and the carbonyl of Gln149, respectively. The 2,3-dihydroindene fragment occupies a “gate-keeper” region of the NAE enzyme. The structural analysis clearly indicates that there is no direct contact around the pyrroles C2 and C3 of the central deazapurine ring (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, marked in red). Compared to AMP and its analogue <b>2</b> both bearing a purine core, compound <b>1</b> and its analogue <b>3</b> are structurally different by containing a deazapurine (pyrrolo[2,3-<i>d</i>]pyrimidine) core. All these compounds have high potency to bind NAE but with different selectivity, indicating that the N6-substituent interacting at the gate-keeper region is a determinant factor for NAE selectivity over other Ub E1 and Ubl E1. In this regard, we first conducted a scaffold-hopping approach to screen a small set of compounds bearing different central cores with both the sulfamoyl group and the 2,3-dihydroindene component intact.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Structure–Activity Relationship Study</h3><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compound <b>4</b> bearing a pyrimidotriazole core structure showed an IC<sub>50</sub> value of 0.21 nM against NAE, which is equally potent to that of the reference compound <b>1</b> (IC<sub>50</sub> = 0.26 nM). However, compound <b>5</b> containing a pyrazolopyridine core completely abolished the activity. Replacement of the deazapurine core of <b>1</b> with a simple pyrimidine moiety led to compound <b>6</b> showing much reduced potency with an IC<sub>50</sub> value of 219 nM, indicating the importance of the central bicyclic core structure. Because compound <b>4</b> is slightly more potent than the reference compound <b>1</b>, and in view of the well acceptance of triazole compounds in drug discovery, we selected this compound as a new lead NAE inhibitor for further structural optimization with the central pyrimidotriazole core intact.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. NAE Inhibition of Compounds Bearing Different Central Core Structures<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0011.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD from at least two separate experiments.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, an array of substituted alkylamino groups were applied to replace the 2,3-dihydro-1<i>H</i>-inden-1-amino component as the C4 substituent of the pyrimidine ring within the pyrimidotriazole core. It was found that opening the five-membered 2,3-dihydro-1<i>H</i>-indene framework and introducing a fluoro-substituent yielded compound <b>7</b>, which retained moderate potency against NAE with an IC<sub>50</sub> value of 6.11 nM, 29-fold less potent than that of compound <b>4</b>. Further replacement of the phenyl with a furyl or thienyl moiety generated compounds <b>8</b> and <b>9</b> showing more reduced potency with IC<sub>50</sub> values of 30.6 and 15.9 nM, respectively. Extension of the linker yielding compounds <b>10–12</b> further reduced the potency against NAE (81–149 nM). Interestingly, compound <b>13</b> obtained by replacing the 2,3-dihydro-1<i>H</i>-indene fragment in compound <b>4</b> with a simple n-hexyl group<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> retained moderate potency by showing an IC<sub>50</sub> value of 21.1 nM, but the cyclopentyl analogue <b>14</b> completely lost the NAE activity. Compound <b>15</b> bearing a 4-methoxycarbonyl cyclopent-2-ene component showed a moderate potency of 80.9 nM. Replacing the 2,3-dihydro-1<i>H</i>-indene fragment of compound <b>4</b> with other bicyclic heterocycles afforded compounds <b>16–18</b>. Unfortunately, all these compounds lost activity against NAE. These results indicate that the pyrimidin-4-yl C4 substituent in pyrimidotriazole <b>4</b> can tolerate limited structural variations and the rigid structure of 2,3-dihydro-1<i>H</i>-indene framework remains the most advantageous to interact with NAE.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. NAE Inhibition of Compounds Bearing Different Pyrimidinyl C4-Substituents<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0012.gif" alt="" id="GRAPHIC-d7e667-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0013.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD from at least two separate experiments.</p></div></div><div></div></div><div class="NLM_p">In view of the structural similarity between compounds <b>1</b> and <b>4</b>, we speculate that both compounds might interact with NAE in a similar mode. A look back of the crystal structure of compound <b>1</b>—NEDD8—NAE complex indicated that there is a large space around the binding domain of the 2,3-dihydro-1<i>H</i>-indene fragment (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, marked in red). Therefore, we decided to test compounds bearing water-soluble groups at the C2-position of the 2,3-dihydro-1<i>H</i>-indene fragment that yielded compounds <b>19–23</b>. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the hydroxyl-substituted compound <b>19</b> showed good potency against NAE with an IC<sub>50</sub> value of 2.28 nM, 10-fold less potent than compound <b>4</b>. Much reduced potency was observed for the dimethylamino substituted compound <b>20</b> (207 nM). Interestingly, the etheric analogue <b>21</b> also showed good potency with an IC<sub>50</sub> value of 2.28 nM, but the amido analogue <b>22</b> exhibited much reduced potency with an IC<sub>50</sub> value of 170 nM. Notably, the <i>trans</i>-isomeric amino-amido analogue <b>23</b> was inactive by showing an IC<sub>50</sub> value greater than 10 μM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. NAE Inhibition of Compounds Bearing Substituted 2,3-Dihydroindene Moieties<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0014.gif" alt="" id="GRAPHIC-d7e749-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0015.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD from at least two separate experiments.</p></div></div><div></div></div><div class="NLM_p">Because the introduction of hydrophilic substituents on the 2,3-dihydro-1<i>H</i>-indene fragment did not afford compounds with higher potency than the lead compound <b>4</b>, we decided to further explore the electronic and steric tolerance by introducing more bulky spiropiperidine framework at the C3-position of the 2,3-dihydro-1<i>H</i>-indene fragment. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, the unsubstituted spiropiperidine compound <b>24</b> and the <i>N</i>-methyl substituted spiropiperidine <b>25</b> displayed modest potency against NAE with IC<sub>50</sub> values of 66.9 and 187 nM, respectively. However, carbamate analogues <b>26–34</b> all showed significantly increased potency. Most of these compounds exhibited subnanomolar potency, among which, carbamates <b>26</b> and <b>34</b> were the most potent with IC<sub>50</sub> values of 0.55 and 0.57 nM, respectively, although they were still 2-fold less potent than compound <b>4</b>, but not statistically different. In order to increase aqueous solubility, an additional water-soluble group was introduced to afford compounds <b>32–33</b>, showing reduced and distinct potency with IC<sub>50</sub> values of 120 and 9.98 nM, respectively. Insertion of a methylene unit to the carbamate <b>26</b> yielded compound <b>35</b>, showing 10-fold reduced potency with an IC<sub>50</sub> value of 5.77 nM. Notably, the <i>N</i>-<i>tert</i>-butyl urea compound <b>36</b> showed an extremely high potency against NAE with an IC<sub>50</sub> value of 0.02 nM, which is 10-fold more potent than that of compound <b>4</b>. These results confirmed that the insertion of bulky spiropiperidine moieties to the 2,3-dihydro-1<i>H</i>-indene component was well-tolerated and both the steric and electronic characters of the N-substituent on the spiropiperidine motif played an important role in the activity against NAE.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. NAE Inhibitors Bearing Substituted 2,3-Dihydrospiro[indene-1,4′-piperidine]<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0016.gif" alt="" id="GRAPHIC-d7e846-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0017.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD from at least two separate experiments.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Cell Proliferation of Selected New NAE Inhibitors</h3><div class="NLM_p">To investigate the inhibitory effects of the new NAE inhibitors on the proliferation of cancer cells, several high-potency compounds with IC<sub>50</sub> values less than 20 nM were selected for cellular assay against the HCT-116 cell. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, all these compounds showed moderate to good inhibitory activity against the growth of HCT-116 cells. Among these, nine compounds (<b>4</b>, <b>19</b>, <b>21</b>, <b>26–29</b>, <b>31</b>, and <b>34</b>) showed IC<sub>50</sub> values less than 150 nM, and three compounds <b>4</b>, <b>19</b>, and <b>26</b> were similarly potent compared to the reference compound <b>1</b>, showing IC<sub>50</sub> values less than 50 nM. It was somewhat disappointing that the highly biochemically potent compound <b>36</b> only showed moderate cell growth inhibition, compared to compound <b>1</b> (151 vs 33.89 nM), likely due to the general poor PK properties and low aqueous solubility of the urea structure in compound <b>36</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Cell Growth and hERG Inhibition as Well as Predicted Physicochemical Properties of Selected Compounds<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">NAE</th><th class="colsep0 rowsep0" align="center">HCT-116</th><th class="colsep0 rowsep0" align="center" char=".">hERG</th><th class="colsep0 rowsep0" align="center" char=".">tPSA<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">LogS<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub>, nM</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>, nM</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center" char=".">Å</th><th class="colsep0 rowsep0" align="center" char=".">μg/mL</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.01</td><td class="colsep0 rowsep0" align="left">43.2 ± 2.29</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">158.14</td><td class="colsep0 rowsep0" align="char" char=".">70.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char="±">6.11 ± 0.45</td><td class="colsep0 rowsep0" align="left">3855 ± 1820</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">15.90 ± 1.79</td><td class="colsep0 rowsep0" align="left">>10,000</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">2.28 ± 1.34</td><td class="colsep0 rowsep0" align="left">38.8 ± 1.41</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">178.34</td><td class="colsep0 rowsep0" align="char" char=".">130.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char="±">3.56 ± 3.42</td><td class="colsep0 rowsep0" align="left">70.2 ± 13.8</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char="±"><b>0.55</b><b>±</b><b>0.07</b></td><td class="colsep0 rowsep0" align="left"><b>36.2 ± 1.31</b></td><td class="colsep0 rowsep0" align="char" char="."><b>>40</b></td><td class="colsep0 rowsep0" align="char" char="."><b>187.68</b></td><td class="colsep0 rowsep0" align="char" char="."><b>128.79</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char="±">2.23 ± 1.30</td><td class="colsep0 rowsep0" align="left">102 ± 51.9</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char="±">6.00 ± 4.58</td><td class="colsep0 rowsep0" align="left">104 ± 13.1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char="±">4.20 ± 2.44</td><td class="colsep0 rowsep0" align="left">121 ± 35.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char="±">9.76 ± 2.71</td><td class="colsep0 rowsep0" align="left">94.4 ± 44.8</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">187.68</td><td class="colsep0 rowsep0" align="char" char=".">72.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char="±">9.98 ± 3.95</td><td class="colsep0 rowsep0" align="left">338 ± 164</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char="±">0.57 ± 0.54</td><td class="colsep0 rowsep0" align="left">110 ± 6.1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char="±">5.77 ± 0.20</td><td class="colsep0 rowsep0" align="left">1418 ± 46.1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char="±">0.02 ± 0.01</td><td class="colsep0 rowsep0" align="left">151 ± 6.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">0.26 ± 0.09</td><td class="colsep0 rowsep0" align="left">33.89 ± 3.95</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">132.36</td><td class="colsep0 rowsep0" align="char" char=".">33.49</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD from at least two separate experiments.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Calculated through ADMET lab software via http://admet.scbdd.com; tPSA, topological polar surface area; LogS, solubility.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> hERG Inhibition and Calculated Physicochemical Properties of Selected Compounds</h3><div class="NLM_p last">To quickly glimpse the overall safety and drug-likeness of these new NAE inhibitors, we tested the four potent compounds <b>4</b>, <b>19</b>, <b>26</b>, and <b>31</b> that possess cellular potency less than 100 nM for their inhibition on the hERG channel and calculated their physicochemical properties through ADMET lab software (<a href="http://admet.scbdd.com/" class="extLink">http://admet.scbdd.com/</a>). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, although the new NAE inhibitors have a high loading of N-atoms, none of them showed inhibition on the hERG with IC<sub>50</sub> values greater than 40 μM, indicating their optimal cardiac safety profile. Meanwhile, these compounds showed a higher polar surface area (tPSA) and improved aqueous solubility potential (LogS), compared to the reference compound <b>1</b>. In view of the high biochemical and cellular potencies, as well as the slightly better predicted physicochemical properties, compound <b>26</b> was selected for further study.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Pharmacokinetic Parameters of Compound <b>26</b></h3><div class="NLM_p">To investigate the developability of compound <b>26</b>, the pharmacokinetic properties of this compound in Sprague–Dawley (SD) rats were profiled. The reference compound <b>1</b> was evaluated as well as a comparison. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, after intravenous injection (iv) at a dose of 1 mg/kg, compound <b>26</b> has lower systemic plasma clearance (CL = 16.5 <i>vs</i> 29.7 mL/min/kg), a longer half-life (<i>T</i><sub>1/2</sub> = 1.36 <i>vs</i> 0.71 h), and two-fold higher plasma exposure (AUC<sub>last</sub> = 1328 vs 563 h·ng/mL), compared to the reference <b>1</b>. The overall improved PK parameters of compound <b>26</b> encouraged further evaluation.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PK Parameters of Potent Compounds After iv Administration (1 mg/kg)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>INF_obs</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>_obs</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">MRT<sub>INF_obs</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Vss<sub>_obs</sub> (mL/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char=".">1.36</td><td class="colsep0 rowsep0" align="char" char=".">1328</td><td class="colsep0 rowsep0" align="char" char=".">1341</td><td class="colsep0 rowsep0" align="char" char=".">16.5</td><td class="colsep0 rowsep0" align="char" char=".">1.90</td><td class="colsep0 rowsep0" align="char" char=".">1631</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">0.71</td><td class="colsep0 rowsep0" align="char" char=".">560</td><td class="colsep0 rowsep0" align="char" char=".">563</td><td class="colsep0 rowsep0" align="char" char=".">29.7</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1783</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Values are the average of three runs. Vehicle: DMSO/EtOH/PEG300/0.9%NaCl (5/5/40/50, v/v/v/v). <i>T</i><sub>1/2</sub>: half-life; AUC: area under the plasma concentration–time curve; CL: clearance; and Vss: volume of distribution.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Kinase Selectivity Assays of Compounds <b>26</b></h3><div class="NLM_p">Because our new NAE inhibitor <b>26</b> bears more N-atoms than the reference compound <b>1</b>, off-targets might be a concern. To exclude the off-target liability, we evaluated the kinase selectivity of both compounds <b>1</b> and <b>26</b> through the KINOMEScan screening against a panel of 468 kinases and their mutants at 1 μM concentration.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, compound <b>1</b> inhibited only one kinase TAOK1 at a concentration of 1 μM and the inhibitory effect is as low as 35% [<i>S</i>-score (35) = 0.002], otherwise both compounds showed high selectivity against NAE without significant inhibition against all the tested kinases and their mutants [<i>S</i>-score (10) and <i>S</i>-score (1) = 0] (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_001.pdf" class="ext-link">Supporting Information</a> for details).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase selectivity of compounds <b>1</b> and <b>26</b> in the DiscoveRx KINOMEScan screening platform. The assays were performed at a single 1 μM concentration. Upper panel: TREEspot interaction maps for compounds <b>1</b> and <b>26</b> in 468 kinase targets. Lower panel: <i>S</i>-scores of compounds <b>1</b> and <b>26</b> with percent control numbers less than 35, 10, and 1, respectively. <i>S</i>-score (<i>S</i> = Number of hits/Number of assays) is a quantitative measure of compound selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Compound <b>26</b> Potently Inhibited Both NAE and UAE Activity In Vitro</h3><div class="NLM_p">Compound <b>26</b> was further evaluated using mechanism-based in vitro assays. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compound <b>26</b> exhibited comparable inhibitory potency against NAE relative to the reference <b>1</b> with IC<sub>50</sub> values of 0.55 and 0.26 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a). At much higher concentrations, compound <b>26</b> was found to inhibit the related ubiquitin-activating enzyme (UAE) with an IC<sub>50</sub> value of 66.84 nM (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c, a concentration-dependent reduction of the intensity of Ubc12-NEDD8 bands (as well as UBA3-NEDD8 and Cul1-NEDD8) was observed and the formation of Ubc12-NEDD8 was evidently inhibited at 0.15 μM. These results indicated that compound <b>26</b> is indeed an effective NAE inhibitor and suppresses NAE-mediated Ubc12-NEDD8 conjugation in cell-based assays.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. NAE and UAE dual inhibition by compound <b>26</b>. (a,b) The dose–response relationship of compound <b>26</b> for inhibition of NAE (a) and UAE (b) assayed by HTRF. Data are expressed as the mean ± SD from three independent experiments. (c) Compound <b>26</b> inhibited neddylation in the cellular-based assay. Whole-cell lysates were prepared from HCT-116 treated with compound <b>26</b> or the positive control for 4 h, as the concentration showed, and analyzed by western blotting. (d) Inhibition of compound <b>26</b> for the E1 enzymes NAE, UAE, and SAE. The activity of NAE, UAE, and SAE was assessed by immunoblot measuring of the thioester levels of Ubc12-NEDD8, UbcH10-Ub, and Ubc9-SUMO, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To determine the probability of compound <b>26</b> suppressing other E1 isoforms, a dose–response experiment was performed to measure levels of E2-UBL thioester products by western blotting. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>d, there was no appreciable suppression of the formation of Ubc9-SUMO even at 10 μM of compound <b>26</b>, suggesting no off-target effect on SAE (SUMO activation enzyme E1). However, in line with enzymatic activity, compound <b>26</b> suppressed UbcH10-Ub formation at 3.3 μM, suggesting its modest inhibition against UAE. Taken together, through enzyme-based and cell-based assays, compound <b>26</b> was validated as a high-potency NAE and modest potency UAE dual inhibitor.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Compound <b>26</b> Inhibited CRL Substrates’ Turnover and Elicited DNA Damage Responses</h3><div class="NLM_p">Because inhibition of NAE can result in inactivation of Cullin-RING ligases (CRLs), leading to the accumulation of CRL substrates,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> therefore, we tested these effects as well. It was found that treatment of compound <b>26</b> inhibited neddylation and increased CRL substrates CDT1, p27, p21, and p-IκBα (Ser32/36) in a concentration-dependent manner, which led to DNA damage (γ-H2AX) accumulation and checkpoint activation (p-Chk1) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibitory effects of compound <b>26</b> on the neddylation and DNA damage pathway. HCT-116 and HuTu80 cancer cells were treated with indicated drugs for 24 h. Whole-cell lysates were immunoblotted for Cul1- or Ubc12-NEDD8, CRL substrates, including CDT1, p27, p21, p-IκBα (Ser32/36), and DNA damage markers γH2AX and p-Chk1(Ser317).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compound <b>26</b> Inhibited the Proliferation of Various Cancer Cells</h3><div class="NLM_p">To assess the overall antiproliferative activity of compound <b>26</b> and identify the most sensitive cancer cells for in vivo study, a panel of cell lines, including leukemia, colon, and prostate cancer, were treated with increasing concentrations of compound <b>26</b> for 72 h. The results showed that the growth was effectively inhibited in all the cell lines tested, with IC<sub>50</sub> values ranging between 33.9 and 482 nM (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). The proliferation inhibition observed for compound <b>26</b> was similar to that for the reference compound <b>1</b> (IC<sub>50</sub>: 36.25–484 nM). Notably, compound <b>26</b> exerted the most potent anticancer effects against HCT-116 colon cancer cells with an IC<sub>50</sub> value of 33.9 nM. Meanwhile, slightly lower but still high potency was observed in the leukemia MV-4-11 cells with an IC<sub>50</sub> value of 106 nM. On the basis of these results, the two cell lines were selected for in vivo studies.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antiproliferation Activity of Compound <b>26</b> in Various Cancer Cells<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center">origin</th><th class="colsep0 rowsep0" align="center" char="±"><b>26</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>1</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MV-4-11</td><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="char" char="±">106 ± 18.0</td><td class="colsep0 rowsep0" align="char" char="±">107 ± 19.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">THP-1</td><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="char" char="±">353 ± 41.6</td><td class="colsep0 rowsep0" align="char" char="±">115 ± 4.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Jurkat</td><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="char" char="±">482 ± 17.2</td><td class="colsep0 rowsep0" align="char" char="±">152 ± 11.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCT-116</td><td class="colsep0 rowsep0" align="left">colon</td><td class="colsep0 rowsep0" align="char" char="±">33.9 ± 3.95</td><td class="colsep0 rowsep0" align="char" char="±">36.2 ± 1.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HuTu80</td><td class="colsep0 rowsep0" align="left">colon</td><td class="colsep0 rowsep0" align="char" char="±">40.0 ± 9.10</td><td class="colsep0 rowsep0" align="char" char="±">42.6 ± 6.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RKO</td><td class="colsep0 rowsep0" align="left">colon</td><td class="colsep0 rowsep0" align="char" char="±">286 ± 20.5</td><td class="colsep0 rowsep0" align="char" char="±">166 ± 25.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT-29</td><td class="colsep0 rowsep0" align="left">colon</td><td class="colsep0 rowsep0" align="char" char="±">407 ± 102</td><td class="colsep0 rowsep0" align="char" char="±">484 ± 76.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LNCaP clone FGC</td><td class="colsep0 rowsep0" align="left">prostate</td><td class="colsep0 rowsep0" align="char" char="±">264 ± 81.2</td><td class="colsep0 rowsep0" align="char" char="±">64.6 ± 13.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DU 145</td><td class="colsep0 rowsep0" align="left">prostate</td><td class="colsep0 rowsep0" align="char" char="±">482 ± 78.0</td><td class="colsep0 rowsep0" align="char" char="±">201 ± 31.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Capan-1</td><td class="colsep0 rowsep0" align="left">pancreas</td><td class="colsep0 rowsep0" align="char" char="±">101 ± 17.4</td><td class="colsep0 rowsep0" align="char" char="±">101 ± 10.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">The mean IC<sub>50</sub> was obtained using the SRB assay and derived from three independent experiments. Data are expressed as the mean ± SD.</p></div></div></div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Compound <b>26</b> Induced Cell Cycle Arrest and Apoptosis in HCT-116 Cells</h3><div class="NLM_p">To clarify the anticancer mechanism of compound <b>26</b> in the most sensitive HCT-116 cells, it was treated at a lower concentration for 24 h. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, an increase in the G2/M phase was observed. However, higher concentrations led to cell accumulation in the S phase, accompanied by an increase of the polyploidy population (DNA content > 4<i>N</i>) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). Consistently, a luminescent assay that measures caspase-3 and -7 activities indicated that compound <b>26</b> promoted cell apoptosis through activating caspase-3/7 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). Furthermore, treatment with compound <b>26</b> increased the expression of cleaved caspase-3, -7, and PARP1 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c). Collectively, these results suggest that compound <b>26</b> suppresses cell proliferation through cell cycle arrest and apoptosis.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cell cycle arrest and apoptosis induced by compound <b>26</b>. (a) Cell cycle arrest was analyzed by PI-staining-based flow cytometry after HCT-116 was treated with the indicated drug for 24 h. (b,c) Compound <b>26</b> induced apoptosis through caspase-3/7 activation. HCT-116 cells were treated with the indicated drugs for 48 h and then subjected to Caspase-Glo 3/7 assays (b) or western blotting (c). Error bars represent the SEM for at least three independent experiments. Data are analyzed by one-way ANOVA, **, <i>p</i> < 0.01, ***, <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Compound <b>26</b> Exhibited Potent Antitumor Efficacy In Vivo in Xenograft Models</h3><div class="NLM_p">Based on the promising in vitro potency of the new NAE inhibitor <b>26</b>, we further evaluated its antitumor activity in vivo in nude mice xenografts from human HCT-116 and MV-4-11 cancer cells. The animals were injected subcutaneously with the vehicle, positive control compound <b>1</b>, or compound <b>26</b> for 18–21 days. A previous study has established the optimal dosing paradigm of compound <b>1</b> to achieve significant antitumor efficacy with good tolerance.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, we followed this schedule as suggested for compound <b>1</b> in the HCT-116 mice: 60 mg/kg twice daily (BID) with 5 on/5 off/8 on. In our preliminary study, the maximum tolerated single-dose for compound <b>26</b> was determined as 150 mg/kg, with 130 mg/kg being well-tolerated (data not shown) in this models. Therefore, compound <b>26</b> was given at either 65 mg/kg or 130 mg/kg once daily (QD) consecutively. In the MV-4-11 mice, the same dosing paradigm (BID) was used for both compounds. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a,b, both compounds <b>26</b>- and <b>1</b>-treated mice showed significant suppression of tumor growth compared to vehicle-treated mice in a dose-dependent manner (compound <b>26</b> at 130 mg/kg, QD: <i>T</i>/<i>C</i> = 0.20 or 0.19; compound <b>1</b> at 60 mg/kg, BID: <i>T</i>/<i>C</i> = 0.36 or 0.10). At these doses, no significant change of the body weight was observed, indicating there was no apparent toxicity upon the treatments in both xenograft models. In general, both compounds showed similar high antitumor efficacy in these models but compound <b>26</b> has a better safety profile with a convenient dosing schedule.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vivo activities of compound <b>26</b> in cell-derived xenografts. Nude mice bearing subcutaneous xenografts derived from HCT-116 (a) or MV-4-11 (b) were injected subcutaneously daily with 65 or 130 mg/kg compound <b>26</b>, or twice daily with 60 mg/kg compound <b>1</b>, respectively. 5 on/5 off/8 on represents 5 days treatment followed by 5 days free of treatment and 8 days treatment in an 18 days study. Relative tumor volume and body weight were separately plotted over the treatment time. Mean tumor volumes ± SEM are shown. <i>n</i> = 6 mice per group. Data are analyzed by Student <i>t</i>-test, *, <i>p</i> < 0.05; **, <i>p</i> < 0.01; and ***, <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24447" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24447" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds <b>4</b> and <b>6–23</b> bearing a pyrimidotriazole core is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The key amino-diol intermediate <b>37</b> was prepared according to the reported process.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> A subsequent reaction of <b>37</b> with 5-amino-4,6-dichloropyrimidine afforded compound <b>38</b> in 73% yield. Cyclization of compound <b>38</b> with isoamyl nitrite delivered unstable intermediate <b>39</b>, which was then subjected to aromatic nucleophilic substitution immediately with (<i>S</i>)-(+)-1-aminoindane hydrochloride in the presence of N, N-diisopropylethylamine (DIPEA) to provide compound <b>40a</b> in 98% yields over two steps. Subsequent sulfamoylation of <b>40a</b> with chlorosulfonamide afforded the pyrimidotriazole core compound <b>4</b> in 17% yield. Similarly, aromatic nucleophilic substitution of the intermediate <b>39</b> by various commercially available primary amines provided compounds <b>40a-k</b> and <b>40n-r</b> in 25–98% yields over two steps. Alternatively, a Pd-catalyzed Buchwald–Hartwig coupling of <b>39</b> with different aromatic primary amines produced <b>40l-m</b> in 40–52% yields over two steps. Meanwhile, the reaction of the intermediate <b>39</b> with 4,5,6-trifluoropyrimidine through a microwave irradiation provided compound <b>41</b> in 46% yield. Aromatic nucleophilic substitution of pyrimidine <b>41</b> with (<i>S</i>)-(+)-1-aminoindane hydrochloride in the presence of DIPEA provided compound <b>42</b> in 25% yield. Finally, synthesis of target compounds <b>6–23</b> was achieved from <b>42</b> and <b>40b-r</b> by using chlorosulfonamide as the sulfonylation reagent.</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds 4, 7–23<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-amino-4,6-dichloropyrimidine, Et<sub>3</sub>N, <i>n</i>-butanol, 120 °C, overnight, and 73%; (b) 1-butyl nitrite or isoamyl nitrite, 4 Å, CH<sub>3</sub>CN, 70 °C, and 1–2 h; (c) for preparation of <b>40a-k</b> and <b>40n-r</b> and <b>42</b>: primary amine DIPEA, CH<sub>3</sub>CN, rt (or 90 °C, MW, for <b>40k</b>), 6–8 h, and 25–98% over two steps; (d) for preparation of <b>40l-m</b>: primary amine Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Xantphos, DMF, N<sub>2</sub>, 100 °C, 4 h, and 40–52% over two steps; (e) NH<sub>2</sub>SO<sub>2</sub>Cl, pyridine, CH<sub>3</sub>CN, 0 °C, 30 min–2 h, and 8.9–25.2%; (f) 4,5,6-trifluoropyrimidine, DIPEA, <i>n</i>-butanol, MW, 120 °C, 1 h, and 46%.</p></p></figure><div class="NLM_p">The preparation of compound <b>5</b> bearing a pyrazolopyridine core is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Compound <b>43</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> reacted with 4-chloro-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine via the Mitsunobu reaction to afford compound <b>44</b>. Subsequent <i>O</i>-Bn deprotection with BCl<sub>3</sub> provided the diol intermediate <b>45</b> in 48% yield over two steps. Substitution of the pyrazolopyridinyl chloride <b>45</b> with (<i>S</i>)-(+)-1-aminoindane under microwave irradiation delivered compound <b>46</b> in 45% yield. Treatment of <b>46</b> with chlorosulfonamide generated pyrazolopyridine <b>5</b> in 15% yield.</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound 5<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-chloro-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine, PPh<sub>3</sub>, DIAD, THF, N<sub>2</sub>, and 0 °C; (b) 1 M BCl<sub>3</sub>, dichloromethane (DCM), 0 °C, 4 h, and 48% over two steps; (c) (<i>S</i>)-(+)-1-aminoindane, MW, 200 °C, and 45%; (d) NH<sub>2</sub>SO<sub>2</sub>Cl, pyridine, CH<sub>3</sub>CN, 0 °C, 30 min–2 h, and 15.4%.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>24-36</b> is described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The chiral amine <b>47</b><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> was treated with intermediate <b>39</b> to provide compound <b>48</b>, which was sulfamoylated with chlorosulfonamide to yield compound <b>31</b> in 7.1% yield over two steps. Subsequent N-Boc deprotection of <b>31</b> with 4 M HCl in methanol afforded compound <b>24</b> in 76.2% yield. Treatment of compound <b>24</b> with CH<sub>3</sub>I or <i>tert</i>-butylisocyanate afforded compounds <b>25</b> and <b>36</b> in 29.6 and 19.5% yields, respectively. Meanwhile, acylation of compound <b>24</b> with various commercially available chloroformate afforded compounds <b>26–29</b> and <b>34–35</b> in 32.7–44.2% yields. Alternatively, treatment of amine <b>24</b> with commercially available 4-nitrophenyl carbonate produced compounds <b>30</b> and <b>33</b> in 23.5 and 26.5% yields, respectively. It is of note that compound <b>32</b> was prepared in 23% overall yield through the reaction of compound <b>24</b> with 2,2-dimethyl-1,3-dioxan-5-yl (4-nitrophenyl)carbonate, followed by hydroxyl deprotection with 2 M HCl (aq).</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>25–30</b> and <b>32–36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>39</b>, DIPEA, CH<sub>3</sub>CN, rt, 6–8 h, and 54.4%; (b) NH<sub>2</sub>SO<sub>2</sub>Cl, pyridine, CH<sub>3</sub>CN, 0 °C, 30 min–2 h, and 13%; (c) 4 M HCl, MeOH, rt, overnight, and 76.2%; (d) for <b>25</b>: CH<sub>3</sub>I, DMF, rt, 15 min, and 29.6%; for <b>26–29</b> and <b>34–35</b>: corresponding chloroformate, DIPEA, DMF, rt, 30 min, and 32.7–44.2%; for <b>30</b> and <b>33</b>: corresponding 4-nitrophenyl carbonate, DIPEA, DMF, rt, 1–2 h, and 23.5–26.5%; for <b>36</b>: <i>tert</i>-butylisocyanate, DIPEA, DMF, rt, 1 h, and 19.5%; (e) for <b>32</b>: 2,2-dimethyl-1,3-dioxan-5-yl (4-nitrophenyl) carbonate, DIPEA, DMF, rt, 2 h, then 2 M HCl (aq), 2 h, and 23%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22557" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In order to develop structurally different high-potency NEDD8-activating enzyme (NAE) inhibitors, we conducted a structural hopping strategy by first investigating the structural variations of the central deazapurine bicyclic framework of the clinical compound <b>1</b>, followed by focused optimization of the solvent interaction region, leading to identification of a new NAE inhibitor <b>26</b> bearing a pyrimidotriazole scaffold. This new inhibitor <b>26</b> has IC<sub>50</sub> values of 0.55 and 36.2 nM, respectively, from the biochemical and HCT-116 cell assays. Compound <b>26</b> also exhibited slightly less-potent activity against UAE with an IC<sub>50</sub> value of 66 nM. Treatment with compound <b>26</b> was found to inhibit the neddylation pathway and increase CRL substrates. Compared to its prototype compound <b>1</b>, compound <b>26</b> displayed obviously higher plasma concentrations and better PK parameters in mice. In vivo, compound <b>26</b> showed significant antitumor efficacy and a good safety profile in both the HCT-116 and MV-4-11 xenograft models. Collectively, compound <b>26</b> is a new high-potency NAE inhibitor with improved PK profiles and worthy of further profiling.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78554" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78554" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Chemistry General</h3><div class="NLM_p last">All reactions were performed in glassware containing a Teflon-coated stir bar. Commercially available solvents and reagents were obtained from Adamas, Accela, Aikonchem, Sinopharm Chemical, Energy Chemical, Aladdin, Innochem, Macklin, Meryer, Leyan, MCE, Bidepharm, Sigma-Aldrich, Alfa Aesar, J&K, and TCI, and used without further purification. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Varian Mercury 300, 400, or 500 NMR spectrometer and referenced to CD<sub>3</sub>OD. Chemical shifts (δ) were reported in ppm downfield from an internal tetramethylsilane standard. High-resolution mass spectrometry (HRMS) analysis was recorded at an anionizing voltage of 70 eV on a Finnigan/MAT95 spectrometer. Flash column chromatography on silica gel (200–300 mesh) was used for the routine purification of reaction products. All reactions were monitored by thin-layer chromatography (TLC) on silica gel plates (15 mm × 50 mm) and spots were visualized under UV light at 254 nm. Optical rotations were measured on a JASCO p-2000 using a 1dm polarimeter tube at 589 nm. HPLC analysis was conducted for all bioassayed compounds on an Agilent Technologies 1260 series LC system (Eclipse XDB-CN, 4.6 mm × 150 mm, 5 μM, MeOH/H<sub>2</sub>O, 25 °C) with two ultraviolet wavelengths (UV 254 and 210 nm). The purities of these compounds were above 95%.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Synthetic Procedures</h3><div class="NLM_p">Compounds <b>1</b>, <b>37</b>, <b>43</b>, and <b>47</b> were prepared according to reported literature procedures.<a onclick="showRef(event, 'ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43 ref44">(41−44)</a> The absolute structure of the synthetic new compounds was confirmed by the X-ray crystals of an analogue of this series (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-(((<i>S</i>)-2,3-Dihydro-1<i>H</i>-inden-1-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>4</b>)</h4><div class="NLM_p">To a solution of <b>37</b> (120 mg, 1.2 mmol) in <i>n</i>-butanol (5 mL) were added 5-amino-4,6-dichloropyrimidine (295 mg, 1.8 mmol) and Et<sub>3</sub>N (0.34 mL, 2.4 mmol). The mixture was refluxed overnight. Upon completion, the solvents were removed in vacuo and the residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 50:1 to 10:1) to give compound <b>38</b> (225.7 mg, 73%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 7.76 (s, 1H), 4.73–4.64 (m, 1H), 4.43–4.37 (m, 1H), 3.77 (dd, <i>J</i> = 10.8, 7.4 Hz, 1H), 3.63 (dd, <i>J</i> = 10.8, 6.3 Hz, 1H), 2.38–2.21 (m, 2H), 2.11–2.01 (m, 1H), 1.93–1.83 (m, 1H), 1.75–1.66 (m, 1H).</div><div class="NLM_p">To a solution of <b>38</b> (129 mg, 0.5 mmol) in CH<sub>3</sub>CN (5 mL) was added isoamyl nitrite (135 μL, 1 mmol). The mixture was stirred at 70 °C for 1 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated in vacuo to give the unstable intermediate <b>39</b>, which was then dissolved in anhydrous CH<sub>3</sub>CN. (<i>S</i>)-(+)-1-Aminoindane hydrochloride (110.5 mg, 0.65 mmol) and DIPEA (248 μL, 1.5 mmol) were added to the solution of <b>39</b> in anhydrous CH<sub>3</sub>CN. The mixture was stirred at rt for 6–8 h. The mixture was concentrated in vacuo and the residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 80:1 to 20:1) to give compound <b>40a</b> (180 mg, 98%) as a white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.38 (s, 0.73H), 8.19 (s, 0.20H), 7.30–7.17 (m, 1H), 7.17–7.10 (m, 1H), 6.54 (t, <i>J</i> = 7.5 Hz, 0.21H), 5.97 (t, <i>J</i> = 7.6 Hz, 0.75H), 5.61–5.51 (m, 1H), 4.60–4.54 (m, 1H), 3.83 (dd, <i>J</i> = 10.8, 7.2 Hz, 1H), 3.70 (dd, <i>J</i> = 10.8, 6.4 Hz, 1H), 3.13–3.04 (m, 1H), 3.00–2.88 (m, 1H), 2.71–2.52 (m, 3H), 2.45–2.36 (m, 1H), 2.33–2.17 (m, 2H), 2.14–2.03 (m, 1H).</div><div class="NLM_p last">To a solution of compound <b>40a</b> (180 mg, 0.49 mmol) in anhydrous CH<sub>3</sub>CN (5 mL) at 0 °C was added a solution of chlorosulfonamide (68 mg, 0.59 mmol) in CH<sub>3</sub>CN and pyridine (118 μL, 1.47 mmol). The mixture was stirred for 30 min–2 h, and additional chlorosulfonamide (0.3 equiv) was added until the completion of the reaction. The mixture was quenched with a small amount of water and concentrated in vacuo. The residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 100:1 to 20:1) to give a crude product, which was further purified using reverse-phase HPLC to afford compound <b>4</b> (38 mg, 17%) as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.39 (s, 0.74 H), 8.21 (s, 0.20 H), 7.20–7.30 (m, 3H), 7.14 (t, <i>J</i> = 7.3 Hz, 1H), 6.54 (t, <i>J</i> = 7.4 Hz, 0.21 H), 5.97 (t, <i>J</i> = 7.5 Hz, 0.74 H), 5.64–5.55 (m, 1H), 4.59–4.54 (m, 1H), 4.40 (dd, <i>J</i> = 9.7, 7.6 Hz, 1H), 4.23 (dd, <i>J</i> = 9.7, 7.4 Hz, 1H), 3.13–3.05 (m, 1H), 3.00–2.85 (m, 2H), 2.71–2.54 (m, 2H), 2.48–2.40 (m, 1H), 2.36–2.26 (m, 2H), 2.13–2.04 (m, 1H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.64, 155.97, 149.26, 144.67, 144.04, 129.03, 127.65, 126.15, 125.80, 125.13, 73.08, 70.49, 57.73, 56.91, 44.77, 42.98, 34.36, 34.25, 31.10. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 443.3. HRMS (ESI): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>7</sub>O<sub>4</sub>S, 444.1459; found, 444.1462. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –15.00 (<i>c</i> 0.08, CH<sub>3</sub>OH).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(4-(((<i>S</i>)-2,3-Dihydro-1<i>H</i>-inden-1-yl)amino)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>5</b>)</h4><div class="NLM_p">To a solution of compound <b>43</b> (1.87 g, 6 mmol) in THF (15 mL) at 0 °C under nitrogen were added 4-chloro-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (920 mg, 6 mmol), PPh<sub>3</sub> (3.14 g, 12 mmol), and DIAD (2.4 mL, 12 mmol). The mixture was stirred for 8 h and then diluted with ethyl acetate. The organic phase was washed with 1 M HCl (30 mL, ×3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product <b>44</b> was obtained as a yellowish solid and used in the next step without further purification.</div><div class="NLM_p">To a solution of crude product <b>44</b> in DCM (50 mL) at −78 °C under nitrogen was added 1 M BCl<sub>3</sub> in DCM (60 mL). The mixture was allowed to slowly warm up to 0 °C and stirred for 4 h. The reaction was quenched with MeOH/Et<sub>3</sub>N (1:1) and the mixture was stirred for 15 min and then concentrated in vacuo. The residue was purified by silica column chromatography (PE/EA from 10:1 to 1:1) to give compound <b>45</b> (384 mg, 48.1%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.20 (s, 1H), 7.95 (d, <i>J</i> = 6.4 Hz, 1H), 6.41 (d, <i>J</i> = 6.4 Hz, 1H), 5.48–5.39 (m, 1H), 4.56–4.50 (m, 1H), 3.81 (dd, <i>J</i> = 10.8, 7.2 Hz, 1H), 3.67 (dd, <i>J</i> = 10.8, 6.5 Hz, 1H), 2.63–2.52 (m, 1H), 2.50–2.39 (m, 1H), 2.34–2.25 (m, 1H), 2.23–2.11 (m, 1H), 2.11–2.01 (m, 1H).</div><div class="NLM_p last">Compound <b>45</b> (384 mg, 1.44 mmol) was converted to the target compound <b>5</b> (44 mg, 6.89%) as a white solid through a procedure similar to the preparation of compound <b>4</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.14 (s, 1H), 8.04 (d, <i>J</i> = 5.7 Hz, 1H), 7.29 (t, <i>J</i> = 7.7 Hz, 2H), 7.24 (t, <i>J</i> = 7.2 Hz, 1H), 7.18 (t, <i>J</i> = 7.3 Hz, 1H), 6.44 (d, <i>J</i> = 5.6 Hz, 1H), 5.66–5.57 (m, 1H), 5.33 (t, <i>J</i> = 6.8 Hz, 1H), 4.54–4.50 (m, 1H), 4.37 (dd, <i>J</i> = 9.6, 7.7 Hz, 1H), 4.20 (dd, <i>J</i> = 9.6, 7.4 Hz, 1H), 3.13–3.02 (m, 1H), 3.00–2.89 (m, 1H), 2.86–2.75 (m, 1H), 2.70–2.59 (m, 1H), 2.47–2.37 (m, 1H), 2.35–2.26 (m, 1H), 2.25–2.14 (m, 1H), 2.14–1.99 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 152.26, 151.07, 150.51, 144.75, 144.45, 132.38, 129.07, 127.68, 125.85, 125.29, 106.67, 97.94, 73.29, 70.79, 59.11, 55.69, 44.80, 42.70, 34.37, 34.12, 31.07. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 444.2. HRMS (ESI): calcd for C<sub>21</sub>H<sub>26</sub>N<sub>5</sub>O<sub>4</sub>S, 444.1697; found, 444.1699. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +18.25 (<i>c</i> 0.04, CH<sub>3</sub>OH).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-((6-(((<i>S</i>)-2,3-Dihydro-1<i>H</i>-inden-1-yl)amino)-5-fluoropyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl Sulfamate (<b>6</b>)</h4><div class="NLM_p">To a microwave vial charged with <b>37</b> (270 mg, 2.06 mmol) in 1-butanol (2 mL) was added 4,5,6-trifluoropyrimidine (0.21 mL, 2.27 mmol) and DIPEA (0.68 mL, 4.12 mmol). The reaction vessel was sealed and heated in a microwave reactor at 120 °C for 1 h. After cooling, the solvents were removed in vacuo and the residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 80:1 to 20:1) to give compound <b>41</b> (232 mg, 46%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 7.98 (d, <i>J</i> = 1.4 Hz, 1H), 4.76 (m, 1H), 4.40–4.35 (m, 1H), 3.75 (dd, <i>J</i> = 10.7, 7.3 Hz, 1H), 3.61 (dd, <i>J</i> = 10.7, 6.4 Hz, 1H), 2.37–2.26 (m, 1H), 2.25–2.17 (m, 1H), 2.08–1.97 (m, 1H), 1.91–1.82 (m, 1H), 1.76–1.66 (m, 1H).</div><div class="NLM_p">Compound <b>41</b> (218.6 mg, 0.89 mmol) was converted to the target compound <b>6</b> (21 mg, 5.38%) as a white solid through a procedure similar to the preparation of compound <b>4</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 7.85 (s, 1H), 7.27–7.12 (m, 4H), 5.62 (t, <i>J</i> = 7.8 Hz, 1H), 4.72–4.63 (m, 1H), 4.39–4.34 (m, 1H), 4.31 (dd, <i>J</i> = 9.5, 7.9 Hz, 1H), 4.14 (dd, <i>J</i> = 9.6, 7.3 Hz, 1H), 3.06–2.96 (m, 1H), 2.93–2.81 (m, 1H), 2.62–2.46 (m, 2H), 2.28–2.19 (m, 1H), 2.10–1.99 (m, 1H), 1.99–1.82 (m, 2H), 1.78–1.68 (m, 1H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 153.23 (d, <i>J</i> = 10.2 Hz), 151.04, 150.98, 145.42, 144.40, 132.78, 130.85, 128.08 (d, <i>J</i> = 141.7 Hz), 125.64, 124.97, 72.96, 70.83, 56.87, 50.61, 44.16, 43.66, 35.11, 30.91. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 438.2. HRMS (ESI): calcd for C<sub>19</sub>H<sub>25</sub>FN<sub>5</sub>O<sub>4</sub>S, 438.1606; found, 438.1595. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –33.33 (<i>c</i> 0.06, CH<sub>3</sub>OH).</div><div class="NLM_p last">Compounds <b>7–16</b> were prepared by following similar procedures to that used for compound <b>4</b>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-((2-Fluorobenzyl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>7</b>)</h4><div class="NLM_p last">White solid (23 mg, 13.2%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.36 (s, 0.76H), 8.27 (s, 0.13H), 7.42 (t, <i>J</i> = 7.4 Hz, 1H), 7.29 (q, <i>J</i> = 7.1 Hz, 1H), 7.16–7.05 (m, 2H), 5.64–5.55 (m, 1H), 4.59–4.53 (m, 1H), 4.39 (dd, <i>J</i> = 9.6, 7.7 Hz, 1H), 4.22 (dd, <i>J</i> = 9.7, 7.2 Hz, 1H), 2.96–2.84 (m, 1H), 2.64–2.55 (m, 1H), 2.47–2.38 (m, 1H), 2.35–2.25 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 162.30 (d, <i>J</i> = 245.6 Hz), 157.53, 156.20, 149.28, 130.72 (d, <i>J</i> = 3.9 Hz), 130.31 (d, <i>J</i> = 8.2 Hz), 126.41(d, <i>J</i> = 20.41 Hz), 126.37, 125.31 (d, <i>J</i> = 3.7 Hz), 116.20 (d, <i>J</i> = 21.4 Hz), 73.09, 70.45, 57.77, 44.80, 42.98, 38.92, 34.36. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 436.4. HRMS (ESI): calcd for C<sub>17</sub>H<sub>19</sub>FN<sub>7</sub>O<sub>4</sub>S, 436.1209; found, 436.1205. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –5.00 (<i>c</i> 0.04, CH<sub>3</sub>OH).</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-((Furan-2-ylmethyl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>8</b>)</h4><div class="NLM_p last">White solid (21 mg, 10.5%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.38 (s, 0.70H), 8.25 (s, 0.14H), 7.43 (s, 1H), 6.34 (s, 2H), 5.66–5.54 (m, 1H), 5.27 (s, 0.36 H), 4.83 (s, 1.68 H), 4.60–4.53 (m, 1H), 4.39 (dd, <i>J</i> = 9.7, 7.5 Hz, 1H), 4.22 (dd, <i>J</i> = 9.7, 7.3 Hz, 1H), 2.96–2.83 (m, 1H), 2.64–2.53 (m, 1H), 2.48–2.38 (m, 1H), 2.38–2.24 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.45, 155.96, 152.74, 149.26, 143.44, 126.31, 111.40, 108.55, 73.09, 70.44, 57.76, 44.80, 42.97, 38.15, 34.35. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 408.4. HRMS (ESI): calcd for C<sub>15</sub>H<sub>18</sub>N<sub>7</sub>O<sub>5</sub>S, 408.1096; found, 408.1103. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +23.75 (<i>c</i> 0.08, CH<sub>3</sub>OH).</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-((thiophen-2-ylmethyl)amino)-3<i>H</i>-[1,2,3]triazolo [4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>9</b>)</h4><div class="NLM_p last">White solid (32.7 mg, 15.9%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.40 (s, 0.75 H), 8.26 (s, 0.13 H), 7.27 (d, <i>J</i> = 5.1 Hz, 1H), 7.13–7.07 (m, 1H), 6.97–6.90 (m, 1H), 5.65–5.53 (m, 1H), 5.46 (s, 0.29 H), 5.01 (s, 1.74 H), 5.60–5.54 (m, 1H), 4.39 (dd, <i>J</i> = 9.7, 7.5 Hz, 1H), 4.22 (dd, <i>J</i> = 9.7, 7.3 Hz, 1H), 2.96–2.84 (m, 1H), 2.65–2.54 (m, 1H), 2.47–2.38 (m, 1H), 2.35–2.25 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.49, 155.77, 149.29, 142.28, 127.63, 127.20, 126.27, 126.07, 73.08, 70.45, 57.76, 44.79, 42.97, 39.80, 34.35. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 424.5. HRMS (ESI): calcd for C<sub>15</sub>H<sub>18</sub>N<sub>7</sub>O<sub>4</sub>S<sub>2</sub>, 424.0867; found, 424.0875. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +33.67 (<i>c</i> 0.09, CH<sub>3</sub>OH).</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-(phenethylamino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>10</b>)</h4><div class="NLM_p last">White solid (46.3 mg, 25.2%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.34 (s, 0.68H), 8.20 (s, 0.21H), 7.33–7.21 (m, 4H), 7.20–7.12 (m, 1H), 5.56–5.53 (m, 1H), 4.60–4.54 (m, 1H), 4.39 (dd, <i>J</i> = 9.9, 7.4 Hz, 1H), 4.29–4.19 (m, 1.48H), 3.85 (t, <i>J</i> = 7.4 Hz, 1.5H), 3.05–2.96 (m, 2H), 2.96–2.84 (m, 1H), 2.64–2.54 (m, 1H), 2.47–2.37 (m Hz, 1H), 2.35–2.24 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.53, 156.17, 149.09, 140.34, 129.89, 129.50, 127.40, 126.30, 73.08, 70.49, 57.70, 49.51, 49.34, 49.28, 49.17, 49.11, 49.00, 48.83, 48.66, 48.49, 44.79, 43.22, 42.99, 36.32, 34.37. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 432.4. HRMS (ESI): calcd for C<sub>18</sub>H<sub>22</sub>N<sub>7</sub>O<sub>4</sub>S, 432.1459; found, 432.1458. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +24.85 (<i>c</i> 0.13, CH<sub>3</sub>OH).</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-((2-(thiophen-2-yl)ethyl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>11</b>)</h4><div class="NLM_p last">White solid (22.3 mg, 12.8%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.35 (s, 0.71H), 8.22 (s, 0.17H), 7.22–7.16 (m, 1H), 6.95–6.87 (m, 2H), 5.63–5.53 (m, 1H), 4.60–4.54 (m, 1H), 4.39 (dd, <i>J</i> = 9.7, 7.5 Hz, 1H), 4.29 (t, <i>J</i> = 7.2 Hz, 0.41H), 4.22 (dd, <i>J</i> = 9.7, 7.3 Hz, 1H), 3.89 (t, <i>J</i> = 7.2 Hz, 1.54H), 3.28–3.20 (m, 2H), 2.96–2.85 (m, 1H), 2.63–2.53 (m, 1H), 2.48–2.39 (m, 1H), 2.37–2.24 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.53, 156.19, 149.14, 142.30, 127.87, 126.44, 124.77, 73.08, 70.49, 57.72, 44.79, 43.32, 43.00, 34.37, 30.29. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 438.4. HRMS (ESI): calcd for C<sub>16</sub>H<sub>20</sub>N<sub>7</sub>O<sub>4</sub>S<sub>2</sub>, 438.1024; found, 438.1022. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +22.50 (<i>c</i> 0.08, CH<sub>3</sub>OH).</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-((3-phenylpropyl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>12</b>)</h4><div class="NLM_p last">White solid (24.1 mg, 12.1%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.32 (s, 0.72H), 8.21 (s, 0.18 H), 7.27–7.16 (m, 4 H), 7.16–7.09 (m, 1H), 5.63–5.52 (m, 1H), 4.60–4.53 (m, 1H), 4.39 (dd, <i>J</i> = 9.7, 7.5 Hz, 1H), 4.22 (dd, <i>J</i> = 9.7, 7.4 Hz, 1H), 4.06 (t, <i>J</i> = 7.1 Hz, 0.41H), 3.65 (t, <i>J</i> = 7.1 Hz, 1.57 H), 2.96–2.84 (m, 1H), 2.79–2.69 (m, 2H), 2.64–2.54 (m, 1H), 2.48–2.38 (m, 1H), 2.37–2.24 (m, 2H), 2.09–1.97 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.49, 156.24, 149.04, 142.89, 129.40, 129.37, 126.87, 126.33, 73.08, 70.49, 57.69, 44.78, 42.99, 41.40, 34.38, 34.20, 31.98. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 446.5. HRMS (ESI): calcd for C<sub>19</sub>H<sub>24</sub>N<sub>7</sub>O<sub>4</sub>S, 446.1616; found, 446.1627. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +25.29 (<i>c</i> 0.07, CH<sub>3</sub>OH).</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-(Hexylamino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>13</b>)</h4><div class="NLM_p last">White solid (26 mg, 12.6%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.32 (s, 0.71H), 8.20 (s, 0.18H), 5.63–5.53 (m, 1H), 4.60–4.53 (m, 1H), 4.39 (dd, <i>J</i> = 9.7, 7.5 Hz, 1H), 4.22 (dd, <i>J</i> = 9.7, 7.3 Hz, 1H), 4.02 (t, <i>J</i> = 7.2 Hz, 0.44 H), 3.61 (t, <i>J</i> = 7.2 Hz, 1.54 H), 2.96–2.85 (m, 1H), 2.64–2.54 (m, 1H), 2.47–2.38 (m, 1H), 2.35–2.26 (m, 2H), 1.77–1.65 (m, 2H), 1.49–1.38 (m, 2H), 1.38–1.27 (m, 4H), 0.94–0.86 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.52, 156.20, 149.03, 126.30, 73.08, 70.48, 57.68, 44.78, 42.99, 41.74, 34.37, 32.70, 30.18, 27.69, 23.65, 14.35. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 412.6. HRMS (ESI): calcd for C<sub>16</sub>H<sub>26</sub>N<sub>7</sub>O<sub>4</sub>S, 412.1772; found, 412.1780. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +27.14 (<i>c</i> 0.07, CH<sub>3</sub>OH).</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-(Cyclopentylamino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>14</b>)</h4><div class="NLM_p last">White solid (22.4 mg, 18.1%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.33 (s, 0.72H), 8.21 (s, 0.21H), 5.63–5.52 (m, 1H), 5.21–5.11 (m, 0.26H), 4.67–4.53 (m, 1.80H), 4.40 (dd, <i>J</i> = 9.8, 7.5 Hz, 1H), 4.22 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 2.97–2.83 (m, 1H), 2.64–2.54 (m, 1H), 2.48–2.39 (m, 1H), 2.35–2.24 (m, 2H), 2.22–2.04 (m, 2H), 1.93–1.77 (m, 2H), 1.76–1.59 (m, 4H). <sup>13</sup>C NMR (151 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.50, 155.69, 149.04, 126.28, 73.08, 70.50, 57.68, 53.71, 44.78, 43.00, 34.38, 33.48, 24.84. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 396.6. HRMS (ESI): calcd for C<sub>15</sub>H<sub>22</sub>N<sub>7</sub>O<sub>4</sub>S, 396.1459; found, 396.1470. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +32.00 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Methyl(1<i>R</i>,4<i>S</i>)-4-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-hydroxy-4 ((Sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)cyclopent-2-ene-1-carboxylate (<b>15</b>)</h4><div class="NLM_p last">White solid (20.8 mg, 12.2%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.37 (s, 0.67H), 8.25 (s, 0.19H), 6.08–6.04 (m, 1H), 6.04–5.97 (m, 1.28 H), 5.59 (m, 1H), 5.50–5.42 (m, 0.76 H), 4.60–4.54 (m, 1H), 4.40 (dd, <i>J</i> = 9.7, 7.5 Hz, 1H), 4.22 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 3.73 (s, 3H), 3.71–3.64 (m, 1H), 2.98–2.85 (m, 1H), 2.75 (dt, <i>J</i> = 13.6, 8.4 Hz, 1H), 2.65–2.54 (m, 1H), 2.49–2.39 (m, 1H), 2.36–2.26 (m, 2H), 2.14–2.03 (m, 1H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 175.99, 157.51, 155.37, 149.25, 134.35, 133.39, 126.19, 73.09, 70.51, 57.75, 57.30, 52.66, 50.51, 44.79, 42.99, 34.99, 34.38. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 452.5. HRMS (ESI): calcd for C<sub>17</sub>H<sub>22</sub>N<sub>7</sub>O<sub>6</sub>S, 452.1358; found, 452.1365. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +17.14 (<i>c</i> 0.07, CH<sub>3</sub>OH).</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-((1<i>H</i>-Indazol-3-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>16</b>)</h4><div class="NLM_p last">White solid (7.6 mg, 9.5%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 9.01–8.94 (m, 1H), 7.68–7.61 (m, 1H), 7.43–7.36 (m, 1H), 7.26 (t, <i>J</i> = 8.1 Hz, 1H), 6.77–6.69 (m, 1H), 5.89–5.75 (m, 1H), 4.66–4.58 (m, 1H), 4.43 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.26 (dd, <i>J</i> = 9.9, 7.3 Hz, 1H), 3.05–2.92 (m, 1H), 2.76–2.64 (m, 1H), 2.58–2.48 (m, 1H), 2.46–2.36 (m, 2H). <sup>13</sup>C NMR (151 MHz, methanol-<i>d</i><sub>4</sub>): δ 155.63, 154.50, 153.64, 152.40, 149.13, 132.16, 127.41, 122.49, 119.01, 116.98, 108.77, 73.13, 70.48, 58.40, 44.92, 43.03, 34.31. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 444.5. HRMS (ESI): calcd for C<sub>17</sub>H<sub>18</sub>N<sub>9</sub>O<sub>4</sub>S, 444.1208; found, 444.1205.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-(imidazo[1,2-<i>a</i>]pyridin-3-ylamino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>17</b>)</h4><div class="NLM_p">To a solution of <b>39</b> (0.5 mmol) in DMF (5 mL) under nitrogen were added imidazo[1,2-<i>a</i>]pyridin-3-amine (100 mg, 0.75 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (46 mg, 0.05 mmol), Xantphos (87 mg, 0.15 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (410 mg, 1.25 mmol). The mixture was stirred at rt for 4 h, concentrated in vacuo and the residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 100:1 to 20:1) to give compound <b>40l</b> (96 mg, 52%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.31 (s, 1H), 8.04 (s, 1H), 7.64–7.52 (m, 2H), 7.38–7.29 (m, 1H), 6.92 (dt, <i>J</i> = 8.1, 4.8 Hz, 1H), 5.65–5.52 (m, 1H), 4.59–4.48 (m, 1H), 3.80 (dd, <i>J</i> = 10.7, 6.5 Hz, 1H), 3.65 (dd, <i>J</i> = 10.7, 6.3 Hz, 1H), 2.73–2.49 (m, 2H), 2.44–2.33 (m, 1H), 2.32–2.14 (m, 2H).</div><div class="NLM_p last">Compound <b>40l</b> (96 mg, 0.26 mmol) was converted to the target compound <b>17</b> (11.4 mg, 9.8%) as a white solid through a procedure similar to the preparation of compound <b>4</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.36 (s, 1H), 8.15 (s, 1H), 7.82–7.62 (m, 2H), 7.48 (t, <i>J</i> = 8.1 Hz, 1H), 7.03 (t, <i>J</i> = 6.9 Hz, 1H), 5.74–5.59 (m, 1H), 4.58 (t, <i>J</i> = 4.0 Hz, 1H), 4.40 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.23 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 2.97–2.85 (m, 1H), 2.67–2.56 (m, 1H), 2.51–2.40 (m, 1H), 2.40–2.28 (m, 2H). <sup>13</sup>C NMR (151 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.11, 155.89, 150.19, 144.38, 127.77, 126.63, 125.27, 117.37, 114.45, 73.09, 70.48, 58.02, 44.83, 43.01, 34.38. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 444.5. HRMS (ESI): calcd for C<sub>17</sub>H<sub>18</sub>N<sub>9</sub>O<sub>4</sub>S, 444.1208; found, 444.1207. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +16.67 (<i>c</i> 0.06, CH<sub>3</sub>OH).</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-((1<i>H</i>-Indol-1-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>18</b>)</h4><div class="NLM_p">This compound was prepared as a white solid (10.8 mg, 12.2%) by following procedures similar to that used for compound <b>17</b>. (<sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.36 (s, 1H), 8.16 (s, 1H), 7.74 (s, 1H), 7.67 (d, <i>J</i> = 9.1 Hz, 1H), 7.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.03 (t, <i>J</i> = 6.8 Hz, 1H), 5.75–5.60 (m, 1H), 4.62–4.53 (m, 1H), 4.40 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.23 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 2.99–2.84 (m, 1H), 2.69–2.56 (m, 1H), 2.53–2.41 (m, 1H), 2.39–2.23 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.16, 137.44, 129.36, 128.37, 123.54, 122.04, 121.43, 109.73, 102.57, 73.08, 70.49, 57.98, 44.81, 42.98, 34.33. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i> 443.6. HRMS (ESI): calcd for C<sub>18</sub>H<sub>19</sub>N<sub>8</sub>O<sub>4</sub>S, 443.1255; found, 443.1257. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +23.40 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div><div class="NLM_p last">Compounds <b>19–23</b> were prepared by following similar procedures to that used for compound <b>4</b>.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-(((1<i>R</i>,2<i>S</i>)-2-hydroxy-2,3-dihydro-1<i>H</i>-inden-1-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>19</b>)</h4><div class="NLM_p last">White solid (18.7 mg, 8.9%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.43 (s, 0.71H), 8.30 (s, 0.19H), 7.33–7.17 (m, 4H), 6.45 (d, <i>J</i> = 5.0 Hz, 0.19H), 5.90 (d, <i>J</i> = 5.0 Hz, 0.75H), 5.68–5.58 (m, 1H), 4.75 (m, 1H), 4.61–4.56 (m, 1H), 4.40 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.23 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 3.25 (dd, <i>J</i> = 16.5, 5.2 Hz, 1H), 3.03 (dd, <i>J</i> = 16.5, 1.9 Hz, 1H), 2.97–2.86 (m, 1H), 2.67–2.57 (m, 1H), 2.51–2.41 (m, 1H), 2.37–2.28 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.68, 156.43, 149.38, 141.92, 141.88, 129.19, 127.92, 126.31, 125.47, 74.01, 73.11, 70.48, 59.73, 57.86, 44.82, 43.01, 40.68, 34.41. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 460.5. HRMS (ESI): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>7</sub>O<sub>5</sub>S, 460.1409; found, 460.1412. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +12.60 (<i>c</i> 0.06, CH<sub>3</sub>OH).</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-(((1<i>R</i>,2<i>S</i>)-2-(Dimethylamino)-2,3-dihydro-1<i>H</i>-inden-1-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>20</b>)</h4><div class="NLM_p last">White solid (18.6 mg, 9.0%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.46 (s, 0.80 H), 8.24 (s, 0.14H), 7.52 (d, <i>J</i> = 7.5 Hz, 0.86H), 7.32 (d, <i>J</i> = 7.4 Hz, 0.19H), 7.29–7.19 (m, 2H), 7.16–7.06 (m, 1H), 6.53 (d, <i>J</i> = 5.6 Hz, 0.14H), 5.86 (d, <i>J</i> = 5.8 Hz, 0.83H), 5.65–5.52 (m, 1H), 4.61–4.52 (m, 1H), 4.38 (dd, <i>J</i> = 9.8, 7.5 Hz, 1H), 4.21 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 3.25–3.15 (m, 1H), 3.15–3.04 (m, 2H), 2.96–2.80 (m, 1H), 2.63–2.53 (m, 1H), 2.47–2.37 (m, 1H), 2.37–2.22 (m, 8H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.68 and 157.56 (1C), 155.63, 149.31, 143.39, 142.67, 129.71, 128.04, 126.73, 126.32, 125.84, 73.04, 70.67, 70.46, 57.79, 56.52, 44.74, 44.64, 42.93, 36.14, 34.34. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 489.2. HRMS (ESI): calcd for C<sub>21</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub>S, 489.2027; found, 489.2026. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +12.60 (<i>c</i> 0.06, CH<sub>3</sub>OH).</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-(((1<i>R</i>,2<i>S</i>)-2-(2-methoxyethoxy)-2,3-dihydro-1<i>H</i>-inden-1-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>21</b>)</h4><div class="NLM_p last">White solid (23.7 mg, 9.1%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.43 (s, 0.71H), 8.27 (s, 0.20H), 7.34–7.12 (m, 4H), 6.59 (d, J = 5.3 Hz, 0.22H), 6.02 (d, J = 5.4 Hz, 0.76H), 5.67–5.57 (m, 1H), 4.60–4.53 (m, 1H), 4.53–4.46 (m, 1H), 4.40 (dd, J = 9.8, 7.5 Hz, 1H), 4.23 (dd, J = 9.8, 7.3 Hz, 1H), 3.77–3.67 (m, 1H), 3.67–3.56 (m, 1H), 3.48–3.38 (m, 2H), 3.25–3.20 (m, 3H), 3.20–3.11 (m, 2H), 2.97–2.85 (m, 1H), 2.66–2.56 (m, 1H), 2.49–2.40 (m, 1H), 2.36–2.27 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.71, 157.58, 156.30, 149.38, 142.16, 141.64, 129.25, 127.92, 126.29, 126.14, 125.45, 82.43, 73.08, 72.91, 70.50, 70.36, 59.11, 58.30, 57.80, 44.78, 42.99, 37.74, 34.41. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 520.2. HRMS (ESI): calcd for C<sub>22</sub>H<sub>30</sub>N<sub>7</sub>O<sub>6</sub>S, 520.1973; found, 520.1973. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +19.00 (<i>c</i> 0.07, CH<sub>3</sub>OH).</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-(((1<i>R</i>,2<i>S</i>)-2-(2-methoxyacetamido)-2,3-dihydro-1<i>H</i>-inden-1-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>22</b>)</h4><div class="NLM_p last">White solid (19.3 mg, 10.2%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.43 (s, 0.73 H), 8.28 (s, 0.20H), 7.42–7.22 (m, 4H), 6.68 (d, <i>J</i> = 6.4 Hz, 0.2H), 6.12 (d, <i>J</i> = 6.6 Hz, 0.76H), 5.67–5.56 (m, 1H), 5.19–5.12 (m, 0.22H), 5.10–5.01 (m, 0.80H), 4.61–4.53 (m, 1H), 4.40 (dd, <i>J</i> = 9.9, 7.4 Hz, 1H), 4.22 (dd, <i>J</i> = 9.8, 7.2 Hz, 1H), 3.78–3.69 (m, 1H), 3.68–3.60 (m, 1H), 3.39–3.32 (m, 1H), 3.20 (s, 0.65 H), 3.15 (d, <i>J</i> = 5.4 Hz, 0.52 H), 3.12 (s, 3H), 2.96–2.82 (m, 1H), 2.65–2.53 (m, 1H), 2.49–2.38 (m, 1H), 2.38–2.24 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 172.59, 157.14, 156.12, 149.37, 141.99, 141.16, 129.89, 128.47, 126.23, 126.03, 73.09, 72.40, 70.54, 59.29, 58.02, 57.88, 53.40, 44.80, 42.98, 37.66, 34.43. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 513.7. HRMS (ESI): calcd for C<sub>22</sub>H<sub>27</sub>N<sub>8</sub>O<sub>6</sub>S, 531.1780; found, 531.1788. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –30.60 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-(((1<i>R</i>,2<i>R</i>)-2-(2-methoxyacetamido)-2,3-dihydro-1<i>H</i>-inden-1-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>23</b>)</h4><div class="NLM_p last">White solid (33.2 mg, 14.7%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.38 (s, 0.73H), 8.27 (s, 0.17H), 7.24 (d, <i>J</i> = 18.1 Hz, 4H), 6.71 (d, <i>J</i> = 8.5 Hz, 0.18H), 6.18 (d, <i>J</i> = 8.9 Hz, 1H), 5.67–5.54 (m, 1H), 4.73 (q, <i>J</i> = 9.0 Hz, 1H), 4.59–4.53 (m, 1H), 4.40 (dd, <i>J</i> = 9.8, 7.5 Hz, 1H), 4.23 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 3.91–3.73 (m, 1.77H), 3.67–3.61 (m, 0.17H), 3.41 (d, <i>J</i> = 8.0 Hz, 0.40H), 3.39 (s, 0.23H), 3.37 (s, 3H), 3.21 (s, 0.6 H), 3.03–2.93 (m, 1H), 2.93–2.84 (m, 1H), 2.65–2.53 (m, 1H), 2.50–2.38 (m, 1H), 2.37–2.25 (m, 2H). <sup>13</sup>C NMR (151 MHz, methanol-<i>d</i><sub>4</sub>): δ 172.99, 157.53, 156.91, 149.40, 141.52, 140.99, 129.36, 128.19, 126.15, 125.89, 124.64, 73.08, 72.60, 70.47, 60.86, 59.55, 59.41, 57.73, 44.78, 42.99, 37.15, 34.39. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 513.6. HRMS (ESI): calcd for C<sub>22</sub>H<sub>27</sub>N<sub>8</sub>O<sub>6</sub>S, 531.1780; found, 531.1785. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +19.00 (<i>c</i> 0.07, CH<sub>3</sub>OH).</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>tert</i>-Butyl(<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>31</b>)</h4><div class="NLM_p">To a solution of <b>39</b> (1 mmol) in CH<sub>3</sub>CN (5 mL) were added compound <b>47</b> (393 mg, 1.3 mmol) and DIPEA (0.5 mL, 3 mmol). The mixture was stirred at rt for 6–8 h. The reaction was monitored by TLC. After completion, the mixture was concentrated in vacuo and the residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 100:1 to 20:1) to give compound <b>48</b> (291 mg, 54.4%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.39 (s, 0.63H), 8.22 (s, 0.20H), 7.35–7.16 (m, 4H), 6.60 (t, <i>J</i> = 7.7 Hz, 0.19H), 6.06 (t, <i>J</i> = 7.9 Hz, 0.69H), 5.63–5.52 (m, 1H), 4.60–4.53 (m, 1H), 4.15–4.06 (m, 2H), 3.84 (dd, <i>J</i> = 10.8, 7.1 Hz, 1H), 3.70 (dd, <i>J</i> = 10.9, 6.3 Hz, 1H), 3.17–2.86 (m, 3H), 2.72–2.51 (m, 2H), 2.46–2.36 (m, 1H), 2.32–2.16 (m, 1H), 2.14–2.03 (m, 1H), 1.96 (dd, <i>J</i> = 13.0, 8.2 Hz, 1H), 1.72–1.55 (m, 3H), 1.48 (s, 9H).</div><div class="NLM_p last">Compound <b>48</b> (294 mg, 0.54 mmol) was converted to the target compound <b>31</b> as a white solid (43.2 mg, 13%) through using chlorosulfonamide as a sulfonylation reagent. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.40 (s, 0.72H), 8.23 (s, 0.18H), 7.35–7.15 (m, 4H), 6.60 (t, <i>J</i> = 7.8 Hz, 0.21H), 6.06 (t, <i>J</i> = 7.9 Hz, 0.77H), 5.66–5.55 (m, 1H), 4.60–4.54 (m, 1H), 4.40 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.23 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 4.11 (d, <i>J</i> = 13.6 Hz, 2H), 3.18–2.95 (m, 2H), 2.95–2.85 (m, 2H), 2.66–2.55 (m, 1H), 2.49–2.40 (m, 1H), 2.36–2.25 (m, 2H), 2.09 (td, <i>J</i> = 13.2, 4.4 Hz, 1H), 1.97 (dd, <i>J</i> = 13.0, 8.2 Hz, 1H), 1.73–1.56 (m, 3H), 1.49 (s, 9H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.64, 156.61, 156.11, 151.47, 149.33, 143.16, 129.59, 128.64, 126.19, 125.39, 123.77, 81.10, 73.09, 70.52, 57.78, 54.58, 46.27, 44.79, 44.03, 43.14, 43.01, 38.67, 37.71, 34.39, 28.73. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 613.8. HRMS (ESI): calcd for C<sub>28</sub>H<sub>37</sub>N<sub>8</sub>O<sub>6</sub>S, 613.2562; found, 613.2560. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –15.67 (<i>c</i> 0.03, CH<sub>3</sub>OH).</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-(((<i>S</i>)-2,3-Dihydrospiro[indene-1,4′-piperidin]-3-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl)methyl Sulfamate (<b>24</b>)</h4><div class="NLM_p last">Compound <b>31</b> (41 mg, 0.067 mmol) was dissolved in MeOH and treated with 4 M HCl in MeOH (0.17 mL, 0.67 mmol). The reaction mixture was then neutralized with NaHCO<sub>3</sub> (aq) and extracted with DCM. The organic phase was separated and washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 60:1 to 15:1) to give a crude product, which was further purified using reverse-phase HPLC to give compound <b>24</b> as a white solid (26.5 mg, 76.2%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.40 (s, 0.73H), 8.24 (s, 0.2H), 7.32 (d, <i>J</i> = 3.5 Hz, 2H), 7.29–7.17 (m, 2H), 6.58 (t, <i>J</i> = 7.6 Hz, 0.21H), 6.04 (t, <i>J</i> = 7.9 Hz, 0.76H), 5.66–5.55 (m, 1H), 4.62–4.53 (m, 1H), 4.40 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.23 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 3.11–2.98 (m, 2H), 2.97–2.86 (m, 3H), 2.80 (td, <i>J</i> = 12.7, 2.6 Hz, 1H), 2.65–2.54 (m, 1H), 2.49–2.39 (m, 1H), 2.37–2.24 (m, 2H), 2.17 (td, <i>J</i> = 13.0, 4.2 Hz, 1H), 1.99–1.89 (m, 1H), 1.82–1.56 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.65, 156.11, 152.07, 149.33, 143.04, 129.54, 128.54, 126.20, 125.37, 123.80, 73.10, 70.49, 57.79, 54.63, 46.30, 44.82, 44.51, 43.93, 43.90, 43.01, 38.94, 37.96, 34.40. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 513.8. HRMS (ESI): calcd for C<sub>23</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub>S, 513.2038; found, 513.2029. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +14.60 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-(((<i>S</i>)-1′-methyl-2,3-dihydrospiro[indene-1,4′-piperidin]-3-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl)methyl Sulfamate (<b>25</b>)</h4><div class="NLM_p last">To a solution of compound <b>24</b> (79 mg, 0.154 mmol) in anhydrous DMF (1 mL) were added DIPEA (30 μL, 0.23 mmol) and CH<sub>3</sub>I (19 mg, 0.13 mmol). The mixture was stirred at rt for 15 min and then concentrated in vacuo. The residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 100:1 to 20:1) to give a crude product, which was further purified using reverse-phase HPLC to give compound <b>25</b> (48 mg, 29.6%) as a white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.41 (s, 0.72 H), 8.24 (s, 0.2 H), 7.32 (d, <i>J</i> = 4.0 Hz, 2H), 7.29–7.19 (m, 2H), 6.57 (t, <i>J</i> = 7.6 Hz, 0.21H), 6.03 (t, <i>J</i> = 7.9 Hz, 0.76H), 5.68–5.55 (m, 1H), 4.60–4.54 (m, 1H), 4.40 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.23 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 2.98–2.79 (m, 4H), 2.66–2.55 (m, 1H), 2.50–2.39 (m, 1H), 2.39–2.20 (m, 8H), 1.95–1.79 (m, 2H), 1.76–1.59 (m, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.65, 156.10, 151.72, 149.33, 143.21, 129.56, 128.59, 126.20, 125.38, 123.75, 73.10, 70.52, 57.78, 54.61, 54.34, 53.71, 46.44, 45.34, 44.81, 43.86, 43.02, 38.63, 37.74, 34.41. ESI ([M – H]<sup>+</sup>) <i>m</i>/<i>z</i>: 527.8. HRMS (ESI): calcd for C<sub>24</sub>H<sub>31</sub>N<sub>8</sub>O<sub>4</sub>S, 527.2194; found, 527.2206. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +2.17 (<i>c</i> 0.06, CH<sub>3</sub>OH).</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Methyl (<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>26</b>)</h4><div class="NLM_p">To a solution of compound <b>24</b> (60 mg, 0.117 mmol) in anhydrous DMF (1 mL) were added DIPEA (39 μL, 0.24 mmol) and methyl chloroformate (12.2 mg, 0.13 mmol). The mixture was stirred at rt for 30 min and then concentrated in vacuo. The residue was purified by silica column chromatography (PE/EA from 1:1 to 1:20) to give a crude product, which was further purified using reverse-phase HPLC to afford compound <b>26</b> as a white solid (39.6 mg, 44.2%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.40 (s, 0.74 H), 8.25 (s, 0.19 H), 7.36–7.20 (m, 4H), 6.61 (t, <i>J</i> = 7.8 Hz, 0.22H), 6.06 (t, <i>J</i> = 7.9 Hz, 0.77H), 5.67–5.56 (m, 1H), 4.61–4.55 (m, 1H), 4.38 (dd, <i>J</i> = 9.8, 7.5 Hz, 1H), 4.21 (dd, <i>J</i> = 9.8, 7.2 Hz, 1H), 4.15 (d, <i>J</i> = 13.4 Hz, 2H), 3.72 (s, 3H), 3.22–3.08 (m, 1H), 3.08–2.98 (m, 1H), 2.97–2.85 (m, 2H), 2.65–2.55 (m, 1H), 2.49–2.40 (m, 1H), 2.37–2.25 (m, 2H), 2.11 (td, <i>J</i> = 13.1, 4.5 Hz, 1H), 1.98 (dd, <i>J</i> = 13.0, 8.2 Hz, 1H), 1.76–1.56 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.77, 157.59, 156.13, 151.42, 149.36, 143.17, 129.61, 128.69, 126.21, 125.44, 123.81, 73.12, 70.26, 57.82, 54.59, 53.28, 46.24, 44.88, 44.02, 43.12, 42.96, 42.42, 38.60, 37.62, 34.38. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 573.2. HRMS (ESI): calcd for C<sub>25</sub>H<sub>33</sub>N<sub>8</sub>O<sub>6</sub>S, 573.2238; found, 573.2240. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –23.83 (<i>c</i> 0.06, CH<sub>3</sub>OH).</div><div class="NLM_p last">Compounds <b>27–29</b> were prepared by following similar procedures to that used for compound <b>26</b>.</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Ethyl (<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>27</b>)</h4><div class="NLM_p last">White solid (19.2 mg, 32.7%). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.38 (s, 0.74H), 8.19 (s, 0.21H), 7.33–7.23 (m, 3H), 7.21 (q, <i>J</i> = 6.6, 6.0 Hz, 1H), 6.59 (t, <i>J</i> = 7.5 Hz, 0.21H), 6.05 (t, <i>J</i> = 7.9 Hz, 0.76H), 5.63–5.55 (m, 1H), 4.58–4.54 (m, 1H), 4.40 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.22 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 4.18–4.09 (m, 4H), 3.20–3.06 (m, 1H), 3.05–2.94 (m, 1H), 2.94–2.84 (m, 2H), 2.62–2.54 (m, 1H), 2.48–2.40 (m, 1H), 2.36–2.25 (m, 2H), 2.10 (td, <i>J</i> = 13.1, 4.5 Hz, 1H), 1.97 (dd, <i>J</i> = 13.0, 8.0 Hz, 1H), 1.72–1.56 (m, 3H), 1.27 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.64, 157.31, 156.07, 151.38, 149.31, 143.11, 129.58, 128.63, 126.17, 125.40, 123.76, 73.08, 70.50, 62.68, 57.78, 54.58, 46.24, 44.78, 44.05, 43.14, 42.98, 42.30, 38.57, 37.59, 34.37, 14.99. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 587.3. HRMS (ESI): calcd for C<sub>26</sub>H<sub>35</sub>N<sub>8</sub>O<sub>6</sub>S, 587.2395; found, 587.2396. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –20.00 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-Fluoroethyl (<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>28</b>)</h4><div class="NLM_p last">White solid (22 mg, 36.4%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.40 (s, 0.73H), 8.24 (s, 0.20H), 7.35–7.20 (m, 4H), 6.61 (t, <i>J</i> = 7.8 Hz, 0.23H), 6.07 (t, <i>J</i> = 7.9 Hz, 0.77H), 5.66–5.56 (m, 1H), 4.71–4.64 (m, 1H), 4.60–4.52 (m, 2H), 4.43–4.35 (m, 2H), 4.32–4.27 (m, 1H), 4.26–4.13 (m, 3H), 3.26–3.12 (m, 1H), 3.10–2.97 (m, 1H), 2.97–2.85 (m, 2H), 2.66–2.55 (m, 1H), 2.48–2.40 (m, 1H), 2.36–2.26 (m, 2H), 2.13 (td, <i>J</i> = 13.1, 4.4 Hz, 1H), 1.98 (dd, <i>J</i> = 13.0, 8.2 Hz, 1H), 1.77–1.58 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.71, 157.59, 156.83, 156.12, 151.37, 149.35, 143.16, 129.61, 128.69, 126.20, 125.43, 123.80, 82.91 (d, <i>J</i> = 169.0 Hz), 73.10, 70.50, 66.03 (d, <i>J</i> = 19.8 Hz), 57.79, 54.58, 46.24, 44.81, 44.03, 43.13, 43.00, 42.47, 38.56, 37.57, 34.39. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 605.2. HRMS (ESI): calcd for C<sub>26</sub>H<sub>34</sub>FN<sub>8</sub>O<sub>6</sub>S, 605.2301; found, 605.2302. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –14.00 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Isopropyl (<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>29</b>)</h4><div class="NLM_p last">White solid (23.6 mg, 33.6%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.38 (s, 0.75H), 8.16 (s, 0.22H), 7.34–7.23 (m, 3H), 7.20 (q, <i>J</i> = 7.3, 6.2 Hz, 1H), 6.58 (t, <i>J</i> = 7.7 Hz, 0.22H), 6.04 (t, <i>J</i> = 7.9 Hz, 0.76H), 5.63–5.53 (m, 1H), 4.59–4.53 (m, 1H), 4.39 (dd, <i>J</i> = 9.7, 7.5 Hz, 1H), 4.22 (dd, <i>J</i> = 9.8, 7.2 Hz, 1H), 4.13 (d, <i>J</i> = 12.9 Hz, 2H), 3.17–3.04 (m, 1H), 3.04–2.94 (m, 1H), 2.94–2.82 (m, 2H), 2.63–2.51 (m, 1H), 2.48–2.38 (m, 1H), 2.35–2.24 (m, 2H), 2.09 (td, <i>J</i> = 13.1, 4.5 Hz, 1H), 1.96 (dd, <i>J</i> = 13.0, 8.2 Hz, 1H), 1.72–1.55 (m, 3H), 1.26 (d, <i>J</i> = 5.5 Hz, 6H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.63, 156.92, 156.05, 151.38, 149.29, 143.10, 129.57, 128.62, 126.15, 125.39, 123.75, 73.06, 70.50, 70.23, 57.77, 54.57, 49.34, 46.24, 44.76, 44.06, 43.14, 42.97, 42.24, 38.58, 37.60, 34.36, 22.46. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 601.3. HRMS (ESI): calcd for C<sub>27</sub>H<sub>37</sub>N<sub>8</sub>O<sub>6</sub>S, 601.2551; found, 601.2550. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –28.60 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1,1,1,3,3,3-Hexafluoropropan-2-yl (<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>30</b>)</h4><div class="NLM_p">To a solution of compound <b>24</b> (70 mg, 0.136 mmol) in anhydrous DMF (1 mL) were added DIPEA (45 μL, 0.27 mmol) and 1,1,1,3,3,3-hexafluoropropan-2-yl (4-nitrophenyl)carbonate (59 mg, 0.18 mmol). The mixture was stirred at rt for 1 h and then concentrated in vacuo. The residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 100:1 to 20:1) to give a crude product, which was further purified using reverse-phase HPLC to afford compound <b>30</b> as a white solid (11.3 mg, 23.5%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.41 (s, 0.72H), 8.27 (s, 0.21 H), 7.37–7.21 (m, 4H), 6.63 (t, <i>J</i> = 7.7 Hz, 0.2 H), 6.23–6.12 (m, 1H), 6.09 (t, <i>J</i> = 7.9 Hz, 0.76H), 5.67–5.56 (m, 1H), 4.60–4.55 (m, 1H), 4.40 (dd, <i>J</i> = 9.7, 7.4 Hz, 1H), 4.27–4.11 (m, 3H), 3.29–3.02 (m, 2H), 3.01–2.84 (m, 2H), 2.67–2.55 (m, 1H), 2.50–2.40 (m, 1H), 2.38–2.24 (m, 2H), 2.24–2.08 (m, 1H), 2.06–1.96 (m, 1H), 1.81–1.65 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.72, 157.59, 157.19, 156.15, 152.82, 150.97, 149.37, 143.22, 129.68, 128.83, 126.23, 125.50, 123.77, 73.11, 70.51, 69.20 (p, <i>J</i> = 34.3 Hz), 57.81, 54.56, 46.12, 44.83, 44.03, 43.52, 43.11, 43.01, 38.58, 37.60, 34.40. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 709.1. HRMS (ESI): calcd for C<sub>27</sub>H<sub>31</sub>F<sub>6</sub>N<sub>8</sub>O<sub>6</sub>S, 709.1986; found, 709.1977. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –8.00 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div><div class="NLM_p last">Compounds <b>32–33</b> were prepared by following similar procedures to that used for compound <b>30</b>.</div></div><div id="sec5_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1,3-Dihydroxypropan-2-yl (<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>32</b>)</h4><div class="NLM_p last">White solid (17 mg, 23.0%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.40 (s, 0.74H), 8.23 (s, 0.21H), 7.37–7.18 (m, 4H), 6.60 (t, <i>J</i> = 7.8 Hz, 0.22H), 6.06 (t, <i>J</i> = 7.9 Hz, 0.76H), 5.66–5.54 (m, 1H), 4.83–4.75 (m, 1H), 4.61–4.53 (m, 1H), 4.39 (dd, <i>J</i> = 9.8, 7.5 Hz, 1H), 4.29–4.11 (m, 3H), 3.80–3.64 (m, 4H), 3.23–3.09 (m, 1H), 3.09–2.96 (m, 1H), 2.96–2.83 (m, 2H), 2.64–2.54 (m, 1H), 2.49–2.39 (m, 1H), 2.36–2.25 (m, 2H), 2.23–2.07 (m, 1H), 1.98 (dd, <i>J</i> = 13.1, 8.1 Hz, 1H), 1.80–1.55 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.64, 157.03, 156.09, 151.48, 149.33, 143.12, 129.57, 128.64, 126.19, 125.40, 123.80, 78.07, 73.10, 70.39, 62.03, 57.80, 54.61, 46.27, 44.82, 44.08, 43.18, 42.97, 42.46, 38.53, 37.56, 34.38. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 633.3. HRMS (ESI): calcd for C<sub>27</sub>H<sub>37</sub>N<sub>8</sub>O<sub>8</sub>S, 633.2450; found, 633.2453. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –14.78 (<i>c</i> 0.09, CH<sub>3</sub>OH).</div></div><div id="sec5_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-Morpholinoethyl (<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>33</b>)</h4><div class="NLM_p">White solid (20.8 mg, 26.5%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.38 (s, 0.74H), 8.16 (s, 0.23H), 7.33–7.16 (m, 4H), 6.58 (t, <i>J</i> = 7.6 Hz, 0.24H), 6.04 (t, <i>J</i> = 7.9 Hz, 0.77H), 5.63–5.53 (m, 1H), 4.58–4.52 (m, 1H), 4.39 (dd, <i>J</i> = 9.8, 7.4 Hz, 1H), 4.28–4.18 (m, 3H), 4.13 (d, <i>J</i> = 12.3 Hz, 2H), 3.69 (t, <i>J</i> = 4.7 Hz, 4H), 3.21–3.05 (m, 1H), 3.05–2.94 (m, 1H), 2.94–2.82 (m, 2H), 2.67 (t, <i>J</i> = 5.7 Hz, 2H), 2.62–2.49 (m, 5H), 2.46–2.38 (m, 1H), 2.34–2.24 (m, 2H), 2.10 (td, <i>J</i> = 13.0, 4.4 Hz, 1H), 1.96 (dd, <i>J</i> = 13.0, 8.1 Hz, 1H), 1.72–1.55 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.64, 157.01, 156.05, 151.36, 149.31, 143.12, 129.59, 128.65, 126.17, 125.43, 123.74, 73.07, 70.51, 67.68, 63.69, 58.50, 57.78, 54.91, 54.58, 46.23, 44.77, 44.10, 43.16, 42.99, 42.44, 38.54, 37.59, 34.39. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 672.4. HRMS (ESI): calcd for C<sub>30</sub>H<sub>42</sub>N<sub>9</sub>O<sub>7</sub>S, 672.2922; found, 672.2923. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –3.33 (<i>c</i> 0.06, CH<sub>3</sub>OH).</div><div class="NLM_p last">Compounds <b>34–35</b> were prepared by following similar procedures to that used for compound <b>26</b>.</div></div><div id="sec5_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>R</i>)-Tetrahydrofuran-3-yl (<i>S</i>)-3-((3-((1<i>R</i>,3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-((sulfamoyloxy)methyl)cyclopentyl)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)amino)-2,3-dihydrospiro[indene-1,4′-piperidine]-1′-carboxylate (<b>34</b>)</h4><div class="NLM_p last">White solid (24.8 mg, 33.7%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.41 (s, 0.72H), 8.26 (s, 0.25H), 7.38–7.17 (m, 4H), 6.61 (t, <i>J</i> = 7.7 Hz, 0.26H), 6.07 (t, <i>J</i> = 7.9 Hz, 0.75H), 5.68–5.55 (m, 1H), 5.28–5.19 (m, 1H), 4.61–4.53 (m, 1H), 4.36 (dd, <i>J</i> = 9.8, 7.7 Hz, 1H), 4.23–4.07 (m, 3H), 3.96–3.77 (m, 4H), 3.26–3.10 (m, 1H), 3.10–2.96 (m, 1H), 2.96–2.84 (m, 2H), 2.66–2.55 (m, 1H), 2.49–2.40 (m, 1H), 2.35–2.27 (m, 2H), 2.27–2.02 (m, 3H), 1.98 (dd, <i>J</i> = 13.0, 8.2 Hz, 1H), 1.76–1.58 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 157.70 and 157.57 (1C), 156.72, 156.12, 151.36, 149.36, 143.18, 129.60, 128.69, 126.21, 125.44, 123.79, 77.47, 74.24, 73.15, 69.87, 67.97, 57.84, 54.58, 46.23, 44.98, 44.02, 43.12, 42.89, 42.38, 38.59, 37.59, 34.35, 33.78. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 629.2. HRMS (ESI): calcd for C<sub>28</sub>H<sub>37</sub>N<sub>8</sub>O<sub>7</sub>S, 629.2500; found, 629.2492. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> +4.00 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div></div><div id="sec5_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-2-Hydroxy-4-(7-(((<i>S</i>)-1′-(2-methoxyacetyl)-2,3-dihydrospiro[indene-1,4′-piperidin]-3-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)cyclopentyl) Methyl Sulfamate (<b>35</b>)</h4><div class="NLM_p last">White solid (23 mg, 33.5%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.40 (s, 0.71H), 8.23 (s, 0.20H), 7.36–7.18 (m, 4H), 6.61 (t, <i>J</i> = 7.8 Hz, 0.22H), 6.07 (t, <i>J</i> = 7.9 Hz, 0.74H), 5.66–5.55 (m, 1H), 4.60–4.49 (m, 2H), 4.37 (dd, <i>J</i> = 9.8, 7.6 Hz, 1H), 4.30–4.14 (m, 3H), 3.89 (d, <i>J</i> = 13.8 Hz, 1H), 3.46–3.41 (m, 3H), 3.39–3.33 (m, 0.41H), 3.28–3.19 (m, 0.59H), 3.10–2.79 (m, 3H), 2.64–2.54 (m, 1H), 2.49–2.39 (m, 1H), 2.35–2.24 (m, 2H), 2.23–2.06 (m, 1H), 2.02 (dd, <i>J</i> = 13.0, 8.1 Hz, 1H), 1.81–1.62 (m, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 169.95, 157.69, 157.58, 157.11, 156.11, 151.14, 151.08, 149.34, 143.18, 129.77, 129.63, 128.75, 126.19, 125.47, 123.79, 73.13, 71.95, 70.05, 59.38, 57.83, 54.60, 54.55, 46.44, 44.93, 44.26, 43.98, 43.46, 43.35, 42.91, 41.02, 40.52, 39.18, 38.44, 38.15, 37.52, 34.36. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 587.3. HRMS (ESI): calcd for C<sub>26</sub>H<sub>35</sub>N<sub>8</sub>O<sub>6</sub>S, 587.2395; found, 587.2384. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –12.83 (<i>c</i> 0.06, CH<sub>3</sub>OH).</div></div><div id="sec5_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> ((1<i>S</i>,2<i>S</i>,4<i>R</i>)-4-(7-(((<i>S</i>)-1′-(<i>tert</i>-Butylcarbamoyl)-2,3-dihydrospiro[indene-1,4′-piperidin]-3-yl)amino)-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-2-hydroxycyclopentyl) Methyl Sulfamate (<b>36</b>)</h4><div class="NLM_p last">To a solution of compound <b>24</b> (60 mg, 0.117 mmol) in anhydrous DMF (1 mL) were added DIPEA (39 μL, 0.24 mmol) and <i>tert</i>-butylisocyanate (15 mg, 0.15 mmol). The mixture was stirred at rt for 1 h and then concentrated in vacuo. The residue was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>3</sub> 7.0 M solution in CH<sub>3</sub>OH from 60:1 to 20:1) to give a crude product, which was further purified using reverse-phase HPLC to give compound <b>36</b> as a white solid (14 mg, 19.5%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>): δ 8.40 (s, 0.68H), 8.23 (s, 0.20H), 7.36–7.18 (m, 4H), 6.61 (t, <i>J</i> = 7.6 Hz, 0.22H), 6.06 (t, <i>J</i> = 7.9 Hz, 0.73H), 5.66–5.55 (m, 1H), 4.60–4.54 (m, 1H), 4.39 (dd, <i>J</i> = 9.8, 7.5 Hz, 1H), 4.22 (dd, <i>J</i> = 9.8, 7.3 Hz, 1H), 4.01 (t, <i>J</i> = 12.0 Hz, 2H), 3.12–2.99 (m, 1H), 2.98–2.85 (m, 3H), 2.65–2.55 (m, 1H), 2.48–2.40 (m, 1H), 2.37–2.26 (m, 2H), 2.13 (td, <i>J</i> = 13.0, 4.3 Hz, 1H), 1.97 (dd, <i>J</i> = 13.1, 8.0 Hz, 1H), 1.76–1.57 (m, 3H), 1.36 (s, 9H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>): δ 159.68, 157.71, 156.11, 151.61, 149.33, 143.17, 129.57, 128.60, 126.19, 125.38, 123.77, 73.10, 70.39, 57.79, 54.58, 51.70, 46.33, 44.84, 43.30, 43.13, 42.99, 42.48, 38.75, 37.80, 34.38, 29.78. ESI ([M + H]<sup>+</sup>) <i>m</i>/<i>z</i>: 614.2. HRMS (ESI): calcd for C<sub>28</sub>H<sub>40</sub>N<sub>9</sub>O<sub>5</sub>S, 614.2868; found, 614.2855. [α]<sub class="stack">D</sub><sup class="stack">26.3</sup> –3.86 (<i>c</i> 0.05, CH<sub>3</sub>OH).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> In Vitro Enzyme Assays</h3><div class="NLM_p last">Homogeneous time-resolved fluorescence (HTRF) assay was used to measure the in vitro activity of NAE or UAE as previously reported.<a onclick="showRef(event, 'ref27 ref45'); return false;" href="javascript:void(0);" class="ref ref27 ref45">(27,45)</a> Briefly, 10 μL of the reaction system containing 150 nM His-NEDD8, 80 nM GST-Ubc12, and 2 nM NAE recombinant enzyme (R&D systems, USA) in reaction buffer [50 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES), 5 mM MgCl<sub>2</sub>, 20 μM ATP, 250 μM <span class="smallcaps smallerCapital">l</span>-glutathione, 0.05% bovine serum albumin, and pH 7.5] was used to identify inhibitors of NAE. The reaction mixture was incubated at 27 °C for 2 h in a 384-well plate, and the reaction was stopped by stop/detection buffer [0.1 M HEPES, 20 mM ethylenediaminetetraacetic acid, 410 mM KF, 0.05% Tween 20, pH 7.5, 0.25 μg/mL MAb anti 6HIS-Eu and 2 μg/mL MAb anti GST-XL665 (CisBio International)]. After incubating overnight, the plate was read on the PerkinElmer EnVision using 330 nm excitation/620 nm emission and 330 nm excitation/665 nm emission. The inhibition rate (%) was calculated as: [1 – (HTRF value (compound)/HTRF value (control)] × 100%. The mean IC<sub>50</sub> values were determined with the Logit method from three independent assays. A similar assay protocol was used to measure UAE enzymes.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Western Blot Analysis</h3><div class="NLM_p last">Immunoblotting after sodium dodecyl sulfate-polyacrylamide gel electrophoresis conducted under nonreducing conditions for E2-UBL thioesters or reducing conditions for other proteins was carried out as previously described.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Primary antibodies against Ubc12 (#5641), NEDD8 (#2754), UbcH10 (#14234), Ubc9 (#4786), CDT1 (#8064), p27 (#3688), p-IκBα (Ser32/36) (#9246), p-Chk1 (Ser317) (#2344), Chk1 (#2360), γ-H2AX (#2577), Caspase-3 (#9662), Cleaved Caspase-3 (#9661), Caspase-7 (#9492), cleaved Caspase-7 (#8438), and cleaved PARP (#5625) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against Cul1 (sc-17775), UBA3 (sc-377272), PARP1 (sc-7150), and p21 (sc-271610) were purchased from Santa Cruz (Dallas, TX, USA). Antibody against GAPDH was purchased from Beyotime Biotechnology (Shanghai, China). The primary antibodies were diluted at 1:1000 with QuickBlock Western dilution reagent (Beyotime). The secondary antibodies (1:2000) including HRP-conjugated goat anti-rabbit and goat anti-mouse antibodies used for Western blotting were purchased from Jackson ImmunoResearch (West Grove, PA, USA).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Cell Viability Assays</h3><div class="NLM_p last">Cells viability was assessed using the sulforhodamine B (SRB) assays as previously described<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> after cells cultured in 96-well plates were treated with the indicated drugs for 3 days.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Cell Cycle Analysis</h3><div class="NLM_p last">HCT-116 cells were incubated with the indicated drugs for 24 h and analyzed by PI staining-based flow cytometry as previously described<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a>. Caspase-Glo 3/7 assays. HCT-116 cells were seeded into the 96-well plates and treated with indicated drugs for 48 h. Caspase-3/7 activities were assessed using the Caspase-Glo 3/7 Assay Reagent (Promega) according to the manufacturer′s protocol.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> In Vivo Anticancer Activity Experiments</h3><div class="NLM_p last">HCT-116 and MV-4-11 xenografts were established by inoculating 5 × 10<sup>6</sup> cells s.c. in nude mice, respectively. The efficacy study was initiated when tumors had reached approximately 150 mm<sup>3</sup>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Tumor-bearing mice were randomly assigned to control and treatment groups and received the corresponding treatments as indicated. Tumor and body weight measurements were performed twice a week. All procedures for animal studies were approved by the Institutional Animal Care and Use Committee of the Shanghai Institute of Materia Medica.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00242" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47671" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47671" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00242?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00242</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H and <sup>13</sup>C spectra of all new compounds, HPLC of representative compounds, X-ray crystallographic data for analogues of compound <b>26</b>, and KINOMEscan kinase selectivity profile for compounds <b>1</b> and <b>26</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_001.pdf">jm1c00242_si_001.pdf (8.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_002.csv">jm1c00242_si_002.csv (3.76 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00242" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin-xue He</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#deb4b7b0a6abbb81b6bb9eadb7b3b3f0bfbdf0bdb0"><span class="__cf_email__" data-cfemail="c3a9aaadbbb6a69caba683b0aaaeaeeda2a0eda0ad">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ze-Hong Miao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9de7f5f0f4fcf2ddeef4f0f0b3fcfeb3fef3"><span class="__cf_email__" data-cfemail="6b110306020a042b18020606450a08450805">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ao Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharm-X
Center, School of Pharmacy, Shanghai Jiao
Tong University, Shanghai 200240, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span>; 
    <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory for Molecular Engineering of Chiral Drugs, School of
Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China</span>; 
    <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Esophageal Cancer Prevention and Treatment, Ministry
of Education of China, Zhengzhou University, Zhengzhou 450001, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7205-9202" title="Orcid link">http://orcid.org/0000-0001-7205-9202</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#23424c151a121a594b424d4463504957560d4647560d404d"><span class="__cf_email__" data-cfemail="15747a232c242c6f7d747b7255667f61603b7071603b767b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chaodong Xiong</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharm-X
Center, School of Pharmacy, Shanghai Jiao
Tong University, Shanghai 200240, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lina Zhou</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Tan</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharm-X
Center, School of Pharmacy, Shanghai Jiao
Tong University, Shanghai 200240, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanshan Song</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xubin Bao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ning Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huaqian Ding</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiannan Zhao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
(SIMM), Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharm-X
Center, School of Pharmacy, Shanghai Jiao
Tong University, Shanghai 200240, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Life Science and Technology, ShanghaiTech
University, Shanghai 201210, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.X. and L.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from the National Natural Science Foundation of China (grants 81773565, 82073875, 82073865, and 81703327). The start-up grants from Shanghai Jiao Tong University to the Research Laboratory of Medicinal Chemical Biology & Frontiers on Drug Discovery (AF1700037 and WF220217002) to the Platform on Target Identification of Innovative drugs (WH10117001) are also appreciated.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviationspara</td></tr><tr><td class="NLM_term">Ub</td><td class="NLM_def"><p class="first last">ubiquitin</p></td></tr><tr><td class="NLM_term">Ubl</td><td class="NLM_def"><p class="first last">ubiquitin-like</p></td></tr><tr><td class="NLM_term">UPS</td><td class="NLM_def"><p class="first last">ubiquitin-proteasome system</p></td></tr><tr><td class="NLM_term">NEDD8</td><td class="NLM_def"><p class="first last">neural precursor cell-expressed developmentally downregulated 8</p></td></tr><tr><td class="NLM_term">NAE</td><td class="NLM_def"><p class="first last">NEDD8-activating enzyme</p></td></tr><tr><td class="NLM_term">AMP</td><td class="NLM_def"><p class="first last">adenosine 5′-monophosphate</p></td></tr><tr><td class="NLM_term">ORR</td><td class="NLM_def"><p class="first last">overall response rate</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">MDS</td><td class="NLM_def"><p class="first last">myelodysplastic syndrome</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">Structure–activity relationship</p></td></tr><tr><td class="NLM_term">UAE</td><td class="NLM_def"><p class="first last">ubiquitin-activating enzyme</p></td></tr><tr><td class="NLM_term">SAE</td><td class="NLM_def"><p class="first last">SUMO activation enzyme E1</p></td></tr><tr><td class="NLM_term">CRLs</td><td class="NLM_def"><p class="first last">Cullin-RING ligases</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the plasma concentration–time curve</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">Vss</td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">tPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">SRB</td><td class="NLM_def"><p class="first last">sulforhodamine B</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hershko, A.</span></span> <span> </span><span class="NLM_article-title">The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1191</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4401702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fsj.cdd.4401702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=16094395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnt1Shtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=1191-1197&author=A.+Hershko&title=The+ubiquitin+system+for+protein+degradation+and+some+of+its+roles+in+the+control+of+the+cell+division+cycle&doi=10.1038%2Fsj.cdd.4401702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle</span></div><div class="casAuthors">Hershko, A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1191-1197</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Owing to the intensive research activity on protein synthesis, little attention was paid in the 1950s and 1960s to protein degrdn.  However, work by the author's group and others between 1970 and 1990 led to the identification of the ubiquitin-dependent degrdn. system.  The author and his coworkers found that this system contained 3 types of enzymes: E1, the ubiquitin-activating enzyme; E2, the ubiquitin-carrier enzyme; and E3, ubiquitin-protein ligase.  The sequential action of these enzymes leads to conjugation of ubiquitin to proteins and then in most cases to their degrdn.  This review briefly tells the story of how this pathway was discovered describing the main findings that during the years allowed the author and his colleagues to draw the complex picture that is currently available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5JJdwpXFipbVg90H21EOLACvtfcHk0lgHNKnGVdw3lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnt1Shtrk%253D&md5=3b1c94038962bf6e62a1882779aeedf4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401702%26sid%3Dliteratum%253Aachs%26aulast%3DHershko%26aufirst%3DA.%26atitle%3DThe%2520ubiquitin%2520system%2520for%2520protein%2520degradation%2520and%2520some%2520of%2520its%2520roles%2520in%2520the%2520control%2520of%2520the%2520cell%2520division%2520cycle%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2005%26volume%3D12%26spage%3D1191%26epage%3D1197%26doi%3D10.1038%2Fsj.cdd.4401702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mocciaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rape, M.</span></span> <span> </span><span class="NLM_article-title">Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1242/jcs.091199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1242%2Fjcs.091199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=22357967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFShs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=255-263&author=A.+Mocciaroauthor=M.+Rape&title=Emerging+regulatory+mechanisms+in+ubiquitin-dependent+cell+cycle+control&doi=10.1242%2Fjcs.091199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control</span></div><div class="casAuthors">Mocciaro, Annamaria; Rape, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-263</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The covalent modification of proteins with ubiquitin is required for accurate cell division in all eukaryotes.  Ubiquitylation depends on an enzymic cascade, in which E3 enzymes recruit specific substrates for modification.  Among ∼600 human E3s, the SCF (Skp1-cullin1-F-box) and the APC/C (anaphase-promoting complex/cyclosome) are known for driving the degrdn. of cell cycle regulators to accomplish irreversible cell cycle transitions.  The cell cycle machinery reciprocally regulates the SCF and APC/C through various mechanisms, including the modification of these E3s or the binding of specific inhibitors.  Recent studies have provided new insight into the intricate relationship between ubiquitylation and the cell division app. as they revealed roles for atypical ubiquitin chains, new mechanisms of substrate and E3 regulation, as well as extensive crosstalk between ubiquitylation enzymes.  Here, we review these emerging regulatory mechanisms of ubiquitin-dependent cell cycle control and discuss how their manipulation might provide therapeutic benefits in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzVnxAN41YDbVg90H21EOLACvtfcHk0lgHNKnGVdw3lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFShs7o%253D&md5=5ea6006fd389bd7f68d6f85dfc218fb0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1242%2Fjcs.091199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.091199%26sid%3Dliteratum%253Aachs%26aulast%3DMocciaro%26aufirst%3DA.%26aulast%3DRape%26aufirst%3DM.%26atitle%3DEmerging%2520regulatory%2520mechanisms%2520in%2520ubiquitin-dependent%2520cell%2520cycle%2520control%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D255%26epage%3D263%26doi%3D10.1242%2Fjcs.091199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">The role of the ubiquitin-proteasome pathway in apoptosis</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4400505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fsj.cdd.4400505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10381632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADyaK1MXivFSqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=303-313&author=R.+Z.+Orlowski&title=The+role+of+the+ubiquitin-proteasome+pathway+in+apoptosis&doi=10.1038%2Fsj.cdd.4400505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the ubiquitin-proteasome pathway in apoptosis</span></div><div class="casAuthors">Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-313</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">A review with 115 refs.  Coordinated intracellular protein degrdn. mediated by the ubiquitin-proteasome pathway is crucial to a vast array of cellular processes including orderly progression through the mitotic cycle.  Similarly important to both the fates of individual cells, as well as to the normal function of multicellular organisms, is the process of apoptosis, or programmed cell death.  Execution of this latter process has been known for some time to be intimately assocd. with the activity of caspases, a family of proteases related to interleukin-1-β-converting enzyme.  Evidence is now accumulating, however, that the ubiquitin-proteasome system itself plays an important role in apoptosis, and some of the cellular pathways that are impacted upon by the proteasome, and may lead to apoptosis, are beginning to be dissected.  This review provides a summary of the exptl. basis by which components of the ubiquitin-proteasome pathway have been linked to apoptosis, and attempts are made to formulate a hypothesis about its role in this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_hhc3DN4q7Vg90H21EOLACvtfcHk0lgHNKnGVdw3lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFSqsr8%253D&md5=c3b8de412ec696079a0914ec125360cf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4400505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4400505%26sid%3Dliteratum%253Aachs%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DThe%2520role%2520of%2520the%2520ubiquitin-proteasome%2520pathway%2520in%2520apoptosis%26jtitle%3DCell%2520Death%2520Differ.%26date%3D1999%26volume%3D6%26spage%3D303%26epage%3D313%26doi%3D10.1038%2Fsj.cdd.4400505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boutillier, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kienlen-Campard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeffler, J. P.</span></span> <span> </span><span class="NLM_article-title">Depolarization regulates cyclin D1 degradation and neuronal apoptosis: a hypothesis about the role of the ubiquitin/proteasome signalling pathway</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1046/j.1460-9568.1999.00451.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1046%2Fj.1460-9568.1999.00451.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10051745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A280%3ADyaK1M7ntF2gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=441-448&author=A.+L.+Boutillierauthor=P.+Kienlen-Campardauthor=J.+P.+Loeffler&title=Depolarization+regulates+cyclin+D1+degradation+and+neuronal+apoptosis%3A+a+hypothesis+about+the+role+of+the+ubiquitin%2Fproteasome+signalling+pathway&doi=10.1046%2Fj.1460-9568.1999.00451.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Depolarization regulates cyclin D1 degradation and neuronal apoptosis: a hypothesis about the role of the ubiquitin/proteasome signalling pathway</span></div><div class="casAuthors">Boutillier A L; Kienlen-Campard P; Loeffler J P</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-8</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Depolarization and subsequent calcium entry exert essential neuroprotective effects but the ultimate effector by which calcium blocks apoptosis is not known.  Here we show that inhibition of calcium entry into cerebellar neurons by switching from high to low extracellular K+ concentrations (30-5 mM) induces apoptosis, that correlates with a rapid accumulation of cyclin D1 (CD1), an early marker of the G1/S transition of the cell cycle.  These effects on apoptosis and cyclin D1 are mimicked either by blocking calcium entry into neurons (LaCl3, 100 microM or nifedipine, 10(-6) M) or by inhibiting the calcium/calmodulin pathway (calmidazolium, 10(-7) M).  The increased CD1 protein levels do not result from a transcriptional upregulation of the CD1 gene by the Ca2+/calmodulin pathway but rather reflect an accumulation due to the lack of degradation by the proteasome-dependent pathway.  Specific proteasome antagonists: carbobenzoxyl-leucinyl-leucinyl-norvalinal-H (MG-115), carbobenzoxyl-leucinyl-leucinyl-leucinal-H (MG-132) and clastolactacystin beta-lactone, induce neuronal apoptosis by themselves.  Finally, this pathway is functional only at neuroprotective concentrations of K+ (30 mM), suggesting that calcium/CamK signalling pathway may regulate neuronal death by regulating the proteasome-mediated degradation activity of rapidly turning-over proteins (constitutively expressed genes or pre-existing pools of mRNA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMy5nNLDzr40kUaC_kzhvyfW6udTcc2eafTBHWSwE8Irntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7ntF2gtg%253D%253D&md5=0ebde53c8d14eea7e24a27bd2b610ef2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1046%2Fj.1460-9568.1999.00451.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1460-9568.1999.00451.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoutillier%26aufirst%3DA.%2BL.%26aulast%3DKienlen-Campard%26aufirst%3DP.%26aulast%3DLoeffler%26aufirst%3DJ.%2BP.%26atitle%3DDepolarization%2520regulates%2520cyclin%2520D1%2520degradation%2520and%2520neuronal%2520apoptosis%253A%2520a%2520hypothesis%2520about%2520the%2520role%2520of%2520the%2520ubiquitin%252Fproteasome%2520signalling%2520pathway%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D1999%26volume%3D11%26spage%3D441%26epage%3D448%26doi%3D10.1046%2Fj.1460-9568.1999.00451.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahimi, N.</span></span> <span> </span><span class="NLM_article-title">The ubiquitin-proteasome system meets angiogenesis</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F1535-7163.MCT-11-0555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=22357635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=538-548&author=N.+Rahimi&title=The+ubiquitin-proteasome+system+meets+angiogenesis&doi=10.1158%2F1535-7163.mct-11-0555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Ubiquitin-Proteasome System Meets Angiogenesis</span></div><div class="casAuthors">Rahimi, Nader</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">538-548</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  A strict physiol. balance between endogenous proangiogenic and antiangiogenic factors controls endothelial cell functions, such that endothelial cell growth is normally restrained.  However, in pathol. angiogenesis, a shift occurs in the balance of regulators, favoring endothelial growth.  Much of the control of angiogenic events is instigated through hypoxia-induced VEGF expression.  The ubiquitin-proteasome system (UPS) plays a central role in fine-tuning the functions of core proangiogenic proteins, including VEGF, VEGFR-2, angiogenic signaling proteins (e.g., the PLCγ1 and PI3 kinase/AKT pathways), and other non-VEGF angiogenic pathways.  The emerging mechanisms by which ubiquitin modification of angiogenic proteins control angiogenesis involve both proteolytic and nonproteolytic functions.  Here, I review recent advances that link the UPS to regulation of angiogenesis and highlight the potential therapeutic value of the UPS in angiogenesis-assocd. diseases.  Mol Cancer Ther; 11(3); 538-48.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqESUzW3iCLh7Vg90H21EOLACvtfcHk0lgg_oA2qM0_Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKjtbY%253D&md5=0d317a32a0e5a0eff6f001d28a47916f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0555%26sid%3Dliteratum%253Aachs%26aulast%3DRahimi%26aufirst%3DN.%26atitle%3DThe%2520ubiquitin-proteasome%2520system%2520meets%2520angiogenesis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D538%26epage%3D548%26doi%3D10.1158%2F1535-7163.mct-11-0555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vucic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikic, I.</span></span> <span> </span><span class="NLM_article-title">Ubiquitination in disease pathogenesis and treatment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1242</span>– <span class="NLM_lpage">1253</span>, <span class="refDoi"> DOI: 10.1038/nm.3739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnm.3739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=25375928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyku73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1242-1253&author=D.+Popovicauthor=D.+Vucicauthor=I.+Dikic&title=Ubiquitination+in+disease+pathogenesis+and+treatment&doi=10.1038%2Fnm.3739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitination in disease pathogenesis and treatment</span></div><div class="casAuthors">Popovic, Doris; Vucic, Domagoj; Dikic, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1242-1253</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ubiquitination is crucial for a plethora of physiol. processes, including cell survival and differentiation and innate and adaptive immunity.  In recent years, considerable progress has been made in the understanding of the mol. action of ubiquitin in signaling pathways and how alterations in the ubiquitin system lead to the development of distinct human diseases.  Here we describe the role of ubiquitination in the onset and progression of cancer, metabolic syndromes, neurodegenerative diseases, autoimmunity, inflammatory disorders, infection and muscle dystrophies.  Moreover, we indicate how current knowledge could be exploited for the development of new clin. therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTMeFCgBByjbVg90H21EOLACvtfcHk0lgg_oA2qM0_Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyku73J&md5=3d943ec2721c980b971d02d4905d5348</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnm.3739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3739%26sid%3Dliteratum%253Aachs%26aulast%3DPopovic%26aufirst%3DD.%26aulast%3DVucic%26aufirst%3DD.%26aulast%3DDikic%26aufirst%3DI.%26atitle%3DUbiquitination%2520in%2520disease%2520pathogenesis%2520and%2520treatment%26jtitle%3DNat.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D1242%26epage%3D1253%26doi%3D10.1038%2Fnm.3739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bross, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Velcade: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.8-6-508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1634%2Ftheoncologist.8-6-508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=14657528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A280%3ADC%252BD3srnslGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=508-513&author=R.+C.+Kaneauthor=P.+F.+Brossauthor=A.+T.+Farrellauthor=R.+Pazdur&title=Velcade%3A+U.S.+FDA+Approval+for+the+Treatment+of+Multiple+Myeloma+Progressing+on+Prior+Therapy&doi=10.1634%2Ftheoncologist.8-6-508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy</span></div><div class="casAuthors">Kane Robert C; Bross Peter F; Farrell Ann T; Pazdur Richard</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">508-13</span>
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    </div><div class="casAbstract">Bortezomib (formerly PS-341), a promising new drug for the treatment of multiple myeloma, recently received accelerated approval from the U.S.  Food and Drug Administration (FDA) for the therapy of patients with progressive myeloma after previous treatment.  Two phase II studies of bortezomib used the same schedule of twice-weekly i.v. dosing for the first 2 weeks of each 3-week cycle.  In a randomized study of 54 patients, two doses were compared (1.0 and 1.3 mg/m2) and objective responses occurred at both dose levels (23% versus 35%), including one complete response in each arm.  In the other phase II study, 202 heavily pretreated patients (median of six prior therapies) all received the same schedule at 1.3 mg/m2.  Of 188 evaluable patients, complete responses occurred in five (3%) and partial responses occurred in 47 (25%).  The median duration of response was 365 days.  The most clinically relevant adverse events were asthenic conditions, nausea, vomiting, diarrhea, thrombocytopenia, and a peripheral neuropathy that often was painful.  This report highlights the FDA analysis supporting the accelerated approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTS_wiRSzN1ZNy3lHz94U-GfW6udTcc2eZN_CSdTvs-bLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srnslGhtQ%253D%253D&md5=e5420a8677aa046abed3f232889d194c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-6-508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-6-508%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DVelcade%253A%2520U.S.%2520FDA%2520Approval%2520for%2520the%2520Treatment%2520of%2520Multiple%2520Myeloma%2520Progressing%2520on%2520Prior%2520Therapy%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26spage%3D508%26epage%3D513%26doi%3D10.1634%2Ftheoncologist.8-6-508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q. P.</span></span> <span> </span><span class="NLM_article-title">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.2174/156800911794519752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.2174%2F156800911794519752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=21247388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=239-253&author=D.+Chenauthor=M.+Frezzaauthor=S.+Schmittauthor=J.+Kanwarauthor=Q.+P.+Dou&title=Bortezomib+as+the+first+proteasome+inhibitor+anticancer+drug%3A+current+status+and+future+perspectives&doi=10.2174%2F156800911794519752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span></div><div class="casAuthors">Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-253</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer.  Based on pos. preclin. and clin. studies, bortezomib was subsequently approved for the clin. use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment.  The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease.  Bortezomib has shown a pos. clin. benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance.  One of the major mechanisms of bortezomib assocd. with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-XL and Bcl-2, and result in apoptotic cell death in malignant cells.  Another important mechanism of bortezomib is through suppression of the NF-κB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes.  Although the majority of success achieved with bortezomib has been in hematol. malignancies, its effect toward solid tumors has been less than encouraging.  Addnl., the widespread clin. use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compds.  These findings could help guide physicians in refining the clin. use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clin. response in cancer patients.  Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4QCk3nP8BLVg90H21EOLACvtfcHk0lhwmkRE7HG86Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D&md5=15becbceb98ec3e244fc066315815dd2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F156800911794519752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911794519752%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFrezza%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DS.%26aulast%3DKanwar%26aufirst%3DJ.%26aulast%3DDou%26aufirst%3DQ.%2BP.%26atitle%3DBortezomib%2520as%2520the%2520first%2520proteasome%2520inhibitor%2520anticancer%2520drug%253A%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26spage%3D239%26epage%3D253%26doi%3D10.2174%2F156800911794519752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerscher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felberbaum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, M.</span></span> <span> </span><span class="NLM_article-title">Modification of proteins by ubiquitin and ubiquitin-like proteins</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.22.010605.093503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1146%2Fannurev.cellbio.22.010605.093503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=16753028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yjs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2006&pages=159-180&author=O.+Kerscherauthor=R.+Felberbaumauthor=M.+Hochstrasser&title=Modification+of+proteins+by+ubiquitin+and+ubiquitin-like+proteins&doi=10.1146%2Fannurev.cellbio.22.010605.093503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of proteins by ubiquitin and ubiquitin-like proteins</span></div><div class="casAuthors">Kerscher, Oliver; Felberbaum, Rachael; Hochstrasser, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Cell and Developmental Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-180</span>CODEN:
                <span class="NLM_cas:coden">ARDBF8</span>;
        ISSN:<span class="NLM_cas:issn">1081-0706</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Following the discovery of protein modification by the small, highly conserved ubiquitin polypeptide, a no. of distinct ubiquitin-like proteins (Ubls) have been found to function as protein modifiers as well.  These Ubls, which include SUMO, ISG15, Nedd8, and Atg8, function as crit. regulators of many cellular processes, including transcription, DNA repair, signal transduction, autophagy, and cell-cycle control.  A growing body of data also implicates the dysregulation of Ubl-substrate modification and mutations in the Ubl-conjugation machinery in the etiol. and progression of a no. of human diseases.  The primary aim of this review is to summarize the latest developments in the understanding of the different Ubl-protein modification systems, including the shared and unique features of these related pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6upobPhWlRrVg90H21EOLACvtfcHk0lhwmkRE7HG86Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yjs7vI&md5=a57eca21879c93167a900caa0b72d008</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.22.010605.093503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.22.010605.093503%26sid%3Dliteratum%253Aachs%26aulast%3DKerscher%26aufirst%3DO.%26aulast%3DFelberbaum%26aufirst%3DR.%26aulast%3DHochstrasser%26aufirst%3DM.%26atitle%3DModification%2520of%2520proteins%2520by%2520ubiquitin%2520and%2520ubiquitin-like%2520proteins%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D2006%26volume%3D22%26spage%3D159%26epage%3D180%26doi%3D10.1146%2Fannurev.cellbio.22.010605.093503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishitani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roukos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obuse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lygerou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, T.</span></span> <span> </span><span class="NLM_article-title">Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1136</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fsj.emboj.7601002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=16482215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVyisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1126-1136&author=H.+Nishitaniauthor=N.+Sugimotoauthor=V.+Roukosauthor=Y.+Nakanishiauthor=M.+Saijoauthor=C.+Obuseauthor=T.+Tsurimotoauthor=K.+I.+Nakayamaauthor=K.+Nakayamaauthor=M.+Fujitaauthor=Z.+Lygerouauthor=T.+Nishimoto&title=Two+E3+ubiquitin+ligases%2C+SCF-Skp2+and+DDB1-Cul4%2C+target+human+Cdt1+for+proteolysis&doi=10.1038%2Fsj.emboj.7601002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis</span></div><div class="casAuthors">Nishitani, Hideo; Sugimoto, Nozomi; Roukos, Vassilis; Nakanishi, Yohsuke; Saijo, Masafumi; Obuse, Chikashi; Tsurimoto, Toshiki; Nakayama, Keiichi I.; Nakayama, Keiko; Fujita, Masatoshi; Lygerou, Zoi; Nishimoto, Takeharu</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1126-1136</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Replication licensing is carefully regulated to restrict replication to once in a cell cycle.  In higher eukaryotes, regulation of the licensing factor Cdt1 by proteolysis and Geminin is essential to prevent re-replication.  We show here that the N-terminal 100 amino acids of human Cdt1 are recognized for proteolysis by two distinct E3 ubiquitin ligases during S-G2 phases.  Six highly conserved amino acids within the 10 first amino acids of Cdt1 are essential for DDB1-Cul4-mediated proteolysis.  This region is also involved in proteolysis following DNA damage.  The second E3 is SCF-Skp2, which recognizes the Cy-motif-mediated Cyclin E/A-cyclin-dependent kinase-phosphorylated region.  Consistently, in HeLa cells cosilenced of Skp2 and Cul4, Cdt1 remained stable in S-G2 phases.  The Cul4-contg. E3 is active during ongoing replication, while SCF-Skp2 operates both in S and G2 phases.  PCNA binds to Cdt1 through the six conserved N-terminal amino acids.  PCNA is essential for Cul4- but not Skp2-directed degrdn. during DNA replication and following UV-irradn.  Our data unravel multiple distinct pathways regulating Cdt1 to block re-replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKYgClHtqRbVg90H21EOLACvtfcHk0lhwmkRE7HG86Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVyisro%253D&md5=5f5d0c891dce6c213212f739a33d3292</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601002%26sid%3Dliteratum%253Aachs%26aulast%3DNishitani%26aufirst%3DH.%26aulast%3DSugimoto%26aufirst%3DN.%26aulast%3DRoukos%26aufirst%3DV.%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DSaijo%26aufirst%3DM.%26aulast%3DObuse%26aufirst%3DC.%26aulast%3DTsurimoto%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26aulast%3DNakayama%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DLygerou%26aufirst%3DZ.%26aulast%3DNishimoto%26aufirst%3DT.%26atitle%3DTwo%2520E3%2520ubiquitin%2520ligases%252C%2520SCF-Skp2%2520and%2520DDB1-Cul4%252C%2520target%2520human%2520Cdt1%2520for%2520proteolysis%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D1126%26epage%3D1136%26doi%3D10.1038%2Fsj.emboj.7601002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liakopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busgen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brychzy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jentsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pause, A.</span></span> <span> </span><span class="NLM_article-title">Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">5510</span>– <span class="NLM_lpage">5515</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.10.5510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1073%2Fpnas.96.10.5510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10318914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADyaK1MXjtFCnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=5510-5515&author=D.+Liakopoulosauthor=T.+Busgenauthor=A.+Brychzyauthor=S.+Jentschauthor=A.+Pause&title=Conjugation+of+the+ubiquitin-like+protein+NEDD8+to+cullin-2+is+linked+to+von+Hippel-Lindau+tumor+suppressor+function&doi=10.1073%2Fpnas.96.10.5510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function</span></div><div class="casAuthors">Liakopoulos, Dimitris; Busgen, Tanja; Brychzy, Alexander; Jentsch, Stefan; Pause, Arnim</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5510-5515</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The von Hippel-Lindau tumor suppressor protein pVHL assembles with cullin-2 (hCUL-2) and elongin B/C forming a protein complex, CBCVHL, that resembles SKP1-CDC53-F-box protein ubiquitin ligases.  Here, we show that hCUL-2 is modified by the conserved ubiquitin-like protein NEDD8 and that NEDD8-hCUL-2 conjugates are part of CBCVHL complexes in vivo.  Remarkably, the formation of these conjugates is stimulated by the pVHL tumor suppressor.  A tumorigenic pVHL variant, however, is essentially deficient in this activity.  Thus, ligation of NEDD8 to hCUL-2 is linked to pVHL activity and may be important for pVHL tumor suppressor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp95mSK379KU7Vg90H21EOLACvtfcHk0lhl61-SLGELFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtFCnsbk%253D&md5=216054cedff1a2ab3709dc4ad81bf7f4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.10.5510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.10.5510%26sid%3Dliteratum%253Aachs%26aulast%3DLiakopoulos%26aufirst%3DD.%26aulast%3DBusgen%26aufirst%3DT.%26aulast%3DBrychzy%26aufirst%3DA.%26aulast%3DJentsch%26aufirst%3DS.%26aulast%3DPause%26aufirst%3DA.%26atitle%3DConjugation%2520of%2520the%2520ubiquitin-like%2520protein%2520NEDD8%2520to%2520cullin-2%2520is%2520linked%2520to%2520von%2520Hippel-Lindau%2520tumor%2520suppressor%2520function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D96%26spage%3D5510%26epage%3D5515%26doi%3D10.1073%2Fpnas.96.10.5510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">7130</span>– <span class="NLM_lpage">7139</span>, <span class="refDoi"> DOI: 10.1128/mcb.24.16.7130-7139.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1128%2FMCB.24.16.7130-7139.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=15282312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlOjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=7130-7139&author=A.+Kobayashiauthor=M.-I.+Kangauthor=H.+Okawaauthor=M.+Ohtsujiauthor=Y.+Zenkeauthor=T.+Chibaauthor=K.+Igarashiauthor=M.+Yamamoto&title=Oxidative+stress+sensor+Keap1+functions+as+an+adaptor+for+Cul3-based+E3+ligase+to+regulate+proteasomal+degradation+of+Nrf2&doi=10.1128%2Fmcb.24.16.7130-7139.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2</span></div><div class="casAuthors">Kobayashi, Akira; Kang, Moon-Il; Okawa, Hiromi; Ohtsuji, Makiko; Zenke, Yukari; Chiba, Tomoki; Igarashi, Kazuhiko; Yamamoto, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7130-7139</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Transcription factor Nrf2 is a major regulator of genes encoding phase 2 detoxifying enzymes and antioxidant stress proteins in response to electrophilic agents and oxidative stress.  In the absence of such stimuli, Nrf2 is inactive owing to its cytoplasmic retention by Keap1 and rapid degrdn. through the proteasome system.  We examd. the contribution of Keap1 to the rapid turnover of Nrf2 (half-life of less than 20 min) and found that a direct assocn. between Keap1 and Nrf2 is required for Nrf2 degrdn.  In a series of domain function analyses of Keap1, we found that both the BTB and intervening-region (IVR) domains are crucial for Nrf2 degrdn., implying that these two domains act to recruit ubiquitin-proteasome factors.  Indeed, Cullin 3 (Cul3), a subunit of the E3 ligase complex, was found to interact specifically with Keap1 in vivo.  Keap1 assocs. with the N-terminal region of Cul3 through the IVR domain and promotes the ubiquitination of Nrf2 in cooperation with the Cul3-Roc1 complex.  These results thus provide solid evidence that Keap1 functions as an adaptor of Cul3-based E3 ligase.  To our knowledge, Nrf2 and Keap1 are the first reported mammalian substrate and adaptor, resp., of the Cul3-based E3 ligase system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrut4YvhAuZKrVg90H21EOLACvtfcHk0lhl61-SLGELFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlOjt7w%253D&md5=3d6e356865cd6f33c800bf9124d7c8da</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.16.7130-7139.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.16.7130-7139.2004%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DA.%26aulast%3DKang%26aufirst%3DM.-I.%26aulast%3DOkawa%26aufirst%3DH.%26aulast%3DOhtsuji%26aufirst%3DM.%26aulast%3DZenke%26aufirst%3DY.%26aulast%3DChiba%26aufirst%3DT.%26aulast%3DIgarashi%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DM.%26atitle%3DOxidative%2520stress%2520sensor%2520Keap1%2520functions%2520as%2520an%2520adaptor%2520for%2520Cul3-based%2520E3%2520ligase%2520to%2520regulate%2520proteasomal%2520degradation%2520of%2520Nrf2%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D7130%26epage%3D7139%26doi%3D10.1128%2Fmcb.24.16.7130-7139.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Read, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladysheva, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hottelet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coggins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podust, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span> <span> </span><span class="NLM_article-title">Nedd8 Modification of Cul-1 Activates SCFβ TrCP-Dependent Ubiquitination of IκBα</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2326</span>, <span class="refDoi"> DOI: 10.1128/mcb.20.7.2326-2333.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1128%2FMCB.20.7.2326-2333.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10713156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvFegtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=2326&author=M.+A.+Readauthor=J.+E.+Brownellauthor=T.+B.+Gladyshevaauthor=M.+Hotteletauthor=L.+A.+Parentauthor=M.+B.+Cogginsauthor=J.+W.+Pierceauthor=V.+N.+Podustauthor=R.-S.+Luoauthor=V.+Chauauthor=V.+J.+Palombella&title=Nedd8+Modification+of+Cul-1+Activates+SCF%CE%B2+TrCP-Dependent+Ubiquitination+of+I%CE%BAB%CE%B1&doi=10.1128%2Fmcb.20.7.2326-2333.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Nedd8 modification of Cul-1 activates SCFβTrCP-dependent ubiquitination of IκBα</span></div><div class="casAuthors">Read, Margaret A.; Brownell, James E.; Gladysheva, Tatiana B.; Hottelet, Maria; Parent, Lana A.; Coggins, Michael B.; Pierce, Jacqueline W.; Podust, Vladimir N.; Luo, Rong-Shu; Chau, Vincent; Palombella, Vito J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2326-2333</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Regulation of NF-κB occurs through phosphorylation-dependent ubiquitination of IκBα, which is degraded by the 26S proteasome.  Recent studies have shown that ubiquitination of IκBα is carried out by a ubiquitinligase enzyme complex called SCFβTrCP.  Here we show that Nedd8 modification of the Cul-1 component of SCFβTrCP is important for function of SCFβTrCP in ubiquitination of IκBα.  In cells, Nedd8-conjugated Cul-1 was complexed with two substrates of SCFβTrCP, phosphorylated IκBα and β-catenin, indicating that Nedd8-Cul-1 conjugates are part of SCFβTrCP in vivo.  Although only a minute fraction of total cellular Cul-1 is modified by Nedd8, the Cul-1 assocd. with ectopically expressed βTrCP was highly enriched for the Nedd8-conjugated form.  Moreover, optimal ubiquitination of IκBα required Nedd8 and the Nedd8-conjugating enzyme, Ubc12.  The site of Nedd8 ligation to Cul-1 is essential, as SCFβTrCP contg. a K720R mutant of Cul-1 only weakly supported IκBα ubiquitination compared to SCFβTrCP contg. WT Cul-1, suggesting that the Nedd8 ligation of Cul-1 affects the ubiquitination activity of SCFβTrCP.  These observations provide a functional link between the highly related ubiquitin and Nedd8 pathways of protein modification and show how they operate together to selectively target the signal-dependent degrdn. of IκBα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqju9vP-J9TFbVg90H21EOLACvtfcHk0lhl61-SLGELFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvFegtbw%253D&md5=0c0448d6d1b25f9235c7e6d401cd9ab7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.7.2326-2333.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.7.2326-2333.2000%26sid%3Dliteratum%253Aachs%26aulast%3DRead%26aufirst%3DM.%2BA.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DGladysheva%26aufirst%3DT.%2BB.%26aulast%3DHottelet%26aufirst%3DM.%26aulast%3DParent%26aufirst%3DL.%2BA.%26aulast%3DCoggins%26aufirst%3DM.%2BB.%26aulast%3DPierce%26aufirst%3DJ.%2BW.%26aulast%3DPodust%26aufirst%3DV.%2BN.%26aulast%3DLuo%26aufirst%3DR.-S.%26aulast%3DChau%26aufirst%3DV.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26atitle%3DNedd8%2520Modification%2520of%2520Cul-1%2520Activates%2520SCF%25CE%25B2%2520TrCP-Dependent%2520Ubiquitination%2520of%2520I%25CE%25BAB%25CE%25B1%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D2326%26doi%3D10.1128%2Fmcb.20.7.2326-2333.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podust, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladysheva, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coggins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightcap, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, V.</span></span> <span> </span><span class="NLM_article-title">Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">4579</span>– <span class="NLM_lpage">4584</span>, <span class="refDoi"> DOI: 10.1073/pnas.090465597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1073%2Fpnas.090465597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10781063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFKjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=4579-4584&author=V.+N.+Podustauthor=J.+E.+Brownellauthor=T.+B.+Gladyshevaauthor=R.-S.+Luoauthor=C.+Wangauthor=M.+B.+Cogginsauthor=J.+W.+Pierceauthor=E.+S.+Lightcapauthor=V.+Chau&title=Nedd8+conjugation+pathway+is+essential+for+proteolytic+targeting+of+p27Kip1+by+ubiquitination&doi=10.1073%2Fpnas.090465597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination</span></div><div class="casAuthors">Podust, Vladimir N.; Brownell, James E.; Gladysheva, Tatiana B.; Luo, Rong-Shu; Wang, Chunhua; Coggins, Michael B.; Pierce, Jacqueline W.; Lightcap, Eric S.; Chau, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4579-4584</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Temporal control of p27Kip1 (p27) degrdn. imposes periodicity in its activity during cell cycle progression and its accumulation during cell cycle exit.  Degrdn. of p27 is initiated by phosphorylation of p27 at Thr-187, which marks the protein for ubiquitination by SCFSkp2 and subsequent proteolysis by the 26S proteasome.  Here we show that the p27 ubiquitination activity in cell exts. depends on the presence of the ubiquitin-like protein Nedd8 and enzymes that catalyze Nedd8 conjugation to proteins.  Moreover, we show that reconstitution of the p27 ubiquitination activity of recombinant SCFSkp2 also requires Nedd8 conjugation pathway components.  Inactivation of the Nedd8 conjugation pathway by a dominant neg. mutant of the Nedd8-conjugating enzyme Nce1/Ubc12 blocks the ubiquitination and degrdn. of p27 in cell exts.  Consistent with a role in cell-cycle progression, Nedd8 is expressed in proliferating cells and is itself down-regulated upon cellular differentiation.  These results suggest that the Nedd8 conjugation pathway may regulate the turnover of p27Kip1, independently of p27 phosphorylation, and further establishes the identity of protein components involved in p27 ubiquitination.  Finally, these findings provide a direct demonstration of a function for Nedd8 in a biol. process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHO24nRBBTpbVg90H21EOLACvtfcHk0lgy0inFllcD2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFKjtr0%253D&md5=ebab54f5e34ee739ed00db716f331034</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.090465597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.090465597%26sid%3Dliteratum%253Aachs%26aulast%3DPodust%26aufirst%3DV.%2BN.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DGladysheva%26aufirst%3DT.%2BB.%26aulast%3DLuo%26aufirst%3DR.-S.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DCoggins%26aufirst%3DM.%2BB.%26aulast%3DPierce%26aufirst%3DJ.%2BW.%26aulast%3DLightcap%26aufirst%3DE.%2BS.%26aulast%3DChau%26aufirst%3DV.%26atitle%3DNedd8%2520conjugation%2520pathway%2520is%2520essential%2520for%2520proteolytic%2520targeting%2520of%2520p27Kip1%2520by%2520ubiquitination%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2000%26volume%3D97%26spage%3D4579%26epage%3D4584%26doi%3D10.1073%2Fpnas.090465597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin ligases: cell-cycle control and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1038/nrc1881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnrc1881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=16633365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD28XjslGitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=369-381&author=K.+I.+Nakayamaauthor=K.+Nakayama&title=Ubiquitin+ligases%3A+cell-cycle+control+and+cancer&doi=10.1038%2Fnrc1881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin ligases: cell-cycle control and cancer</span></div><div class="casAuthors">Nakayama, Keiichi I.; Nakayama, Keiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">369-381</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A driving force of the cell cycle is the activation of cyclin-dependent kinases (CDKs), the activities of which are controlled by the ubiquitin-mediated proteolysis of key regulators such as cyclins and CDK inhibitors.  Two ubiquitin ligases, the SKP1-CUL1-F-box-protein (SCF) complex and the anaphase-promoting complex/cyclosome (APC/C), are responsible for the specific ubiquitylation of many of these regulators.  Deregulation of the proteolytic system might result in uncontrolled proliferation, genomic instability and cancer.  Cumulative clin. evidence shows alterations in the ubiquitylation of cell-cycle regulators in the etiol. of many human malignancies.  A better understanding of the ubiquitylation machinery will provide new insights into the regulatory biol. of cell-cycle transitions and the development of anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeQVKJ7pAqq7Vg90H21EOLACvtfcHk0lgy0inFllcD2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjslGitb4%253D&md5=23f2eff17be746153edf5be9e733bb21</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc1881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1881%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26aulast%3DNakayama%26aufirst%3DK.%26atitle%3DUbiquitin%2520ligases%253A%2520cell-cycle%2520control%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D369%26epage%3D381%26doi%3D10.1038%2Fnrc1881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsunematsu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2116</span>– <span class="NLM_lpage">2125</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7600217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fsj.emboj.7600217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=15103331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktVGjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=2116-2125&author=M.+Yadaauthor=S.+Hatakeyamaauthor=T.+Kamuraauthor=M.+Nishiyamaauthor=R.+Tsunematsuauthor=H.+Imakiauthor=N.+Ishidaauthor=F.+Okumuraauthor=K.+Nakayamaauthor=K.+I.+Nakayama&title=Phosphorylation-dependent+degradation+of+c-Myc+is+mediated+by+the+F-box+protein+Fbw7&doi=10.1038%2Fsj.emboj.7600217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7</span></div><div class="casAuthors">Yada, Masayoshi; Hatakeyama, Shigetsugu; Kamura, Takumi; Nishiyama, Masaaki; Tsunematsu, Ryosuke; Imaki, Hiroyuki; Ishida, Noriko; Okumura, Fumihiko; Nakayama, Keiko; Nakayama, Keiichi I.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2116-2125</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The F-box protein Skp2 mediates c-Myc ubiquitylation by binding to the MB2 domain.  However, the turnover of c-Myc is largely dependent on phosphorylation of threonine-58 and serine-62 in MB1, residues that are often mutated in cancer.  We now show that the F-box protein Fbw7 interacts with and thereby destabilizes c-Myc in a manner dependent on phosphorylation of MB1.  Whereas wild-type Fbw7 promoted c-Myc turnover in cells, an Fbw7 mutant lacking the F-box domain delayed it.  Furthermore, depletion of Fbw7 by RNA interference increased both the abundance and transactivation activity of c-Myc.  Accumulation of c-Myc was also apparent in mouse Fbw7-/- embryonic stem cells.  These observations suggest that two F-box proteins, Fbw7 and Skp2, differentially regulate c-Myc stability by targeting MB1 and MB2, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAzziISTkJnLVg90H21EOLACvtfcHk0lgy0inFllcD2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktVGjtL0%253D&md5=30c2067e35099668b37a6ad7dcd591b1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600217%26sid%3Dliteratum%253Aachs%26aulast%3DYada%26aufirst%3DM.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DKamura%26aufirst%3DT.%26aulast%3DNishiyama%26aufirst%3DM.%26aulast%3DTsunematsu%26aufirst%3DR.%26aulast%3DImaki%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DN.%26aulast%3DOkumura%26aufirst%3DF.%26aulast%3DNakayama%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26atitle%3DPhosphorylation-dependent%2520degradation%2520of%2520c-Myc%2520is%2520mediated%2520by%2520the%2520F-box%2520protein%2520Fbw7%26jtitle%3DEMBO%2520J.%26date%3D2004%26volume%3D23%26spage%3D2116%26epage%3D2125%26doi%3D10.1038%2Fsj.emboj.7600217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Climent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DelRosario, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmain, A.</span></span> <span> </span><span class="NLM_article-title">FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1502</span>, <span class="refDoi"> DOI: 10.1126/science.1162981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1126%2Fscience.1162981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=18787170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2jsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2008&pages=1499-1502&author=J.-H.+Maoauthor=I.-J.+Kimauthor=D.+Wuauthor=J.+Climentauthor=H.+C.+Kangauthor=R.+DelRosarioauthor=A.+Balmain&title=FBXW7+targets+mTOR+for+degradation+and+cooperates+with+PTEN+in+tumor+suppression&doi=10.1126%2Fscience.1162981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">FBXW7 Targets mTOR for degradation and cooperates with PTEN in tumor suppression</span></div><div class="casAuthors">Mao, Jian-Hua; Kim, Il-Jin; Wu, Di; Climent, Joan; Kang, Hio Chung; DelRosario, Reyno; Balmain, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">5895</span>),
    <span class="NLM_cas:pages">1499-1502</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The enzyme mTOR (mammalian target of rapamycin) is a major target for therapeutic intervention to treat many human diseases, including cancer, but very little is known about the processes that control levels of mTOR protein.  Here, we show that mTOR is targeted for ubiquitination and consequent degrdn. by binding to the tumor suppressor protein FBXW7.  Human breast cancer cell lines and primary tumors showed a reciprocal relation between loss of FBXW7 and deletion or mutation of PTEN (phosphatase and tensin homolog), which also activates mTOR.  Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVmj3M3SluzLVg90H21EOLACvtfcHk0lgMWuy_3WKryg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2jsb7I&md5=d40961d1707d2d499a77a4e45e5db3cf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.1162981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1162981%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DI.-J.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DCliment%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DH.%2BC.%26aulast%3DDelRosario%26aufirst%3DR.%26aulast%3DBalmain%26aufirst%3DA.%26atitle%3DFBXW7%2520targets%2520mTOR%2520for%2520degradation%2520and%2520cooperates%2520with%2520PTEN%2520in%2520tumor%2520suppression%26jtitle%3DScience%26date%3D2008%26volume%3D321%26spage%3D1499%26epage%3D1502%26doi%3D10.1126%2Fscience.1162981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chairatvit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngamkitidechakul, C.</span></span> <span> </span><span class="NLM_article-title">Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1007/s11010-007-9566-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1007%2Fs11010-007-9566-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=17660949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyru7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2007&pages=163-169&author=K.+Chairatvitauthor=C.+Ngamkitidechakul&title=Control+of+cell+proliferation+via+elevated+NEDD8+conjugation+in+oral+squamous+cell+carcinoma&doi=10.1007%2Fs11010-007-9566-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma</span></div><div class="casAuthors">Chairatvit, Kongthawat; Ngamkitidechakul, Chatri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1&2</span>),
    <span class="NLM_cas:pages">163-169</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A prominent feature of all cancers including oral carcinoma is an abnormality in cellular proliferation.  Neural precursor cell-expressed developmentally down-regulated 8 (NEDD8) is a ubiquitin-like protein exerting its biol. function through covalent ligation to a family of cullin proteins, which act as a component of the Skp1, cullin, and F-box protein complex that plays a crit. role in the regulation of cell cycle.  Using Western blot anal., an increase in NEDD8 conjugation was obsd. in all highly proliferative cells, including immortalized normal oral keratinocyte (NOK), oral-derived carcinoma (KB, HSC4), and several types of human carcinoma cell lines as compared to normal human gingival fibroblast.  The level of NEDD8 conjugation was proportionally dependent on the concn. of serum in culture medium, which also affected proliferation status of oral squamous cell carcinoma.  NEDD8 conjugation was required for proliferation of the carcinoma cell since the transfection of dominant neg. Ubc12 (Ubc12C111S) could prolong the rate of proliferation.  Taken together, up-regulation of the NEDD8 conjugation is an essential requirement for the enhancement of proliferation of oral carcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroreuc9FDbo7Vg90H21EOLACvtfcHk0lgMWuy_3WKryg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyru7jK&md5=8bb3d0e4c580317f8ba6ecfe6970d2f8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs11010-007-9566-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-007-9566-7%26sid%3Dliteratum%253Aachs%26aulast%3DChairatvit%26aufirst%3DK.%26aulast%3DNgamkitidechakul%26aufirst%3DC.%26atitle%3DControl%2520of%2520cell%2520proliferation%2520via%2520elevated%2520NEDD8%2520conjugation%2520in%2520oral%2520squamous%2520cell%2520carcinoma%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2007%26volume%3D306%26spage%3D163%26epage%3D169%26doi%3D10.1007%2Fs11010-007-9566-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span> <span> </span><span class="NLM_article-title">Overactivated neddylation pathway as a therapeutic target in lung cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">dju083</span>, <span class="refDoi"> DOI: 10.1093/jnci/dju083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1093%2Fjnci%2Fdju083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=24853380" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=dju083&author=L.+Liauthor=M.+Wangauthor=G.+Yuauthor=P.+Chenauthor=H.+Liauthor=D.+Weiauthor=J.+Zhuauthor=L.+Xieauthor=H.+Jiaauthor=J.+Shiauthor=C.+Liauthor=W.+Yaoauthor=Y.+Wangauthor=Q.+Gaoauthor=L.+S.+Jeongauthor=H.+W.+Leeauthor=J.+Yuauthor=F.+Huauthor=J.+Meiauthor=P.+Wangauthor=Y.+Chuauthor=H.+Qiauthor=M.+Yangauthor=Z.+Dongauthor=Y.+Sunauthor=R.+M.+Hoffmanauthor=L.+Jia&title=Overactivated+neddylation+pathway+as+a+therapeutic+target+in+lung+cancer&doi=10.1093%2Fjnci%2Fdju083"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdju083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdju083%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DJia%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DF.%26aulast%3DMei%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHoffman%26aufirst%3DR.%2BM.%26aulast%3DJia%26aufirst%3DL.%26atitle%3DOveractivated%2520neddylation%2520pathway%2520as%2520a%2520therapeutic%2520target%2520in%2520lung%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2014%26volume%3D106%26spage%3Ddju083%26doi%3D10.1093%2Fjnci%2Fdju083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. Q.</span></span> <span> </span><span class="NLM_article-title">The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3733</span>, <span class="refDoi"> DOI: 10.1038/ncomms4733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fncomms4733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=24821572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVCjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3733&author=P.+Xieauthor=M.+H.+Zhangauthor=S.+Heauthor=K.+F.+Luauthor=Y.+C.+Chenauthor=G.+C.+Xingauthor=Y.+M.+Luauthor=P.+Liuauthor=Y.+Liauthor=S.+X.+Wangauthor=N.+Chaiauthor=J.+W.+Wuauthor=H.+T.+Dengauthor=H.+R.+Wangauthor=Y.+Caoauthor=F.+Zhaoauthor=Y.+Cuiauthor=J.+Wangauthor=F.+C.+Heauthor=L.+Q.+Zhang&title=The+covalent+modifier+Nedd8+is+critical+for+the+activation+of+Smurf1+ubiquitin+ligase+in+tumorigenesis&doi=10.1038%2Fncomms4733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis</span></div><div class="casAuthors">Xie, Ping; Zhang, Minghua; He, Shan; Lu, Kefeng; Chen, Yuhan; Xing, Guichun; Lu, Yiming; Liu, Ping; Li, Yang; Wang, Shaoxia; Chai, Nan; Wu, Jiawei; Deng, Haiteng; Wang, Hong-Rui; Cao, Yu; Zhao, Fei; Cui, Yu; Wang, Jian; He, Fuchu; Zhang, Lingqiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3733</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neddylation, the covalent attachment of ubiquitin-like protein Nedd8, of the Cullin-RING E3 ligase family regulates their ubiquitylation activity.  However, regulation of HECT ligases by neddylation has not been reported to date.  Here we show that the C2-WW-HECT ligase Smurf1 is activated by neddylation.  Smurf1 phys. interacts with Nedd8 and Ubc12, forms a Nedd8-thioester intermediate, and then catalyzes its own neddylation on multiple lysine residues.  Intriguingly, this autoneddylation needs an active site at C426 in the HECT N-lobe.  Neddylation of Smurf1 potently enhances ubiquitin E2 recruitment and augments the ubiquitin ligase activity of Smurf1.  The regulatory role of neddylation is conserved in human Smurf1 and yeast Rsp5.  Furthermore, in human colorectal cancers, the elevated expression of Smurf1, Nedd8, NAE1 and Ubc12 correlates with cancer progression and poor prognosis.  These findings provide evidence that neddylation is important in HECT ubiquitin ligase activation and shed new light on the tumor-promoting role of Smurf1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx6S-UZ8f-y7Vg90H21EOLACvtfcHk0lh1ip4d1R3SBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVCjsL0%253D&md5=a42d6c5b256fd17cc12eb2cb85b74c02</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fncomms4733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4733%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DM.%2BH.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DK.%2BF.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DXing%26aufirst%3DG.%2BC.%26aulast%3DLu%26aufirst%3DY.%2BM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%2BX.%26aulast%3DChai%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DJ.%2BW.%26aulast%3DDeng%26aufirst%3DH.%2BT.%26aulast%3DWang%26aufirst%3DH.%2BR.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DF.%2BC.%26aulast%3DZhang%26aufirst%3DL.%2BQ.%26atitle%3DThe%2520covalent%2520modifier%2520Nedd8%2520is%2520critical%2520for%2520the%2520activation%2520of%2520Smurf1%2520ubiquitin%2520ligase%2520in%2520tumorigenesis%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3733%26doi%3D10.1038%2Fncomms4733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lukkarila, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahani, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1021/ml2000615</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml2000615" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlCku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=577-582&author=J.+L.+Lukkarilaauthor=S.+R.+da+Silvaauthor=M.+Aliauthor=V.+M.+Shahaniauthor=G.+W.+Xuauthor=J.+Bermanauthor=A.+Roughtonauthor=S.+Dhe-Paganonauthor=A.+D.+Schimmerauthor=P.+T.+Gunning&title=Identification+of+NAE+Inhibitors+Exhibiting+Potent+Activity+in+Leukemia+Cells%3A+Exploring+the+Structural+Determinants+of+NAE+Specificity&doi=10.1021%2Fml2000615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity</span></div><div class="casAuthors">Lukkarila, Julie L.; da Silva, Sara R.; Ali, Mohsin; Shahani, Vijay M.; Xu, G. Wei; Berman, Judd; Roughton, Andrew; Dhe-Paganon, Sirano; Schimmer, Aaron D.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">577-582</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MLN4924 is a selective inhibitor of the NEDD8-activating enzyme (NAE) and has advanced into clin. trials for the treatment of both solid and hematol. malignancies.  In contrast, the structurally similar compd. 1 (developed by Millennium: The Takeda Oncol. Company) is a pan inhibitor of the E1 enzymes NAE, ubiquitin activating enzyme (UAE), and SUMO-activating enzyme (SAE) and is currently viewed as unsuitable for clin. use given its broad spectrum of E1 inhibition.  Here, we sought to understand the determinants of NAE selectivity.  A series of compd. 1 analogs were synthesized through iterative functionalization of the purine C6 position and evaluated for NAE specificity.  Optimal NAE specificity was achieved through substitution with primary N-alkyl groups, while bulky or secondary N-alkyl substituents were poorly tolerated.  When assessed in vitro, inhibitors reduced the growth and viability of malignant K562 leukemia cells.  Through this study, we have successfully identified a series of sub-10 nM NAE-specific inhibitors and thereby highlighted the functionalities that promote NAE selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbNgZ42C7Y7Vg90H21EOLACvtfcHk0lh1ip4d1R3SBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlCku78%253D&md5=d522810186b43a4f45990f7cff9b1254</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml2000615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml2000615%26sid%3Dliteratum%253Aachs%26aulast%3DLukkarila%26aufirst%3DJ.%2BL.%26aulast%3Dda%2BSilva%26aufirst%3DS.%2BR.%26aulast%3DAli%26aufirst%3DM.%26aulast%3DShahani%26aufirst%3DV.%2BM.%26aulast%3DXu%26aufirst%3DG.%2BW.%26aulast%3DBerman%26aufirst%3DJ.%26aulast%3DRoughton%26aufirst%3DA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DIdentification%2520of%2520NAE%2520Inhibitors%2520Exhibiting%2520Potent%2520Activity%2520in%2520Leukemia%2520Cells%253A%2520Exploring%2520the%2520Structural%2520Determinants%2520of%2520NAE%2520Specificity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D577%26epage%3D582%26doi%3D10.1021%2Fml2000615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, P.-k.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel NEDD8 Activating Enzyme Inhibitor with Piperidin-4-amine Scaffold by Structure-Based Virtual Screening</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1901</span>– <span class="NLM_lpage">1907</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00159</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00159" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFKqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1901-1907&author=P.+Luauthor=X.+Liuauthor=X.+Yuanauthor=M.+Heauthor=Y.+Wangauthor=Q.+Zhangauthor=P.-k.+Ouyang&title=Discovery+of+a+novel+NEDD8+Activating+Enzyme+Inhibitor+with+Piperidin-4-amine+Scaffold+by+Structure-Based+Virtual+Screening&doi=10.1021%2Facschembio.6b00159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel NEDD8 Activating Enzyme Inhibitor with Piperidin-4-amine Scaffold by Structure-Based Virtual Screening</span></div><div class="casAuthors">Lu, Peng; Liu, Xiaoxin; Yuan, Xinrui; He, Minfang; Wang, Yubin; Zhang, Qi; Ouyang, Ping-kai</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1901-1907</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NEDD8 activating enzyme (NAE) plays an important role in regulating intracellular proteins with key parts in a broad array of cellular functions.  Here, we report a structure-based virtual screening of a compd. library contg. 50000 small mol. entities against the active site of NAE.  Computational docking and scoring followed by biochem. screening and target validation lead to the identification of 1-benzyl-N-(2,4-dichlorophenethyl) piperidin-4-amine (M22) as a selective NAE inhibitor.  M22 is reversible for NAE, inhibits multiple cancer cell lines with GI50 values in the low micromolar range, and induces apoptosis in A549 cells.  Furthermore, it produces tumor inhibition in AGS xenografts in nude mice and low acute toxicity in a zebrafish model.  M22, a novel NAE inhibitor, represents a promising lead structure for the development of new antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3wkfzasykYrVg90H21EOLACvtfcHk0lh1ip4d1R3SBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFKqurg%253D&md5=75b21e45e1698ccca8f4ac4a92a0a3b8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00159%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DOuyang%26aufirst%3DP.-k.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520NEDD8%2520Activating%2520Enzyme%2520Inhibitor%2520with%2520Piperidin-4-amine%2520Scaffold%2520by%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D1901%26epage%3D1907%26doi%3D10.1021%2Facschembio.6b00159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1027</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1016%2Fj.ejmech.2017.11.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=29232579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1021-1027&author=K.-J.+Wuauthor=H.-J.+Zhongauthor=G.+Liauthor=C.+Liuauthor=H.-M.+D.+Wangauthor=D.-L.+Maauthor=C.-H.+Leung&title=Structure-based+identification+of+a+NEDD8-activating+enzyme+inhibitor+via+drug+repurposing&doi=10.1016%2Fj.ejmech.2017.11.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</span></div><div class="casAuthors">Wu, Ke-Jia; Zhong, Hai-Jing; Li, Guodong; Liu, Chenfu; Wang, Hui-Min David; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1021-1027</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">NEDD8-activating enzyme (NAE) is an essential player of the NEDD8 conjugation pathway that regulates protein degrdn.  Meanwhile, drug repurposing is a cost-efficient strategy to identify new therapeutic uses for existing scaffolds.  In this report, mitoxantrone (1) was repurposed as an inhibitor of NAE by virtual screening of an FDA-approved drug database.  Compd. 1 inhibited NAE activity in cell-free and cell-based systems with high selectivity and was competitive with ATP.  Furthermore, compd. 1 induced apoptosis of colorectal adenocarcinoma cancer cells through inhibiting the degrdn. of the neddylation substrate p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUAq1axDoEP7Vg90H21EOLACvtfcHk0lj8bta4gKiqWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3I&md5=c9d129e8a7887bcdc3e77cdc27e4fdbf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.101%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DK.-J.%26aulast%3DZhong%26aufirst%3DH.-J.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.-M.%2BD.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DStructure-based%2520identification%2520of%2520a%2520NEDD8-activating%2520enzyme%2520inhibitor%2520via%2520drug%2520repurposing%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1021%26epage%3D1027%26doi%3D10.1016%2Fj.ejmech.2017.11.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Targeting the DCN1-UBC12 Protein-Protein Interaction for Selective Modulation of Cullin Substrates</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1425</span>, <span class="refDoi"> DOI: 10.2174/156802661817181107151134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.2174%2F156802661817181107151134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=30497356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSgu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=1423-1425&author=Y.+Fangauthor=L.+Yuauthor=G.+Liaoauthor=B.+Yu&title=Targeting+the+DCN1-UBC12+Protein-Protein+Interaction+for+Selective+Modulation+of+Cullin+Substrates&doi=10.2174%2F156802661817181107151134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DCN1-UBC12 Protein-Protein Interaction for Selective Modulation of Cullin Substrates</span></div><div class="casAuthors">Fang, Yuan; Yu, Lei; Liao, Guochao; Yu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1423-1425</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review discussing about the targeting of the DCN1-UBC12 protein-protein interaction (PPI) for selective modulation of Cullin substrates.  The findings in this review suggested that the DCN1-UBC12 PPI plays crucial roles in modulating neddylation of specific downstream Cul3/1 substrates, and targeting this PPI may have applications in CUL3 dysregulated diseases.  The development of inhibitors targeting DCN1-UBC12 interaction ares currently undergoing worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7vtIBLyRf4bVg90H21EOLACvtfcHk0lj8bta4gKiqWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSgu7jL&md5=236bb62a84c26179302b7385960791b3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F156802661817181107151134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661817181107151134%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DB.%26atitle%3DTargeting%2520the%2520DCN1-UBC12%2520Protein-Protein%2520Interaction%2520for%2520Selective%2520Modulation%2520of%2520Cullin%2520Substrates%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D18%26spage%3D1423%26epage%3D1425%26doi%3D10.2174%2F156802661817181107151134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span> <span> </span><span class="NLM_article-title">Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5382</span>– <span class="NLM_lpage">5403</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOntrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5382-5403&author=W.+Zhouauthor=L.+Maauthor=L.+Dingauthor=Q.+Guoauthor=Z.+Heauthor=J.+Yangauthor=H.+Qiaoauthor=L.+Liauthor=J.+Yangauthor=S.+Yuauthor=L.+Zhaoauthor=S.+Wangauthor=H.-M.+Liuauthor=Z.+Suoauthor=W.+Zhao&title=Potent+5-Cyano-6-phenyl-pyrimidin-Based+Derivatives+Targeting+DCN1-UBE2M+Interaction&doi=10.1021%2Facs.jmedchem.9b00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction</span></div><div class="casAuthors">Zhou, Wenjuan; Ma, Liying; Ding, Lina; Guo, Qian; He, Zhangxu; Yang, Jing; Qiao, Hui; Li, Lingyu; Yang, Jie; Yu, Shimin; Zhao, Lili; Wang, Shaomeng; Liu, Hong-Min; Suo, Zhenhe; Zhao, Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5382-5403</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neddylation of the Cullin-RING E3 ligases (CRLs) regulates the homeostasis of approx. 20% of cellular proteins.  Defective in cullin neddylation 1 (DCN1), as a co-E3 ligase, interacts with UBE2M to enhance the activation of CRLs, and this interaction is emerging as a therapeutic target for human diseases.  Here, we present a series of pyrimidin-based small mol. inhibitors targeting DCN1-UBE2M interaction.  After finding a novel inhibitor DC-1 with IC50 = 1.2 μM, we performed a series of chem. optimizations, which finally led to the discovery of a potent thiazole contg. 5-cyano-6-phenylpyrimidin-based inhibitor DC-2 (IC50 = 15 nM).  Next, using protein and cellular thermal shift assays, coimmunopptn., mol. docking, and site-specific mutation expts., we further proved that DC-2 specifically inhibited the interaction of UBE2M and DCN1 at mol. and cellular levels, resulting in the decrease of cullin3 neddylation and accumulation of its substrate, NRF2.  Our findings indicate that DC-2 may serve as a novel lead compd. for specific derivs. targeting DCN1-UBE2M interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqFJ-HvcKxn7Vg90H21EOLACvtfcHk0lj8bta4gKiqWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOntrzI&md5=b0b7b00a80e377905d1532b4e2c5992b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00003%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DH.-M.%26aulast%3DSuo%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DW.%26atitle%3DPotent%25205-Cyano-6-phenyl-pyrimidin-Based%2520Derivatives%2520Targeting%2520DCN1-UBE2M%2520Interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5382%26epage%3D5403%26doi%3D10.1021%2Facs.jmedchem.9b00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraj, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spelman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sells, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visiers, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2009.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1016%2Fj.molcel.2009.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=20129059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFKgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=102-111&author=J.+E.+Brownellauthor=M.+D.+Sintchakauthor=J.+M.+Gavinauthor=H.+Liaoauthor=F.+J.+Bruzzeseauthor=N.+J.+Bumpauthor=T.+A.+Soucyauthor=M.+A.+Milhollenauthor=X.+Yangauthor=A.+L.+Burkhardtauthor=J.+Maauthor=H.-K.+Lokeauthor=T.+Lingarajauthor=D.+Wuauthor=K.+B.+Hammanauthor=J.+J.+Spelmanauthor=C.+A.+Cullisauthor=S.+P.+Langstonauthor=S.+Vyskocilauthor=T.+B.+Sellsauthor=W.+D.+Mallenderauthor=I.+Visiersauthor=P.+Liauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=L.+R.+Dick&title=Substrate-assisted+inhibition+of+ubiquitin-like+protein-activating+enzymes%3A+the+NEDD8+E1+inhibitor+MLN4924+forms+a+NEDD8-AMP+mimetic+in+situ&doi=10.1016%2Fj.molcel.2009.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ</span></div><div class="casAuthors">Brownell, James E.; Sintchak, Michael D.; Gavin, James M.; Liao, Hua; Bruzzese, Frank J.; Bump, Nancy J.; Soucy, Teresa A.; Milhollen, Michael A.; Yang, Xiaofeng; Burkhardt, Anne L.; Ma, Jingya; Loke, Huay-Keng; Lingaraj, Trupti; Wu, Dongyun; Hamman, Kristin B.; Spelman, James J.; Cullis, Courtney A.; Langston, Steven P.; Vyskocil, Stepan; Sells, Todd B.; Mallender, William D.; Visiers, Irache; Li, Ping; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The NEDD8-activating enzyme (NAE) initiates a protein homeostatic pathway essential for cancer cell growth and survival.  MLN4924 is a selective inhibitor of NAE currently in clin. trials for the treatment of cancer.  Here, we show that MLN4924 is a mechanism-based inhibitor of NAE and creates a covalent NEDD8-MLN4924 adduct catalyzed by the enzyme.  The NEDD8-MLN4924 adduct resembles NEDD8 adenylate, the first intermediate in the NAE reaction cycle, but cannot be further utilized in subsequent intraenzyme reactions.  The stability of the NEDD8-MLN4924 adduct within the NAE active site blocks enzyme activity, thereby accounting for the potent inhibition of the NEDD8 pathway by MLN4924.  Importantly, we have detd. that compds. resembling MLN4924 demonstrate the ability to form analogous adducts with other ubiquitin-like proteins (UBLs) catalyzed by their cognate-activating enzymes.  These findings reveal insights into the mechanism of E1s and suggest a general strategy for selective inhibition of UBL conjugation pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrGGYI7bTPerVg90H21EOLACvtfcHk0liWDYOT2mYVEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFKgsbw%253D&md5=b080f6ec40864164ab2252f629975456</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2009.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2009.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DLiao%26aufirst%3DH.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBurkhardt%26aufirst%3DA.%2BL.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.-K.%26aulast%3DLingaraj%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DHamman%26aufirst%3DK.%2BB.%26aulast%3DSpelman%26aufirst%3DJ.%2BJ.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DSells%26aufirst%3DT.%2BB.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DVisiers%26aufirst%3DI.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DSubstrate-assisted%2520inhibition%2520of%2520ubiquitin-like%2520protein-activating%2520enzymes%253A%2520the%2520NEDD8%2520E1%2520inhibitor%2520MLN4924%2520forms%2520a%2520NEDD8-AMP%2520mimetic%2520in%2520situ%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D37%26spage%3D102%26epage%3D111%26doi%3D10.1016%2Fj.molcel.2009.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talreja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span> <span> </span><span class="NLM_article-title">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>458</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1038/nature07884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnature07884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=19360080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=732-736&author=T.+A.+Soucyauthor=P.+G.+Smithauthor=M.+A.+Milhollenauthor=A.+J.+Bergerauthor=J.+M.+Gavinauthor=S.+Adhikariauthor=J.+E.+Brownellauthor=K.+E.+Burkeauthor=D.+P.+Cardinauthor=S.+Critchleyauthor=C.+A.+Cullisauthor=A.+Doucetteauthor=J.+J.+Garnseyauthor=J.+L.+Gaulinauthor=R.+E.+Gershmanauthor=A.+R.+Lublinskyauthor=A.+McDonaldauthor=H.+Mizutaniauthor=U.+Narayananauthor=E.+J.+Olhavaauthor=S.+Pelusoauthor=M.+Rezaeiauthor=M.+D.+Sintchakauthor=T.+Talrejaauthor=M.+P.+Thomasauthor=T.+Traoreauthor=S.+Vyskocilauthor=G.+S.+Weatherheadauthor=J.+Yuauthor=J.+Zhangauthor=L.+R.+Dickauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=S.+P.+Langston&title=An+inhibitor+of+NEDD8-activating+enzyme+as+a+new+approach+to+treat+cancer&doi=10.1038%2Fnature07884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span></div><div class="casAuthors">Soucy, Teresa A.; Smith, Peter G.; Milhollen, Michael A.; Berger, Allison J.; Gavin, James M.; Adhikari, Sharmila; Brownell, James E.; Burke, Kristine E.; Cardin, David P.; Critchley, Stephen; Cullis, Courtney A.; Doucette, Amanda; Garnsey, James J.; Gaulin, Jeffrey L.; Gershman, Rachel E.; Lublinsky, Anna R.; McDonald, Alice; Mizutani, Hirotake; Narayanan, Usha; Olhava, Edward J.; Peluso, Stephane; Rezaei, Mansoureh; Sintchak, Michael D.; Talreja, Tina; Thomas, Michael P.; Traore, Tary; Vyskocil, Stepan; Weatherhead, Gabriel S.; Yu, Jie; Zhang, Julie; Dick, Lawrence R.; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Langston, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7239</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. development of an inhibitor of cellular proteasome function suggests that compds. targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies.  NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome.  Substrates of cullin-RING ligases have important roles in cellular processes assocd. with cancer cell growth and survival pathways.  Here we describe MLN4924, a potent and selective inhibitor of NAE.  MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumor cells by a new mechanism of action, the deregulation of S-phase DNA synthesis.  MLN4924 suppressed the growth of human tumor xenografts in mice at compd. exposures that were well tolerated.  Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8fx7OnZtYjbVg90H21EOLACvtfcHk0liWDYOT2mYVEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D&md5=365d4b4feac3994849050e00f1aae5e0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature07884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07884%26sid%3Dliteratum%253Aachs%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DK.%2BE.%26aulast%3DCardin%26aufirst%3DD.%2BP.%26aulast%3DCritchley%26aufirst%3DS.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DDoucette%26aufirst%3DA.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DGaulin%26aufirst%3DJ.%2BL.%26aulast%3DGershman%26aufirst%3DR.%2BE.%26aulast%3DLublinsky%26aufirst%3DA.%2BR.%26aulast%3DMcDonald%26aufirst%3DA.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DPeluso%26aufirst%3DS.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DTalreja%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26atitle%3DAn%2520inhibitor%2520of%2520NEDD8-activating%2520enzyme%2520as%2520a%2520new%2520approach%2520to%2520treat%2520cancer%26jtitle%3DNature%26date%3D2009%26volume%3D458%26spage%3D732%26epage%3D736%26doi%3D10.1038%2Fnature07884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">40867</span>– <span class="NLM_lpage">40877</span>, <span class="refDoi"> DOI: 10.1074/jbc.m111.279984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1074%2Fjbc.M111.279984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=21969368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=40867-40877&author=J.+J.+Chenauthor=C.+A.+Tsuauthor=J.+M.+Gavinauthor=M.+A.+Milhollenauthor=F.+J.+Bruzzeseauthor=W.+D.+Mallenderauthor=M.+D.+Sintchakauthor=N.+J.+Bumpauthor=X.+Yangauthor=J.+Maauthor=H.-K.+Lokeauthor=Q.+Xuauthor=P.+Liauthor=N.+F.+Benceauthor=J.+E.+Brownellauthor=L.+R.+Dick&title=Mechanistic+studies+of+substrate-assisted+inhibition+of+ubiquitin-activating+enzyme+by+adenosine+sulfamate+analogues&doi=10.1074%2Fjbc.m111.279984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues</span></div><div class="casAuthors">Chen, Jesse J.; Tsu, Christopher A.; Gavin, James M.; Milhollen, Michael A.; Bruzzese, Frank J.; Mallender, William D.; Sintchak, Michael D.; Bump, Nancy J.; Yang, Xiaofeng; Ma, Jingya; Loke, Huay-Keng; Xu, Qing; Li, Ping; Bence, Neil F.; Brownell, James E.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">40867-40877</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ubiquitin-activating enzyme (UAE or E1) activates ubiquitin via an adenylate intermediate and catalyzes its transfer to a ubiquitin-conjugating enzyme (E2).  MLN4924 is an adenosine sulfamate analog that was identified as a selective, mechanism-based inhibitor of NEDD8-activating enzyme (NAE), another E1 enzyme, by forming a NEDD8-MLN4924 adduct that tightly binds at the active site of NAE, a novel mechanism termed substrate-assisted inhibition.  In the present study, substrate-assisted inhibition of human UAE (Ube1) by another adenosine sulfamate analog, 5'-O-sulfamoyl-N6-[(1S)-2,3-dihydro-1H-inden-1-yl]-adenosine (Compd. I), a nonselective E1 inhibitor, was characterized.  Compd. I inhibited UAE-dependent ATP-PPi exchange activity, caused loss of UAE thioester, and inhibited E1-E2 transthiolation in a dose-dependent manner.  Mechanistic studies on Compd. I and its purified ubiquitin adduct demonstrate that the proposed substrate-assisted inhibition via covalent adduct formation is entirely consistent with the three-step ubiquitin activation process and that the adduct is formed via nucleophilic attack of UAE thioester by the sulfamate group of Compd. I after completion of step 2.  Kinetic and affinity anal. of Compd. I, MLN4924, and their purified ubiquitin adducts suggest that both the rate of adduct formation and the affinity between the adduct and E1 contribute to the overall potency.  Because all E1s are thought to use a similar mechanism to activate their cognate ubiquitin-like proteins, the substrate-assisted inhibition by adenosine sulfamate analogs represents a promising strategy to develop potent and selective E1 inhibitors that can modulate diverse biol. pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiclhUT_b-7Vg90H21EOLACvtfcHk0liAkm_TjwlTlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE&md5=2362ac83bb8acf0de63162bac731c6e7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.279984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.279984%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DTsu%26aufirst%3DC.%2BA.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.-K.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBence%26aufirst%3DN.%2BF.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DMechanistic%2520studies%2520of%2520substrate-assisted%2520inhibition%2520of%2520ubiquitin-activating%2520enzyme%2520by%2520adenosine%2520sulfamate%2520analogues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D40867%26epage%3D40877%26doi%3D10.1074%2Fjbc.m111.279984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiiwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazuno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span> <span> </span><span class="NLM_article-title">TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-18-0644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F1535-7163.MCT-18-0644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=31092565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1205-1216&author=C.+Yoshimuraauthor=H.+Muraokaauthor=H.+Ochiiwaauthor=S.+Tsujiauthor=A.+Hashimotoauthor=H.+Kazunoauthor=F.+Nakagawaauthor=Y.+Komiyaauthor=S.+Suzukiauthor=T.+Takenakaauthor=M.+Kumazakiauthor=N.+Fujitaauthor=T.+Mizutaniauthor=S.+Ohkubo&title=TAS4464%2C+A+Highly+Potent+and+Selective+Inhibitor+of+NEDD8-Activating+Enzyme%2C+Suppresses+Neddylation+and+Shows+Antitumor+Activity+in+Diverse+Cancer+Models&doi=10.1158%2F1535-7163.mct-18-0644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">TAS4464, a highly potent and selective inhibitor of NEDD8-activating enzyme, suppresses neddylation and shows antitumor activity in diverse cancer models</span></div><div class="casAuthors">Yoshimura, Chihoko; Muraoka, Hiromi; Ochiiwa, Hiroaki; Tsuji, Shingo; Hashimoto, Akihiro; Kazuno, Hiromi; Nakagawa, Fumio; Komiya, Yu; Suzuki, Satoshi; Takenaka, Toru; Kumazaki, Masafumi; Fujita, Naoya; Mizutani, Takashi; Ohkubo, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1205-1216</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In this study, we describe the preclin. profile of a novel, highly potent, and selective NAE inhibitor, TAS4464.  TAS4464 selectively inhibited NAE relative to the other E1s UAE and SAE.  TAS4464 treatment inhibited cullin neddylation and subsequently induced the accumulation of CRL substrates such as CDT1, p27, and phosphorylated IkBa in human cancer cell lines.  TAS4464 showed greater inhibitory effects than those of the known NAE inhibitor MLN4924 both in enzyme assay and in cells.  Cytotoxicity profiling revealed that TAS4464 is highly potent with widespread antiproliferative activity not only for cancer cell lines, but also patient-derived tumor cells.  TAS4464 showed prolonged target inhibition in human tumor xenograft mouse models; weekly or twice a week TAS4464 administration led to prominent antitumor activity in multiple human tumor xenograft mouse models including both hematol. and solid tumors without marked wt. loss.  As a conclusion, TAS4464 is the most potent and highly selective NAE inhibitor reported to date, showing superior antitumor activity with prolonged target inhibition.  It is, therefore, a promising agent for the treatment of a variety of tumors including both hematol. and solid tumors.  These results support the clin. evaluation of TAS4464 in hematol. and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLvsFtDEsV3rVg90H21EOLACvtfcHk0liAkm_TjwlTlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsLfL&md5=39762fcc9437ca90e5160ab0be09f6b6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0644%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DOchiiwa%26aufirst%3DH.%26aulast%3DTsuji%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DKazuno%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DF.%26aulast%3DKomiya%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DTakenaka%26aufirst%3DT.%26aulast%3DKumazaki%26aufirst%3DM.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DOhkubo%26aufirst%3DS.%26atitle%3DTAS4464%252C%2520A%2520Highly%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520NEDD8-Activating%2520Enzyme%252C%2520Suppresses%2520Neddylation%2520and%2520Shows%2520Antitumor%2520Activity%2520in%2520Diverse%2520Cancer%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26spage%3D1205%26epage%3D1216%26doi%3D10.1158%2F1535-7163.mct-18-0644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocki, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carew, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3800</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-11-254862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1182%2Fblood-2009-11-254862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=20203261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1ensrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3796-3800&author=R.+T.+Swordsauthor=K.+R.+Kellyauthor=P.+G.+Smithauthor=J.+J.+Garnseyauthor=D.+Mahalingamauthor=E.+Medinaauthor=K.+Oberheuauthor=S.+Padmanabhanauthor=M.+O%E2%80%99Dwyerauthor=S.+T.+Nawrockiauthor=F.+J.+Gilesauthor=J.+S.+Carew&title=Inhibition+of+NEDD8-activating+enzyme%3A+a+novel+approach+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1182%2Fblood-2009-11-254862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Swords, Ronan T.; Kelly, Kevin R.; Smith, Peter G.; Garnsey, James J.; Mahalingam, Devalingam; Medina, Ernest; Oberheu, Kelli; Padmanabhan, Swaminathan; O'Dwyer, Michael; Nawrocki, Steffan T.; Giles, Francis J.; Carew, Jennifer S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3796-3800</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">NEDD8 activating enzyme (NAE) has been identified as an essential regulator of the NEDD8 conjugation pathway, which controls the degrdn. of many proteins with important roles in cell-cycle progression, DNA damage, and stress responses.  Here we report that MLN4924, a novel inhibitor of NAE, has potent activity in acute myeloid leukemia (AML) models.  MLN4924 induced cell death in AML cell lines and primary patient specimens independent of Fms-like tyrosine kinase 3 expression and stromal-mediated survival signaling and led to the stabilization of key NAE targets, inhibition of nuclear factor-κB activity, DNA damage, and reactive oxygen species generation.  Disruption of cellular redox status was shown to be a key event in MLN4924-induced apoptosis.  Administration of MLN4924 to mice bearing AML xenografts led to stable disease regression and inhibition of NEDDy-lated cullins.  Our findings indicate that MLN4924 is a highly promising novel agent that has advanced into clin. trials for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfgbcmAqI5mbVg90H21EOLACvtfcHk0liAkm_TjwlTlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1ensrw%253D&md5=081233e7c0651a42ddb52979c200b60d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-11-254862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-11-254862%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DMahalingam%26aufirst%3DD.%26aulast%3DMedina%26aufirst%3DE.%26aulast%3DOberheu%26aufirst%3DK.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DM.%26aulast%3DNawrocki%26aufirst%3DS.%2BT.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCarew%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520NEDD8-activating%2520enzyme%253A%2520a%2520novel%2520approach%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3796%26epage%3D3800%26doi%3D10.1182%2Fblood-2009-11-254862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMillin, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmore, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monrose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span> <span> </span><span class="NLM_article-title">Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F1535-7163.MCT-11-0563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=22246439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=942-951&author=D.+W.+McMillinauthor=H.+M.+Jacobsauthor=J.+E.+Delmoreauthor=L.+Buonauthor=Z.+R.+Hunterauthor=V.+Monroseauthor=J.+Yuauthor=P.+G.+Smithauthor=P.+G.+Richardsonauthor=K.+C.+Andersonauthor=S.+P.+Treonauthor=A.+L.+Kungauthor=C.+S.+Mitsiades&title=Molecular+and+cellular+effects+of+NEDD8-activating+enzyme+inhibition+in+myeloma&doi=10.1158%2F1535-7163.mct-11-0563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma</span></div><div class="casAuthors">McMillin, Douglas W.; Jacobs, Hannah M.; Delmore, Jake E.; Buon, Leutz; Hunter, Zachary R.; Monrose, Val; Yu, Jie; Smith, Peter G.; Richardson, Paul G.; Anderson, Kenneth C.; Treon, Steven P.; Kung, Andrew L.; Mitsiades, Constantine S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">942-951</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The NEDD8-activating enzyme is upstream of the 20S proteasome in the ubiquitin/proteasome pathway and catalyzes the first step in the neddylation pathway.  NEDD8 modification of cullins is required for ubiquitination of cullin-ring ligases that regulate degrdn. of a distinct subset of proteins.  The more targeted impact of NEDD8-activating enzyme on protein degrdn. prompted us to study MLN4924, an investigational NEDD8-activating enzyme inhibitor, in preclin. multiple myeloma models.  In vitro treatment with MLN4924 led to dose-dependent decrease of viability (EC50 = 25-150 nmol/L) in a panel of human multiple myeloma cell lines.  MLN4924 was similarly active against a bortezomib-resistant ANBL-6 subline and its bortezomib-sensitive parental cells.  MLN4924 had submicromolar activity (EC50 values <500 nmol/L) against primary CD138+ multiple myeloma patient cells and exhibited at least additive effect when combined with dexamethasone, doxorubicin, and bortezomib against MM.1S cells.  The bortezomib-induced compensatory upregulation of transcripts for ubiquitin/proteasome was not obsd. with MLN4924 treatment, suggesting distinct functional roles of NEDD8-activating enzyme vs. 20S proteasome.  MLN4924 was well tolerated at doses up to 60 mg/kg 2x daily and significantly reduced tumor burden in both a s.c. and an orthotopic mouse model of multiple myeloma.  These studies provide the framework for the clin. investigation of MLN4924 in multiple myeloma.  Mol Cancer Ther; 11(4); 942-51.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocMb3UagwGorVg90H21EOLACvtfcHk0lgr7w9jvIY6ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2nur8%253D&md5=e3a5f1f8f5334296e5c289674d6f3e02</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0563%26sid%3Dliteratum%253Aachs%26aulast%3DMcMillin%26aufirst%3DD.%2BW.%26aulast%3DJacobs%26aufirst%3DH.%2BM.%26aulast%3DDelmore%26aufirst%3DJ.%2BE.%26aulast%3DBuon%26aufirst%3DL.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DMonrose%26aufirst%3DV.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26atitle%3DMolecular%2520and%2520cellular%2520effects%2520of%2520NEDD8-activating%2520enzyme%2520inhibition%2520in%2520myeloma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D942%26epage%3D951%26doi%3D10.1158%2F1535-7163.mct-11-0563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams-Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span> <span> </span><span class="NLM_article-title">MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-03-272567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1182%2Fblood-2010-03-272567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=20525923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2qsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=1515-1523&author=M.+A.+Milhollenauthor=T.+Traoreauthor=J.+Adams-Duffyauthor=M.+P.+Thomasauthor=A.+J.+Bergerauthor=L.+Dangauthor=L.+R.+Dickauthor=J.+J.+Garnseyauthor=E.+Koenigauthor=S.+P.+Langstonauthor=M.+Manfrediauthor=U.+Narayananauthor=M.+Rolfeauthor=L.+M.+Staudtauthor=T.+A.+Soucyauthor=J.+Yuauthor=J.+Zhangauthor=J.+B.+Bolenauthor=P.+G.+Smith&title=MLN4924%2C+a+NEDD8-activating+enzyme+inhibitor%2C+is+active+in+diffuse+large+B-cell+lymphoma+models%3A+rationale+for+treatment+of+NF-%7Bkappa%7DB-dependent+lymphoma&doi=10.1182%2Fblood-2010-03-272567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma</span></div><div class="casAuthors">Milhollen, Michael A.; Traore, Tary; Adams-Duffy, Jennifer; Thomas, Michael P.; Berger, Allison J.; Dang, Lenny; Dick, Lawrence R.; Gamsey, James J.; Koenig, Erik; Langston, Steven P.; Manfredi, Mark; Narayanan, Usha; Rolfe, Mark; Staudt, Louis M.; Soucy, Teresa A.; Yu, Jie; Zhang, Julie; Bolen, Joseph B.; Smith, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1515-1523</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">MLN4924 is a potent and selective small mol. NEDD8-activating enzyme (NAE) inhibitor.  In most cancer cells tested, inhibition of NAE leads to induction of DNA rereplication, resulting in DNA damage and cell death.  However, in preclin. models of activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), we show that MLN4924 induces an alternative mechanism of action.  Treatment of ABC DLBCL cells with MLN4924 resulted in rapid accumulation of pIκBα, decrease in nuclear p65 content, redn. of nuclear factor-κB (NF-κB) transcriptional activity, and G1 arrest, ultimately resulting in apoptosis induction, events consistent with potent NF-κB pathway inhibition.  Treatment of germinal-center B cell-like (GCB) DLBCL cells resulted in an increase in cellular Cdt-1 and accumulation of cells in S-phase, consistent with cells undergoing DNA rereplication.  In vivo administration of MLN4924 to mice bearing human xenograft tumors of ABC- and GCB-DLBCL blocked NAE pathway biomarkers and resulted in complete tumor growth inhibition.  In primary human tumor models of ABC-DLBCL, MLN4924 treatment resulted in NF-κB pathway inhibition accompanied by tumor regressions.  This work describes a novel mechanism of targeted NF-κB pathway modulation in DLBCL and provides strong rationale for clin. development of MLN4924 against NF-κB-dependent lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Ez4BtgNx0LVg90H21EOLACvtfcHk0lgr7w9jvIY6ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2qsbzO&md5=6100194d48b30325e94b3b0cdb77fae0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-272567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-272567%26sid%3Dliteratum%253Aachs%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DAdams-Duffy%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DKoenig%26aufirst%3DE.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26atitle%3DMLN4924%252C%2520a%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520is%2520active%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%2520models%253A%2520rationale%2520for%2520treatment%2520of%2520NF-%257Bkappa%257DB-dependent%2520lymphoma%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D1515%26epage%3D1523%26doi%3D10.1182%2Fblood-2010-03-272567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span> <span> </span><span class="NLM_article-title">The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3360</span>– <span class="NLM_lpage">3371</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-12-0388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F0008-5472.CAN-12-0388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=22562464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3360-3371&author=Z.+Luoauthor=G.+Yuauthor=H.+W.+Leeauthor=L.+Liauthor=L.+Wangauthor=D.+Yangauthor=Y.+Panauthor=C.+Dingauthor=J.+Qianauthor=L.+Wuauthor=Y.+Chuauthor=J.+Yiauthor=X.+Wangauthor=Y.+Sunauthor=L.+S.+Jeongauthor=J.+Liuauthor=L.+Jia&title=The+Nedd8-activating+enzyme+inhibitor+MLN4924+induces+autophagy+and+apoptosis+to+suppress+liver+cancer+cell+growth&doi=10.1158%2F0008-5472.can-12-0388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth</span></div><div class="casAuthors">Luo, Zhongguang; Yu, Guangyang; Lee, Hyuk Woo; Li, Lihui; Wang, Lingyan; Yang, Dongqin; Pan, Yongfu; Ding, Chan; Qian, Jing; Wu, Lijun; Chu, Yiwei; Yi, Jing; Wang, Xiangdong; Sun, Yi; Jeong, Lak Shin; Liu, Jie; Jia, Lijun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3360-3371</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings offer preclin. evidence for therapeutic efficacy of a first-in-class neddylation inhibitor to treat liver cancer and provide a mechanistic rationale for its combination with an autophagy inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0YYRMtkc5JLVg90H21EOLACvtfcHk0lgr7w9jvIY6ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKrsr8%253D&md5=174581252b4b0b165279ab719c794bd9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-0388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-0388%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DYi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DL.%26atitle%3DThe%2520Nedd8-activating%2520enzyme%2520inhibitor%2520MLN4924%2520induces%2520autophagy%2520and%2520apoptosis%2520to%2520suppress%2520liver%2520cancer%2520cell%2520growth%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3360%26epage%3D3371%26doi%3D10.1158%2F0008-5472.can-12-0388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span> <span> </span><span class="NLM_article-title">Targeting the neddylation pathway to suppress the growth of prostate cancer cells: therapeutic implication for the men’s cancer</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">974309</span>, <span class="refDoi"> DOI: 10.1155/2014/974309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1155%2F2014%2F974309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=25093192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A280%3ADC%252BC2cbptVyktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=974309&author=X.+Wangauthor=L.+Liauthor=Y.+Liangauthor=C.+Liauthor=H.+Zhaoauthor=D.+Yeauthor=M.+Sunauthor=L.+S.+Jeongauthor=Y.+Fengauthor=S.+Fuauthor=L.+Jiaauthor=X.+Guo&title=Targeting+the+neddylation+pathway+to+suppress+the+growth+of+prostate+cancer+cells%3A+therapeutic+implication+for+the+men%E2%80%99s+cancer&doi=10.1155%2F2014%2F974309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the neddylation pathway to suppress the growth of prostate cancer cells: therapeutic implication for the men's cancer</span></div><div class="casAuthors">Wang Xiaofang; Li Lihui; Liang Yupei; Li Chunjie; Jia Lijun; Zhao Hu; Ye Dingwei; Sun Menghong; Jeong Lak Shin; Feng Yan; Fu Shen; Guo Xiaomao</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">974309</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The neddylation pathway has been recognized as an attractive anticancer target in several malignancies, and its selective inhibitor, MLN4924, has recently advanced to clinical development.  However, the anticancer effect of this compound against prostate cancer has not been well investigated.  In this study, we demonstrated that the neddylation pathway was functional and targetable in prostate cancer cells.  Specific inhibition of this pathway with MLN4924 suppressed the proliferation and clonogenic survival of prostate cancer cells.  Mechanistically, MLN4924 treatment inhibited cullin neddylation, inactivated Cullin-RING E3 ligases (CRLs), and led to accumulation of tumor-suppressive CRLs substrates, including cell cycle inhibitors (p21, p27, and WEE1), NF-κB signaling inhibitor IκBα, and DNA replication licensing proteins (CDT1 and ORC1).  As a result, MLN4924 triggered DNA damage, G2 phase cell cycle arrest, and apoptosis.  Taken together, our results demonstrate the effectiveness of targeting the neddylation pathway with MLN4924 in suppressing the growth of prostate cancer cells, implicating a potentially new therapeutic approach for the men's cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTRSSZ-9zT-MULxIEhxUjPfW6udTcc2eb_lEtlaQUTk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbptVyktA%253D%253D&md5=29fc252ddf8c28018bd954563ddc52fe</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1155%2F2014%2F974309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F974309%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DX.%26atitle%3DTargeting%2520the%2520neddylation%2520pathway%2520to%2520suppress%2520the%2520growth%2520of%2520prostate%2520cancer%2520cells%253A%2520therapeutic%2520implication%2520for%2520the%2520men%25E2%2580%2599s%2520cancer%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2014%26volume%3D2014%26spage%3D974309%26doi%3D10.1155%2F2014%2F974309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.-Y.</span></span> <span> </span><span class="NLM_article-title">The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2415</span>– <span class="NLM_lpage">2425</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F1535-7163.MCT-11-0401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=21914854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2415-2425&author=L.+Zhaoauthor=P.+Yueauthor=S.+Lonialauthor=F.+R.+Khuriauthor=S.-Y.+Sun&title=The+NEDD8-activating+enzyme+inhibitor%2C+MLN4924%2C+cooperates+with+TRAIL+to+augment+apoptosis+through+facilitating+c-FLIP+degradation+in+head+and+neck+cancer+cells&doi=10.1158%2F1535-7163.mct-11-0401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells</span></div><div class="casAuthors">Zhao, Liqun; Yue, Ping; Lonial, Sagar; Khuri, Fadlo R.; Sun, Shi-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2415-2425</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">TNF-related apoptosis-inducing ligand (TRAIL) is a tumor-selective cytokine with potential anticancer activity and is currently under clin. testing.  Head and neck squamous cell carcinoma (HNSCC), like other cancer types, exhibits varied sensitivity to TRAIL.  MLN4924 is a newly developed investigational small mol. inhibitor of NEDD8-activating enzyme with potent anticancer activity.  This study reveals a novel function of MLN4924 in synergizing with TRAIL to induce apoptosis in HNSCC cells.  MLN4924 alone effectively inhibited the growth of HNSCC cells and induced apoptosis.  When combined with TRAIL, synergistic effects on decreasing the survival and inducing apoptosis of HNSCC cells occurred.  MLN4924 decreased c-FLIP levels without modulating death receptor 4 and death receptor 5 expression.  Enforced expression of c-FLIP substantially attenuated MLN4924/TRAIL-induced apoptosis.  Thus c-FLIP redn. plays an important role in mediating MLN4924/TRAIL-induced apoptosis.  Moreover, MLN4924 decreased c-FLIP stability, increased c-FLIP ubiquitination, and facilitated c-FLIP degrdn., suggesting that MLN4924 decreases c-FLIP levels through promoting its degrdn.  MLN4924 activated c-jun-NH2-kinase (JNK) signaling, evidenced by increased levels of phospho-c-Jun in MLN4924-treated cells.  Chem. inhibition of JNK activation not only prevented MLN4924-induced c-FLIP redn., but also inhibited MLN4924/TRAIL-induced apoptosis, suggesting that JNK activation mediates c-FLIP downregulation and subsequent enhancement of TRAIL-induced apoptosis by MLN4924.  Because knockdown of NEDD8 failed to activate JNK signaling and downregulate c-FLIP, it is likely that MLN4924 reduces c-FLIP levels and enhances TRAIL-induced apoptosis independent of NEDD8 inhibition.  Mol Cancer Ther; 10(12); 2415-25.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRM_UK5KRWp7Vg90H21EOLACvtfcHk0liMCjHeLoDoXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfI&md5=132fc8fcb08e34d4592b325e2aaf98d5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0401%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DSun%26aufirst%3DS.-Y.%26atitle%3DThe%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520MLN4924%252C%2520cooperates%2520with%2520TRAIL%2520to%2520augment%2520apoptosis%2520through%2520facilitating%2520c-FLIP%2520degradation%2520in%2520head%2520and%2520neck%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2415%26epage%3D2425%26doi%3D10.1158%2F1535-7163.mct-11-0401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.-Y.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">29680</span>– <span class="NLM_lpage">29691</span>, <span class="refDoi"> DOI: 10.1074/jbc.m113.495069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1074%2Fjbc.M113.495069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=23995842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ShsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=29680-29691&author=W.-W.+Panauthor=J.-J.+Zhouauthor=C.+Yuauthor=Y.+Xuauthor=L.-J.+Guoauthor=H.-Y.+Zhangauthor=D.+Zhouauthor=F.-Z.+Songauthor=H.-Y.+Fan&title=Ubiquitin+E3+ligase+CRL4%28CDT2%2FDCAF2%29+as+a+potential+chemotherapeutic+target+for+ovarian+surface+epithelial+cancer&doi=10.1074%2Fjbc.m113.495069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin E3 ligase CRL4CDT2/DCAF2 as a potential chemotherapeutic target for ovarian surface epithelial cancer</span></div><div class="casAuthors">Pan, Wei-Wei; Zhou, Jian-Jie; Yu, Chao; Xu, Ying; Guo, Lian-Jun; Zhang, Hai-Yi; Zhou, Dawang; Song, Fang-Zhou; Fan, Heng-Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">29680-29691</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cullin-RING ubiquitin ligases (CRLs) are the largest family of E3 ligases and require cullin neddylation for their activation.  The NEDD8-activating enzyme inhibitor MLN4924 reportedly blocked cullin neddylation and inactivated CRLs, which resulted in apoptosis induction and tumor suppression.  However, CRL roles in ovarian cancer cell survival and the ovarian tumor repressing effects of MLN4924 are unknown.  We show here that CRL4 components are highly expressed in human epithelial ovarian cancer tissues.  MLN4924-induced DNA damage, cell cycle arrest, and apoptosis in ovarian cancer cells in a time- and dose-dependent manner.  In addn., MLN4924 sensitized ovarian cancer cells to other chemotherapeutic drug treatments.  Depletion of CRL4 components Roc1/2, Cul4a, and DDB1 had inhibitory effects on ovarian cancer cells similar to MLN4924 treatment, which suggested that CRL4 inhibition contributed to the chemotherapeutic effect of MLN4924 in ovarian cancers.  We also investigated for key CRL4 substrate adaptors required for ovarian cancer cells.  Depleting Vprbp/Dcaf1 did not significantly affect ovarian cancer cell growth, even though it was expressed by ovarian cancer tissues.  However, depleting Cdt2/Dcaf2 mimicked the pharmacol. effects of MLN4924 and caused the accumulation of its substrate, CDT1, both in vitro and in vivo.  MLN4924-induced DNA damage and apoptosis were partially rescued by Cdt1 depletion, suggesting that CRL4CDT2 repression and CDT1 accumulation were key biochem. events contributing to the genotoxic effects of MLN4924 in ovarian cancer cells.  Taken together, these results indicate that CRL4CDT2 is a potential drug target in ovarian cancers and that MLN4924 may be an effective anticancer agent for targeted ovarian cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8_uVQfMphY7Vg90H21EOLACvtfcHk0liMCjHeLoDoXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ShsrbN&md5=048dec2acd31a0805f9287dd72c73424</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.495069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.495069%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DW.-W.%26aulast%3DZhou%26aufirst%3DJ.-J.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DL.-J.%26aulast%3DZhang%26aufirst%3DH.-Y.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DF.-Z.%26aulast%3DFan%26aufirst%3DH.-Y.%26atitle%3DUbiquitin%2520E3%2520ligase%2520CRL4%2528CDT2%252FDCAF2%2529%2520as%2520a%2520potential%2520chemotherapeutic%2520target%2520for%2520ovarian%2520surface%2520epithelial%2520cancer%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D29680%26epage%3D29691%26doi%3D10.1074%2Fjbc.m113.495069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faessel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedarati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span> <span> </span><span class="NLM_article-title">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1111/bjh.13323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1111%2Fbjh.13323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=25733005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2015&pages=534-543&author=R.+T.+Swordsauthor=H.+P.+Erbaauthor=D.+J.+DeAngeloauthor=D.+L.+Bixbyauthor=J.+K.+Altmanauthor=M.+Marisauthor=Z.+Huaauthor=S.+J.+Blakemoreauthor=H.+Faesselauthor=F.+Sedaratiauthor=B.+J.+Dezubeauthor=F.+J.+Gilesauthor=B.+C.+Medeiros&title=Pevonedistat+%28MLN4924%29%2C+a+First-in-Class+NEDD8-activating+enzyme+inhibitor%2C+in+patients+with+acute+myeloid+leukaemia+and+myelodysplastic+syndromes%3A+a+phase+1+study&doi=10.1111%2Fbjh.13323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</span></div><div class="casAuthors">Swords, Ronan T.; Erba, Harry P.; DeAngelo, Daniel J.; Bixby, Dale L.; Altman, Jessica K.; Maris, Michael; Hua, Zhaowei; Blakemore, Stephen J.; Faessel, Helene; Sedarati, Farhad; Dezube, Bruce J.; Giles, Francis J.; Medeiros, Bruno C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">534-543</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : This trial was conducted to det. the dose-limiting toxicities (DLTs) and max. tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).  Pevonedistat was administered via a 60-min i.v. infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days.  Dose escalation proceeded using a std. '3 + 3' design.  Responses were assessed according to published guidelines.  The MTD for schedules A and B were 59 and 83 mg/m2, resp.  On schedule A, hepatotoxicity was dose limiting.  Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concns. peaked after infusion followed by elimination in a biphasic pattern.  Pharmacodynamic studies of biol. correlates of NAE inhibition demonstrated target-specific activity of pevonedistat.  In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clin. activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKvj57_N1VFrVg90H21EOLACvtfcHk0liKzK-1K_i0YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOntLY%253D&md5=435529c5ec061a767d00a3feb6589bb1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13323%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DMaris%26aufirst%3DM.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DBlakemore%26aufirst%3DS.%2BJ.%26aulast%3DFaessel%26aufirst%3DH.%26aulast%3DSedarati%26aufirst%3DF.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26atitle%3DPevonedistat%2520%2528MLN4924%2529%252C%2520a%2520First-in-Class%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukaemia%2520and%2520myelodysplastic%2520syndromes%253A%2520a%2520phase%25201%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D169%26spage%3D534%26epage%3D543%26doi%3D10.1111%2Fbjh.13323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidner, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardhanabhuti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlikowska-Dobler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faessel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedarati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savona, M. R.</span></span> <span> </span><span class="NLM_article-title">Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-09-805895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1182%2Fblood-2017-09-805895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=29348128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVemtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=1415-1424&author=R.+T.+Swordsauthor=S.+Coutreauthor=M.+B.+Marisauthor=J.+F.+Zeidnerauthor=J.+M.+Foranauthor=J.+Cruzauthor=H.+P.+Erbaauthor=J.+G.+Berdejaauthor=W.+Tamauthor=S.+Vardhanabhutiauthor=I.+Pawlikowska-Doblerauthor=H.+M.+Faesselauthor=A.+B.+Dashauthor=F.+Sedaratiauthor=B.+J.+Dezubeauthor=D.+V.+Fallerauthor=M.+R.+Savona&title=Pevonedistat%2C+a+first-in-class+NEDD8-activating+enzyme+inhibitor%2C+combined+with+azacitidine+in+patients+with+AML&doi=10.1182%2Fblood-2017-09-805895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML</span></div><div class="casAuthors">Swords, Ronan T.; Coutre, Steven; Maris, Michael B.; Zeidner, Joshua F.; Foran, James M.; Cruz, Jose; Erba, Harry P.; Berdeja, Jesus G.; Tam, Wayne; Vardhanabhuti, Saran; Pawlikowska-Dobler, Iwona; Faessel, Helene M.; Dash, Ajeeta B.; Sedarati, Farhad; Dezube, Bruce J.; Faller, Douglas V.; Savona, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1415-1424</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme (NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia (AML).  We performed a phase 1b study of pevonedistat (PEV) with azacitidine (AZA) based on synergistic activity seen preclinically.  Primary objectives included safety and tolerability, and secondary objectives included pharmacokinetics (PK) and disease response.  Patients ≥60 years with treatment-naive AML (unfit for std. induction therapy) received PEV 20 or 30 mg/m2 IV on days 1, 3, and 5 combined with fixed-dose AZA (75 mg/m2 IV/ s.c.) on days 1 to 5, 8, and 9, every 28 days.  The most common treatmentemergent adverse events were constipation (48%), nausea (42%), fatigue (42%), and anemia (39%).  In total, 11 deaths were obsd. and considered unrelated to study therapy by the investigators.  Transient elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were dose limiting.  The recommended phase 2 dose (RP2D) of PEV in this combination is 20 mg/m2.  PEV PK was not altered by the addn. of AZA.  Overall response rate (ORR) based on an intent-to-treat anal. was 50% (20 complete remissions [CRs], 5 complete remission with incomplete peripheral count recovery, 7 partial remissions [PRs]), with an 8.3-mo median duration of remission.  In patients receiving =6 cycles of therapy (n 5 23, 44%), ORR was 83%.  In patients with TP53 mutations, the composite CR/PR rate was 80% (4/5).  Two of these patients stayed on study for >10 cycles.  Baseline bone marrow blast percentage or cytogenetic/mol. risk did not influence ORR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWP3dayPgwy7Vg90H21EOLACvtfcHk0liKzK-1K_i0YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVemtr%252FL&md5=7890ca924d46b4bb1a5e039f5d137fd7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-09-805895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-09-805895%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DMaris%26aufirst%3DM.%2BB.%26aulast%3DZeidner%26aufirst%3DJ.%2BF.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DCruz%26aufirst%3DJ.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DTam%26aufirst%3DW.%26aulast%3DVardhanabhuti%26aufirst%3DS.%26aulast%3DPawlikowska-Dobler%26aufirst%3DI.%26aulast%3DFaessel%26aufirst%3DH.%2BM.%26aulast%3DDash%26aufirst%3DA.%2BB.%26aulast%3DSedarati%26aufirst%3DF.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DFaller%26aufirst%3DD.%2BV.%26aulast%3DSavona%26aufirst%3DM.%2BR.%26atitle%3DPevonedistat%252C%2520a%2520first-in-class%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520combined%2520with%2520azacitidine%2520in%2520patients%2520with%2520AML%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D1415%26epage%3D1424%26doi%3D10.1182%2Fblood-2017-09-805895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekeres, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radinoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangerman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerrano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidner, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campelo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liesveld, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selleslag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzvetkov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fram, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ades, L.</span></span> <span> </span><span class="NLM_article-title">Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1038/s41375-021-01125-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fs41375-021-01125-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2021&pages=1&author=M.+A.+Sekeresauthor=J.+Wattsauthor=A.+Radinoffauthor=M.+A.+Sangermanauthor=M.+Cerranoauthor=P.+F.+Lopezauthor=J.+F.+Zeidnerauthor=M.+D.+Campeloauthor=C.+Grauxauthor=J.+Liesveldauthor=D.+Selleslagauthor=N.+Tzvetkovauthor=R.+J.+Framauthor=D.+Zhaoauthor=J.+Bellauthor=S.+Friedlanderauthor=D.+V.+Fallerauthor=L.+Ades&title=Randomized+phase+2+trial+of+pevonedistat+plus+azacitidine+versus+azacitidine+for+higher-risk+MDS%2FCMML+or+low-blast+AML&doi=10.1038%2Fs41375-021-01125-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fs41375-021-01125-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-021-01125-4%26sid%3Dliteratum%253Aachs%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DRadinoff%26aufirst%3DA.%26aulast%3DSangerman%26aufirst%3DM.%2BA.%26aulast%3DCerrano%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DP.%2BF.%26aulast%3DZeidner%26aufirst%3DJ.%2BF.%26aulast%3DCampelo%26aufirst%3DM.%2BD.%26aulast%3DGraux%26aufirst%3DC.%26aulast%3DLiesveld%26aufirst%3DJ.%26aulast%3DSelleslag%26aufirst%3DD.%26aulast%3DTzvetkov%26aufirst%3DN.%26aulast%3DFram%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DBell%26aufirst%3DJ.%26aulast%3DFriedlander%26aufirst%3DS.%26aulast%3DFaller%26aufirst%3DD.%2BV.%26aulast%3DAdes%26aufirst%3DL.%26atitle%3DRandomized%2520phase%25202%2520trial%2520of%2520pevonedistat%2520plus%2520azacitidine%2520versus%2520azacitidine%2520for%2520higher-risk%2520MDS%252FCMML%2520or%2520low-blast%2520AML%26jtitle%3DLeukemia%26date%3D2021%26volume%3D18%26spage%3D1%26doi%3D10.1038%2Fs41375-021-01125-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0liQgRt0hlDwjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armitage, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubbin, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span> <span> </span><span class="NLM_article-title">Process Development and GMP Production of a Potent NAE Inhibitor Pevonedistat</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1299</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.5b00209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlehu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1299-1307&author=I.+Armitageauthor=E.+L.+Elliottauthor=F.+Hicksauthor=M.+Langstonauthor=A.+McCarronauthor=Q.+J.+McCubbinauthor=E.+O%E2%80%99Brienauthor=M.+Stirlingauthor=L.+Zhu&title=Process+Development+and+GMP+Production+of+a+Potent+NAE+Inhibitor+Pevonedistat&doi=10.1021%2Facs.oprd.5b00209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development and GMP Production of a Potent NAE Inhibitor Pevonedistat</span></div><div class="casAuthors">Armitage, Ian; Elliott, Eric L.; Hicks, Frederick; Langston, Marianne; McCarron, Ashley; McCubbin, Quentin J.; O'Brien, Erin; Stirling, Matt; Zhu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1299-1307</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical synthesis of a novel NEDD8-activating enzyme (NAE) inhibitor pevonedistat (MLN4924) is described.  Key steps include an enantioselective synthesis of an amino-diol cyclopentane intermediate contg. three chiral centers and a novel, regioselective sulfamoylation using N-(tert-butoxycarbonyl)-N-[(triethylenediammonium)sulfonyl]azanide.  The linear process, involving six solid isolations, has been carried out in multiple cGMP productions on 15-30 kg scale to produce pevonedistat in 98% (a/a) chem. purity and 25% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroYA4DtDY5BrVg90H21EOLACvtfcHk0liQgRt0hlDwjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlehu77N&md5=0551462cca51b7a2cdde0eb21cc0acdc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00209%26sid%3Dliteratum%253Aachs%26aulast%3DArmitage%26aufirst%3DI.%26aulast%3DElliott%26aufirst%3DE.%2BL.%26aulast%3DHicks%26aufirst%3DF.%26aulast%3DLangston%26aufirst%3DM.%26aulast%3DMcCarron%26aufirst%3DA.%26aulast%3DMcCubbin%26aufirst%3DQ.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DE.%26aulast%3DStirling%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DL.%26atitle%3DProcess%2520Development%2520and%2520GMP%2520Production%2520of%2520a%2520Potent%2520NAE%2520Inhibitor%2520Pevonedistat%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D1299%26epage%3D1307%26doi%3D10.1021%2Facs.oprd.5b00209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarron, A. S.</span>; <span class="NLM_string-name">Sells, T. B.</span>; <span class="NLM_string-name">Stirling, M.</span>; <span class="NLM_string-name">Stroud, S. G.</span></span> <span> </span><span class="NLM_article-title">Preparation of chloromethoxydihydroindenylaminopyrimidinyloxyhydroxycyclopentylmethyl sulfamate as Nedd8-activating enzyme inhibitors for treatment of cancer</span>. <span class="NLM_patent">WO 2013028832 A2</span>, Feb 28, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+S.+McCarron&author=T.+B.+Sells&author=M.+Stirling&author=S.+G.+Stroud&title=Preparation+of+chloromethoxydihydroindenylaminopyrimidinyloxyhydroxycyclopentylmethyl+sulfamate+as+Nedd8-activating+enzyme+inhibitors+for+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarron%26aufirst%3DA.%2BS.%26atitle%3DPreparation%2520of%2520chloromethoxydihydroindenylaminopyrimidinyloxyhydroxycyclopentylmethyl%2520sulfamate%2520as%2520Nedd8-activating%2520enzyme%2520inhibitors%2520for%2520treatment%2520of%2520cancer%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makings, L. R.</span>; <span class="NLM_string-name">Garcia-Guzman, B. M.</span>; <span class="NLM_string-name">Hurley, D. J.</span>; <span class="NLM_string-name">Drutu, I.</span>; <span class="NLM_string-name">Raffai, G.</span>; <span class="NLM_string-name">Bergeron, D. J.</span>; <span class="NLM_string-name">Nakatani, A.</span>; <span class="NLM_string-name">Termin, A. P.</span>; <span class="NLM_string-name">Silinas, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of spiro-fused piperidines as as modulators of muscarinic receptors</span>. <span class="NLM_patent">WO 2006023852 A2</span>, Mar 2, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=L.+R.+Makings&author=B.+M.+Garcia-Guzman&author=D.+J.+Hurley&author=I.+Drutu&author=G.+Raffai&author=D.+J.+Bergeron&author=A.+Nakatani&author=A.+P.+Termin&author=A.+Silinas&title=Preparation+of+spiro-fused+piperidines+as+as+modulators+of+muscarinic+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMakings%26aufirst%3DL.%2BR.%26atitle%3DPreparation%2520of%2520spiro-fused%2520piperidines%2520as%2520as%2520modulators%2520of%2520muscarinic%2520receptors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span> <span> </span><span class="NLM_article-title">Stereoselective synthesis of MLN4924, an inhibitor of NEDD8-activating enzyme</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3557</span>– <span class="NLM_lpage">3561</span>, <span class="refDoi"> DOI: 10.1021/jo2001897</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo2001897" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFKntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=3557-3561&author=H.+W.+Leeauthor=S.+K.+Namauthor=W.+J.+Choiauthor=H.+O.+Kimauthor=L.+S.+Jeong&title=Stereoselective+synthesis+of+MLN4924%2C+an+inhibitor+of+NEDD8-activating+enzyme&doi=10.1021%2Fjo2001897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective Synthesis of MLN4924, an Inhibitor of NEDD8-Activating Enzyme</span></div><div class="casAuthors">Lee, Hyuk Woo; Nam, Soo Kyung; Choi, Won Jun; Kim, Hea Ok; Jeong, Lak Shin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3557-3561</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carbocyclic nucleoside MLN4924 I, which is in clin. trials as an anticancer agent, was stereoselectively synthesized from D-ribose via a route involving stereoselective redn., regioselective cleavage of an isopropylidene moiety, and selective displacement of a cyclic sulfate moiety as key steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppbnZAsQWf57Vg90H21EOLACvtfcHk0liQgRt0hlDwjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFKntLo%253D&md5=0526e0d5d7b9ece1c7cd1f3d44da7657</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjo2001897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo2001897%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DNam%26aufirst%3DS.%2BK.%26aulast%3DChoi%26aufirst%3DW.%2BJ.%26aulast%3DKim%26aufirst%3DH.%2BO.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26atitle%3DStereoselective%2520synthesis%2520of%2520MLN4924%252C%2520an%2520inhibitor%2520of%2520NEDD8-activating%2520enzyme%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D3557%26epage%3D3561%26doi%3D10.1021%2Fjo2001897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciavarri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/nm.4474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnm.4474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=29334375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=186-193&author=M.+L.+Hyerauthor=M.+A.+Milhollenauthor=J.+Ciavarriauthor=P.+Flemingauthor=T.+Traoreauthor=D.+Sappalauthor=J.+Huckauthor=J.+Shiauthor=J.+Gavinauthor=J.+Brownellauthor=Y.+Yangauthor=B.+Stringerauthor=R.+Griffinauthor=F.+Bruzzeseauthor=T.+Soucyauthor=J.+Duffyauthor=C.+Rabinoauthor=J.+Ricebergauthor=K.+Hoarauthor=A.+Lublinskyauthor=S.+Menonauthor=M.+Sintchakauthor=N.+Bumpauthor=S.+M.+Pulukuriauthor=S.+Langstonauthor=S.+Tirrellauthor=M.+Kurandaauthor=P.+Veibyauthor=J.+Newcombauthor=P.+Liauthor=J.+T.+Wuauthor=J.+Poweauthor=L.+R.+Dickauthor=P.+Greenspanauthor=K.+Galvinauthor=M.+Manfrediauthor=C.+Claiborneauthor=B.+S.+Amidonauthor=N.+F.+Bence&title=A+small-molecule+inhibitor+of+the+ubiquitin+activating+enzyme+for+cancer+treatment&doi=10.1038%2Fnm.4474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span></div><div class="casAuthors">Hyer, Marc L.; Milhollen, Michael A.; Ciavarri, Jeff; Fleming, Paul; Traore, Tary; Sappal, Darshan; Huck, Jessica; Shi, Judy; Gavin, James; Brownell, Jim; Yang, Yu; Stringer, Bradley; Griffin, Robert; Bruzzese, Frank; Soucy, Teresa; Duffy, Jennifer; Rabino, Claudia; Riceberg, Jessica; Hoar, Kara; Lublinsky, Anya; Menon, Saurabh; Sintchak, Michael; Bump, Nancy; Pulukuri, Sai M.; Langston, Steve; Tirrell, Stephen; Kuranda, Mike; Veiby, Petter; Newcomb, John; Li, Ping; Wu, Jing Tao; Powe, Josh; Dick, Lawrence R.; Greenspan, Paul; Galvin, Katherine; Manfredi, Mark; Claiborne, Chris; Amidon, Benjamin S.; Bence, Neil F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-193</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis.  The therapeutic potential of this pathway has been validated by the clin. successes of a no. of UPS modulators, including proteasome inhibitors and immunomodulatory imide drugs (IMiDs).  Here we identified TAK-243 (formerly known as MLN7243) as a potent, mechanism-based small-mol. inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade.  TAK-243 treatment caused depletion of cellular ubiquitin conjugates, resulting in disruption of signaling events, induction of proteotoxic stress, and impairment of cell cycle progression and DNA damage repair pathways.  TAK-243 treatment caused death of cancer cells and, in primary human xenograft studies, demonstrated antitumor activity at tolerated doses.  Due to its specificity and potency, TAK-243 allows for interrogation of ubiquitin biol. and for assessment of UAE inhibition as a new approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GCsna-MdUrVg90H21EOLACvtfcHk0lhgSPpfXZ0Qbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D&md5=06010b7eb1cc59cf3687b9c52844eb96</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnm.4474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4474%26sid%3Dliteratum%253Aachs%26aulast%3DHyer%26aufirst%3DM.%2BL.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DCiavarri%26aufirst%3DJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DSappal%26aufirst%3DD.%26aulast%3DHuck%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DGavin%26aufirst%3DJ.%26aulast%3DBrownell%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DStringer%26aufirst%3DB.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DSoucy%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DRabino%26aufirst%3DC.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DHoar%26aufirst%3DK.%26aulast%3DLublinsky%26aufirst%3DA.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DTirrell%26aufirst%3DS.%26aulast%3DKuranda%26aufirst%3DM.%26aulast%3DVeiby%26aufirst%3DP.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%2BT.%26aulast%3DPowe%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGreenspan%26aufirst%3DP.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DClaiborne%26aufirst%3DC.%26aulast%3DAmidon%26aufirst%3DB.%2BS.%26aulast%3DBence%26aufirst%3DN.%2BF.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520the%2520ubiquitin%2520activating%2520enzyme%2520for%2520cancer%2520treatment%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D186%26epage%3D193%26doi%3D10.1038%2Fnm.4474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.-H.</span></span> <span> </span><span class="NLM_article-title">Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials</span>. <i>Canc. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1016%2Fj.canlet.2016.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=27847302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOgsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2017&pages=47-56&author=B.+Yuanauthor=N.+Yeauthor=S.-S.+Songauthor=Y.-T.+Wangauthor=Z.+Songauthor=H.-D.+Chenauthor=C.-H.+Chenauthor=X.-J.+Huanauthor=Y.-Q.+Wangauthor=Y.+Suauthor=Y.-Y.+Shenauthor=Y.-M.+Sunauthor=X.-Y.+Yangauthor=Y.+Chenauthor=S.-Y.+Guoauthor=Y.+Ganauthor=Z.-W.+Gaoauthor=X.-Y.+Chenauthor=J.+Dingauthor=J.-X.+Heauthor=A.+Zhangauthor=Z.-H.+Miao&title=Poly%28ADP-ribose%29polymerase+%28PARP%29+inhibition+and+anticancer+activity+of+simmiparib%2C+a+new+inhibitor+undergoing+clinical+trials&doi=10.1016%2Fj.canlet.2016.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials</span></div><div class="casAuthors">Yuan, Bo; Ye, Na; Song, Shan-Shan; Wang, Yu-Ting; Song, Zilan; Chen, Hua-Dong; Chen, Chuan-Huizi; Huan, Xia-Juan; Wang, Ying-Qing; Su, Yi; Shen, Yan-Yan; Sun, Yi-Ming; Yang, Xin-Ying; Chen, Yi; Guo, Shi-Yan; Gan, Yong; Gao, Zhi-Wei; Chen, Xiao-Yan; Ding, Jian; He, Jin-Xue; Zhang, Ao; Miao, Ze-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Poly(ADP-ribose)polymerase (PARP)1/2 inhibitors have been proved to be clin. effective anticancer drugs.  Here we report a new PARP1/2 inhibitor, simmiparib, displaying apparently improved preclin. anticancer activities relative to the first approved inhibitor olaparib.  Simmiparib inhibited PARP1/2 approx. 2-fold more potently than olaparib, with more than 90-fold selectivity over the other tested PARP family members.  Simmiparib and olaparib caused similar cellular PARP1-DNA trapping.  Simmiparib selectively induced the accumulation of DNA double-strand breaks, G2/M arrest and apoptosis in homologous recombination repair (HR)-deficient cells.  Consistently, simmiparib showed 26- to 235-fold selectivity in its antiproliferative activity against HR-deficient cells over the corresponding isogenic HR-proficient cells.  Notably, its antiproliferative activity was 43.8-fold more potent than that of olaparib in 11 HR-deficient cancer cell lines.  Simmiparib also potentiated the proliferative inhibition of several conventional anticancer drugs.  Simmiparib reduced the poly(ADP-ribose) formation in HR-deficient cancer cells and xenografts.  When orally administered to nude mice bearing xenografts, simmiparib revealed excellent pharmacokinetic properties.  Simmiparib caused approx. 10-fold greater growth inhibition than olaparib against HR-deficient human cancer cell- or tissue-derived xenografts in nude mice.  Collectively, these findings support the undergoing clin. trials of simmiparib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxJ6byH62sDrVg90H21EOLACvtfcHk0lhgSPpfXZ0Qbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOgsbrK&md5=d9d0bab15554c03d964ced3448d6f9d7</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DS.-S.%26aulast%3DWang%26aufirst%3DY.-T.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DH.-D.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DHuan%26aufirst%3DX.-J.%26aulast%3DWang%26aufirst%3DY.-Q.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.-Y.%26aulast%3DSun%26aufirst%3DY.-M.%26aulast%3DYang%26aufirst%3DX.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DS.-Y.%26aulast%3DGan%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DZ.-W.%26aulast%3DChen%26aufirst%3DX.-Y.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DJ.-X.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DMiao%26aufirst%3DZ.-H.%26atitle%3DPoly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%2520inhibition%2520and%2520anticancer%2520activity%2520of%2520simmiparib%252C%2520a%2520new%2520inhibitor%2520undergoing%2520clinical%2520trials%26jtitle%3DCanc.%2520Lett.%26date%3D2017%26volume%3D386%26spage%3D47%26epage%3D56%26doi%3D10.1016%2Fj.canlet.2016.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Represented AMP mimics as NAE inhibitors. Scaffold hopping refers to the search for active compounds containing different core structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase selectivity of compounds <b>1</b> and <b>26</b> in the DiscoveRx KINOMEScan screening platform. The assays were performed at a single 1 μM concentration. Upper panel: TREEspot interaction maps for compounds <b>1</b> and <b>26</b> in 468 kinase targets. Lower panel: <i>S</i>-scores of compounds <b>1</b> and <b>26</b> with percent control numbers less than 35, 10, and 1, respectively. <i>S</i>-score (<i>S</i> = Number of hits/Number of assays) is a quantitative measure of compound selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. NAE and UAE dual inhibition by compound <b>26</b>. (a,b) The dose–response relationship of compound <b>26</b> for inhibition of NAE (a) and UAE (b) assayed by HTRF. Data are expressed as the mean ± SD from three independent experiments. (c) Compound <b>26</b> inhibited neddylation in the cellular-based assay. Whole-cell lysates were prepared from HCT-116 treated with compound <b>26</b> or the positive control for 4 h, as the concentration showed, and analyzed by western blotting. (d) Inhibition of compound <b>26</b> for the E1 enzymes NAE, UAE, and SAE. The activity of NAE, UAE, and SAE was assessed by immunoblot measuring of the thioester levels of Ubc12-NEDD8, UbcH10-Ub, and Ubc9-SUMO, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibitory effects of compound <b>26</b> on the neddylation and DNA damage pathway. HCT-116 and HuTu80 cancer cells were treated with indicated drugs for 24 h. Whole-cell lysates were immunoblotted for Cul1- or Ubc12-NEDD8, CRL substrates, including CDT1, p27, p21, p-IκBα (Ser32/36), and DNA damage markers γH2AX and p-Chk1(Ser317).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cell cycle arrest and apoptosis induced by compound <b>26</b>. (a) Cell cycle arrest was analyzed by PI-staining-based flow cytometry after HCT-116 was treated with the indicated drug for 24 h. (b,c) Compound <b>26</b> induced apoptosis through caspase-3/7 activation. HCT-116 cells were treated with the indicated drugs for 48 h and then subjected to Caspase-Glo 3/7 assays (b) or western blotting (c). Error bars represent the SEM for at least three independent experiments. Data are analyzed by one-way ANOVA, **, <i>p</i> < 0.01, ***, <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vivo activities of compound <b>26</b> in cell-derived xenografts. Nude mice bearing subcutaneous xenografts derived from HCT-116 (a) or MV-4-11 (b) were injected subcutaneously daily with 65 or 130 mg/kg compound <b>26</b>, or twice daily with 60 mg/kg compound <b>1</b>, respectively. 5 on/5 off/8 on represents 5 days treatment followed by 5 days free of treatment and 8 days treatment in an 18 days study. Relative tumor volume and body weight were separately plotted over the treatment time. Mean tumor volumes ± SEM are shown. <i>n</i> = 6 mice per group. Data are analyzed by Student <i>t</i>-test, *, <i>p</i> < 0.05; **, <i>p</i> < 0.01; and ***, <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds 4, 7–23<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-amino-4,6-dichloropyrimidine, Et<sub>3</sub>N, <i>n</i>-butanol, 120 °C, overnight, and 73%; (b) 1-butyl nitrite or isoamyl nitrite, 4 Å, CH<sub>3</sub>CN, 70 °C, and 1–2 h; (c) for preparation of <b>40a-k</b> and <b>40n-r</b> and <b>42</b>: primary amine DIPEA, CH<sub>3</sub>CN, rt (or 90 °C, MW, for <b>40k</b>), 6–8 h, and 25–98% over two steps; (d) for preparation of <b>40l-m</b>: primary amine Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Xantphos, DMF, N<sub>2</sub>, 100 °C, 4 h, and 40–52% over two steps; (e) NH<sub>2</sub>SO<sub>2</sub>Cl, pyridine, CH<sub>3</sub>CN, 0 °C, 30 min–2 h, and 8.9–25.2%; (f) 4,5,6-trifluoropyrimidine, DIPEA, <i>n</i>-butanol, MW, 120 °C, 1 h, and 46%.</p></p></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound 5<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-chloro-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine, PPh<sub>3</sub>, DIAD, THF, N<sub>2</sub>, and 0 °C; (b) 1 M BCl<sub>3</sub>, dichloromethane (DCM), 0 °C, 4 h, and 48% over two steps; (c) (<i>S</i>)-(+)-1-aminoindane, MW, 200 °C, and 45%; (d) NH<sub>2</sub>SO<sub>2</sub>Cl, pyridine, CH<sub>3</sub>CN, 0 °C, 30 min–2 h, and 15.4%.</p></p></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/medium/jm1c00242_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>25–30</b> and <b>32–36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.1c00242/20210506/images/large/jm1c00242_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00242&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>39</b>, DIPEA, CH<sub>3</sub>CN, rt, 6–8 h, and 54.4%; (b) NH<sub>2</sub>SO<sub>2</sub>Cl, pyridine, CH<sub>3</sub>CN, 0 °C, 30 min–2 h, and 13%; (c) 4 M HCl, MeOH, rt, overnight, and 76.2%; (d) for <b>25</b>: CH<sub>3</sub>I, DMF, rt, 15 min, and 29.6%; for <b>26–29</b> and <b>34–35</b>: corresponding chloroformate, DIPEA, DMF, rt, 30 min, and 32.7–44.2%; for <b>30</b> and <b>33</b>: corresponding 4-nitrophenyl carbonate, DIPEA, DMF, rt, 1–2 h, and 23.5–26.5%; for <b>36</b>: <i>tert</i>-butylisocyanate, DIPEA, DMF, rt, 1 h, and 19.5%; (e) for <b>32</b>: 2,2-dimethyl-1,3-dioxan-5-yl (4-nitrophenyl) carbonate, DIPEA, DMF, rt, 2 h, then 2 M HCl (aq), 2 h, and 23%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hershko, A.</span></span> <span> </span><span class="NLM_article-title">The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1191</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4401702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fsj.cdd.4401702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=16094395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnt1Shtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=1191-1197&author=A.+Hershko&title=The+ubiquitin+system+for+protein+degradation+and+some+of+its+roles+in+the+control+of+the+cell+division+cycle&doi=10.1038%2Fsj.cdd.4401702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle</span></div><div class="casAuthors">Hershko, A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1191-1197</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Owing to the intensive research activity on protein synthesis, little attention was paid in the 1950s and 1960s to protein degrdn.  However, work by the author's group and others between 1970 and 1990 led to the identification of the ubiquitin-dependent degrdn. system.  The author and his coworkers found that this system contained 3 types of enzymes: E1, the ubiquitin-activating enzyme; E2, the ubiquitin-carrier enzyme; and E3, ubiquitin-protein ligase.  The sequential action of these enzymes leads to conjugation of ubiquitin to proteins and then in most cases to their degrdn.  This review briefly tells the story of how this pathway was discovered describing the main findings that during the years allowed the author and his colleagues to draw the complex picture that is currently available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5JJdwpXFipbVg90H21EOLACvtfcHk0lgB0PHe--7uMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnt1Shtrk%253D&md5=3b1c94038962bf6e62a1882779aeedf4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401702%26sid%3Dliteratum%253Aachs%26aulast%3DHershko%26aufirst%3DA.%26atitle%3DThe%2520ubiquitin%2520system%2520for%2520protein%2520degradation%2520and%2520some%2520of%2520its%2520roles%2520in%2520the%2520control%2520of%2520the%2520cell%2520division%2520cycle%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2005%26volume%3D12%26spage%3D1191%26epage%3D1197%26doi%3D10.1038%2Fsj.cdd.4401702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mocciaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rape, M.</span></span> <span> </span><span class="NLM_article-title">Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1242/jcs.091199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1242%2Fjcs.091199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=22357967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFShs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=255-263&author=A.+Mocciaroauthor=M.+Rape&title=Emerging+regulatory+mechanisms+in+ubiquitin-dependent+cell+cycle+control&doi=10.1242%2Fjcs.091199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control</span></div><div class="casAuthors">Mocciaro, Annamaria; Rape, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-263</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The covalent modification of proteins with ubiquitin is required for accurate cell division in all eukaryotes.  Ubiquitylation depends on an enzymic cascade, in which E3 enzymes recruit specific substrates for modification.  Among ∼600 human E3s, the SCF (Skp1-cullin1-F-box) and the APC/C (anaphase-promoting complex/cyclosome) are known for driving the degrdn. of cell cycle regulators to accomplish irreversible cell cycle transitions.  The cell cycle machinery reciprocally regulates the SCF and APC/C through various mechanisms, including the modification of these E3s or the binding of specific inhibitors.  Recent studies have provided new insight into the intricate relationship between ubiquitylation and the cell division app. as they revealed roles for atypical ubiquitin chains, new mechanisms of substrate and E3 regulation, as well as extensive crosstalk between ubiquitylation enzymes.  Here, we review these emerging regulatory mechanisms of ubiquitin-dependent cell cycle control and discuss how their manipulation might provide therapeutic benefits in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzVnxAN41YDbVg90H21EOLACvtfcHk0lhxyiY4IWnnwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFShs7o%253D&md5=5ea6006fd389bd7f68d6f85dfc218fb0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1242%2Fjcs.091199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.091199%26sid%3Dliteratum%253Aachs%26aulast%3DMocciaro%26aufirst%3DA.%26aulast%3DRape%26aufirst%3DM.%26atitle%3DEmerging%2520regulatory%2520mechanisms%2520in%2520ubiquitin-dependent%2520cell%2520cycle%2520control%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D255%26epage%3D263%26doi%3D10.1242%2Fjcs.091199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">The role of the ubiquitin-proteasome pathway in apoptosis</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4400505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fsj.cdd.4400505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10381632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADyaK1MXivFSqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=303-313&author=R.+Z.+Orlowski&title=The+role+of+the+ubiquitin-proteasome+pathway+in+apoptosis&doi=10.1038%2Fsj.cdd.4400505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the ubiquitin-proteasome pathway in apoptosis</span></div><div class="casAuthors">Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-313</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">A review with 115 refs.  Coordinated intracellular protein degrdn. mediated by the ubiquitin-proteasome pathway is crucial to a vast array of cellular processes including orderly progression through the mitotic cycle.  Similarly important to both the fates of individual cells, as well as to the normal function of multicellular organisms, is the process of apoptosis, or programmed cell death.  Execution of this latter process has been known for some time to be intimately assocd. with the activity of caspases, a family of proteases related to interleukin-1-β-converting enzyme.  Evidence is now accumulating, however, that the ubiquitin-proteasome system itself plays an important role in apoptosis, and some of the cellular pathways that are impacted upon by the proteasome, and may lead to apoptosis, are beginning to be dissected.  This review provides a summary of the exptl. basis by which components of the ubiquitin-proteasome pathway have been linked to apoptosis, and attempts are made to formulate a hypothesis about its role in this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_hhc3DN4q7Vg90H21EOLACvtfcHk0lhxyiY4IWnnwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFSqsr8%253D&md5=c3b8de412ec696079a0914ec125360cf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4400505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4400505%26sid%3Dliteratum%253Aachs%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DThe%2520role%2520of%2520the%2520ubiquitin-proteasome%2520pathway%2520in%2520apoptosis%26jtitle%3DCell%2520Death%2520Differ.%26date%3D1999%26volume%3D6%26spage%3D303%26epage%3D313%26doi%3D10.1038%2Fsj.cdd.4400505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boutillier, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kienlen-Campard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeffler, J. P.</span></span> <span> </span><span class="NLM_article-title">Depolarization regulates cyclin D1 degradation and neuronal apoptosis: a hypothesis about the role of the ubiquitin/proteasome signalling pathway</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1046/j.1460-9568.1999.00451.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1046%2Fj.1460-9568.1999.00451.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10051745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A280%3ADyaK1M7ntF2gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=441-448&author=A.+L.+Boutillierauthor=P.+Kienlen-Campardauthor=J.+P.+Loeffler&title=Depolarization+regulates+cyclin+D1+degradation+and+neuronal+apoptosis%3A+a+hypothesis+about+the+role+of+the+ubiquitin%2Fproteasome+signalling+pathway&doi=10.1046%2Fj.1460-9568.1999.00451.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Depolarization regulates cyclin D1 degradation and neuronal apoptosis: a hypothesis about the role of the ubiquitin/proteasome signalling pathway</span></div><div class="casAuthors">Boutillier A L; Kienlen-Campard P; Loeffler J P</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-8</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Depolarization and subsequent calcium entry exert essential neuroprotective effects but the ultimate effector by which calcium blocks apoptosis is not known.  Here we show that inhibition of calcium entry into cerebellar neurons by switching from high to low extracellular K+ concentrations (30-5 mM) induces apoptosis, that correlates with a rapid accumulation of cyclin D1 (CD1), an early marker of the G1/S transition of the cell cycle.  These effects on apoptosis and cyclin D1 are mimicked either by blocking calcium entry into neurons (LaCl3, 100 microM or nifedipine, 10(-6) M) or by inhibiting the calcium/calmodulin pathway (calmidazolium, 10(-7) M).  The increased CD1 protein levels do not result from a transcriptional upregulation of the CD1 gene by the Ca2+/calmodulin pathway but rather reflect an accumulation due to the lack of degradation by the proteasome-dependent pathway.  Specific proteasome antagonists: carbobenzoxyl-leucinyl-leucinyl-norvalinal-H (MG-115), carbobenzoxyl-leucinyl-leucinyl-leucinal-H (MG-132) and clastolactacystin beta-lactone, induce neuronal apoptosis by themselves.  Finally, this pathway is functional only at neuroprotective concentrations of K+ (30 mM), suggesting that calcium/CamK signalling pathway may regulate neuronal death by regulating the proteasome-mediated degradation activity of rapidly turning-over proteins (constitutively expressed genes or pre-existing pools of mRNA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMy5nNLDzr40kUaC_kzhvyfW6udTcc2ebpfZ8RiGqUo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7ntF2gtg%253D%253D&md5=0ebde53c8d14eea7e24a27bd2b610ef2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1046%2Fj.1460-9568.1999.00451.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1460-9568.1999.00451.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoutillier%26aufirst%3DA.%2BL.%26aulast%3DKienlen-Campard%26aufirst%3DP.%26aulast%3DLoeffler%26aufirst%3DJ.%2BP.%26atitle%3DDepolarization%2520regulates%2520cyclin%2520D1%2520degradation%2520and%2520neuronal%2520apoptosis%253A%2520a%2520hypothesis%2520about%2520the%2520role%2520of%2520the%2520ubiquitin%252Fproteasome%2520signalling%2520pathway%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D1999%26volume%3D11%26spage%3D441%26epage%3D448%26doi%3D10.1046%2Fj.1460-9568.1999.00451.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahimi, N.</span></span> <span> </span><span class="NLM_article-title">The ubiquitin-proteasome system meets angiogenesis</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F1535-7163.MCT-11-0555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=22357635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=538-548&author=N.+Rahimi&title=The+ubiquitin-proteasome+system+meets+angiogenesis&doi=10.1158%2F1535-7163.mct-11-0555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The Ubiquitin-Proteasome System Meets Angiogenesis</span></div><div class="casAuthors">Rahimi, Nader</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">538-548</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  A strict physiol. balance between endogenous proangiogenic and antiangiogenic factors controls endothelial cell functions, such that endothelial cell growth is normally restrained.  However, in pathol. angiogenesis, a shift occurs in the balance of regulators, favoring endothelial growth.  Much of the control of angiogenic events is instigated through hypoxia-induced VEGF expression.  The ubiquitin-proteasome system (UPS) plays a central role in fine-tuning the functions of core proangiogenic proteins, including VEGF, VEGFR-2, angiogenic signaling proteins (e.g., the PLCγ1 and PI3 kinase/AKT pathways), and other non-VEGF angiogenic pathways.  The emerging mechanisms by which ubiquitin modification of angiogenic proteins control angiogenesis involve both proteolytic and nonproteolytic functions.  Here, I review recent advances that link the UPS to regulation of angiogenesis and highlight the potential therapeutic value of the UPS in angiogenesis-assocd. diseases.  Mol Cancer Ther; 11(3); 538-48.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqESUzW3iCLh7Vg90H21EOLACvtfcHk0lhxyiY4IWnnwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKjtbY%253D&md5=0d317a32a0e5a0eff6f001d28a47916f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0555%26sid%3Dliteratum%253Aachs%26aulast%3DRahimi%26aufirst%3DN.%26atitle%3DThe%2520ubiquitin-proteasome%2520system%2520meets%2520angiogenesis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D538%26epage%3D548%26doi%3D10.1158%2F1535-7163.mct-11-0555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vucic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikic, I.</span></span> <span> </span><span class="NLM_article-title">Ubiquitination in disease pathogenesis and treatment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1242</span>– <span class="NLM_lpage">1253</span>, <span class="refDoi"> DOI: 10.1038/nm.3739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnm.3739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=25375928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyku73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1242-1253&author=D.+Popovicauthor=D.+Vucicauthor=I.+Dikic&title=Ubiquitination+in+disease+pathogenesis+and+treatment&doi=10.1038%2Fnm.3739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitination in disease pathogenesis and treatment</span></div><div class="casAuthors">Popovic, Doris; Vucic, Domagoj; Dikic, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1242-1253</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ubiquitination is crucial for a plethora of physiol. processes, including cell survival and differentiation and innate and adaptive immunity.  In recent years, considerable progress has been made in the understanding of the mol. action of ubiquitin in signaling pathways and how alterations in the ubiquitin system lead to the development of distinct human diseases.  Here we describe the role of ubiquitination in the onset and progression of cancer, metabolic syndromes, neurodegenerative diseases, autoimmunity, inflammatory disorders, infection and muscle dystrophies.  Moreover, we indicate how current knowledge could be exploited for the development of new clin. therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTMeFCgBByjbVg90H21EOLACvtfcHk0lgrf42EN0Cn6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyku73J&md5=3d943ec2721c980b971d02d4905d5348</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnm.3739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3739%26sid%3Dliteratum%253Aachs%26aulast%3DPopovic%26aufirst%3DD.%26aulast%3DVucic%26aufirst%3DD.%26aulast%3DDikic%26aufirst%3DI.%26atitle%3DUbiquitination%2520in%2520disease%2520pathogenesis%2520and%2520treatment%26jtitle%3DNat.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D1242%26epage%3D1253%26doi%3D10.1038%2Fnm.3739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bross, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Velcade: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.8-6-508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1634%2Ftheoncologist.8-6-508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=14657528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A280%3ADC%252BD3srnslGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=508-513&author=R.+C.+Kaneauthor=P.+F.+Brossauthor=A.+T.+Farrellauthor=R.+Pazdur&title=Velcade%3A+U.S.+FDA+Approval+for+the+Treatment+of+Multiple+Myeloma+Progressing+on+Prior+Therapy&doi=10.1634%2Ftheoncologist.8-6-508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy</span></div><div class="casAuthors">Kane Robert C; Bross Peter F; Farrell Ann T; Pazdur Richard</div><div class="citationInfo"><span class="NLM_cas:title">The oncologist</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">508-13</span>
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    </div><div class="casAbstract">Bortezomib (formerly PS-341), a promising new drug for the treatment of multiple myeloma, recently received accelerated approval from the U.S.  Food and Drug Administration (FDA) for the therapy of patients with progressive myeloma after previous treatment.  Two phase II studies of bortezomib used the same schedule of twice-weekly i.v. dosing for the first 2 weeks of each 3-week cycle.  In a randomized study of 54 patients, two doses were compared (1.0 and 1.3 mg/m2) and objective responses occurred at both dose levels (23% versus 35%), including one complete response in each arm.  In the other phase II study, 202 heavily pretreated patients (median of six prior therapies) all received the same schedule at 1.3 mg/m2.  Of 188 evaluable patients, complete responses occurred in five (3%) and partial responses occurred in 47 (25%).  The median duration of response was 365 days.  The most clinically relevant adverse events were asthenic conditions, nausea, vomiting, diarrhea, thrombocytopenia, and a peripheral neuropathy that often was painful.  This report highlights the FDA analysis supporting the accelerated approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTS_wiRSzN1ZNy3lHz94U-GfW6udTcc2eaSQucbDuv47bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srnslGhtQ%253D%253D&md5=e5420a8677aa046abed3f232889d194c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-6-508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-6-508%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DVelcade%253A%2520U.S.%2520FDA%2520Approval%2520for%2520the%2520Treatment%2520of%2520Multiple%2520Myeloma%2520Progressing%2520on%2520Prior%2520Therapy%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26spage%3D508%26epage%3D513%26doi%3D10.1634%2Ftheoncologist.8-6-508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Q. P.</span></span> <span> </span><span class="NLM_article-title">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.2174/156800911794519752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.2174%2F156800911794519752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=21247388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=239-253&author=D.+Chenauthor=M.+Frezzaauthor=S.+Schmittauthor=J.+Kanwarauthor=Q.+P.+Dou&title=Bortezomib+as+the+first+proteasome+inhibitor+anticancer+drug%3A+current+status+and+future+perspectives&doi=10.2174%2F156800911794519752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</span></div><div class="casAuthors">Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-253</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer.  Based on pos. preclin. and clin. studies, bortezomib was subsequently approved for the clin. use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment.  The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease.  Bortezomib has shown a pos. clin. benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance.  One of the major mechanisms of bortezomib assocd. with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-XL and Bcl-2, and result in apoptotic cell death in malignant cells.  Another important mechanism of bortezomib is through suppression of the NF-κB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes.  Although the majority of success achieved with bortezomib has been in hematol. malignancies, its effect toward solid tumors has been less than encouraging.  Addnl., the widespread clin. use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compds.  These findings could help guide physicians in refining the clin. use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clin. response in cancer patients.  Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4QCk3nP8BLVg90H21EOLACvtfcHk0lgrf42EN0Cn6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1agtbs%253D&md5=15becbceb98ec3e244fc066315815dd2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F156800911794519752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911794519752%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFrezza%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DS.%26aulast%3DKanwar%26aufirst%3DJ.%26aulast%3DDou%26aufirst%3DQ.%2BP.%26atitle%3DBortezomib%2520as%2520the%2520first%2520proteasome%2520inhibitor%2520anticancer%2520drug%253A%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26spage%3D239%26epage%3D253%26doi%3D10.2174%2F156800911794519752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerscher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felberbaum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, M.</span></span> <span> </span><span class="NLM_article-title">Modification of proteins by ubiquitin and ubiquitin-like proteins</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.22.010605.093503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1146%2Fannurev.cellbio.22.010605.093503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=16753028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yjs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2006&pages=159-180&author=O.+Kerscherauthor=R.+Felberbaumauthor=M.+Hochstrasser&title=Modification+of+proteins+by+ubiquitin+and+ubiquitin-like+proteins&doi=10.1146%2Fannurev.cellbio.22.010605.093503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of proteins by ubiquitin and ubiquitin-like proteins</span></div><div class="casAuthors">Kerscher, Oliver; Felberbaum, Rachael; Hochstrasser, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Cell and Developmental Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-180</span>CODEN:
                <span class="NLM_cas:coden">ARDBF8</span>;
        ISSN:<span class="NLM_cas:issn">1081-0706</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Following the discovery of protein modification by the small, highly conserved ubiquitin polypeptide, a no. of distinct ubiquitin-like proteins (Ubls) have been found to function as protein modifiers as well.  These Ubls, which include SUMO, ISG15, Nedd8, and Atg8, function as crit. regulators of many cellular processes, including transcription, DNA repair, signal transduction, autophagy, and cell-cycle control.  A growing body of data also implicates the dysregulation of Ubl-substrate modification and mutations in the Ubl-conjugation machinery in the etiol. and progression of a no. of human diseases.  The primary aim of this review is to summarize the latest developments in the understanding of the different Ubl-protein modification systems, including the shared and unique features of these related pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6upobPhWlRrVg90H21EOLACvtfcHk0lh74X6sp1XmRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yjs7vI&md5=a57eca21879c93167a900caa0b72d008</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.22.010605.093503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.22.010605.093503%26sid%3Dliteratum%253Aachs%26aulast%3DKerscher%26aufirst%3DO.%26aulast%3DFelberbaum%26aufirst%3DR.%26aulast%3DHochstrasser%26aufirst%3DM.%26atitle%3DModification%2520of%2520proteins%2520by%2520ubiquitin%2520and%2520ubiquitin-like%2520proteins%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D2006%26volume%3D22%26spage%3D159%26epage%3D180%26doi%3D10.1146%2Fannurev.cellbio.22.010605.093503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishitani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roukos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obuse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lygerou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, T.</span></span> <span> </span><span class="NLM_article-title">Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1136</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fsj.emboj.7601002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=16482215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVyisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=1126-1136&author=H.+Nishitaniauthor=N.+Sugimotoauthor=V.+Roukosauthor=Y.+Nakanishiauthor=M.+Saijoauthor=C.+Obuseauthor=T.+Tsurimotoauthor=K.+I.+Nakayamaauthor=K.+Nakayamaauthor=M.+Fujitaauthor=Z.+Lygerouauthor=T.+Nishimoto&title=Two+E3+ubiquitin+ligases%2C+SCF-Skp2+and+DDB1-Cul4%2C+target+human+Cdt1+for+proteolysis&doi=10.1038%2Fsj.emboj.7601002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis</span></div><div class="casAuthors">Nishitani, Hideo; Sugimoto, Nozomi; Roukos, Vassilis; Nakanishi, Yohsuke; Saijo, Masafumi; Obuse, Chikashi; Tsurimoto, Toshiki; Nakayama, Keiichi I.; Nakayama, Keiko; Fujita, Masatoshi; Lygerou, Zoi; Nishimoto, Takeharu</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1126-1136</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Replication licensing is carefully regulated to restrict replication to once in a cell cycle.  In higher eukaryotes, regulation of the licensing factor Cdt1 by proteolysis and Geminin is essential to prevent re-replication.  We show here that the N-terminal 100 amino acids of human Cdt1 are recognized for proteolysis by two distinct E3 ubiquitin ligases during S-G2 phases.  Six highly conserved amino acids within the 10 first amino acids of Cdt1 are essential for DDB1-Cul4-mediated proteolysis.  This region is also involved in proteolysis following DNA damage.  The second E3 is SCF-Skp2, which recognizes the Cy-motif-mediated Cyclin E/A-cyclin-dependent kinase-phosphorylated region.  Consistently, in HeLa cells cosilenced of Skp2 and Cul4, Cdt1 remained stable in S-G2 phases.  The Cul4-contg. E3 is active during ongoing replication, while SCF-Skp2 operates both in S and G2 phases.  PCNA binds to Cdt1 through the six conserved N-terminal amino acids.  PCNA is essential for Cul4- but not Skp2-directed degrdn. during DNA replication and following UV-irradn.  Our data unravel multiple distinct pathways regulating Cdt1 to block re-replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKYgClHtqRbVg90H21EOLACvtfcHk0lh74X6sp1XmRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVyisro%253D&md5=5f5d0c891dce6c213212f739a33d3292</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601002%26sid%3Dliteratum%253Aachs%26aulast%3DNishitani%26aufirst%3DH.%26aulast%3DSugimoto%26aufirst%3DN.%26aulast%3DRoukos%26aufirst%3DV.%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DSaijo%26aufirst%3DM.%26aulast%3DObuse%26aufirst%3DC.%26aulast%3DTsurimoto%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26aulast%3DNakayama%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DLygerou%26aufirst%3DZ.%26aulast%3DNishimoto%26aufirst%3DT.%26atitle%3DTwo%2520E3%2520ubiquitin%2520ligases%252C%2520SCF-Skp2%2520and%2520DDB1-Cul4%252C%2520target%2520human%2520Cdt1%2520for%2520proteolysis%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D1126%26epage%3D1136%26doi%3D10.1038%2Fsj.emboj.7601002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liakopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busgen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brychzy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jentsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pause, A.</span></span> <span> </span><span class="NLM_article-title">Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">5510</span>– <span class="NLM_lpage">5515</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.10.5510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1073%2Fpnas.96.10.5510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10318914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADyaK1MXjtFCnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=5510-5515&author=D.+Liakopoulosauthor=T.+Busgenauthor=A.+Brychzyauthor=S.+Jentschauthor=A.+Pause&title=Conjugation+of+the+ubiquitin-like+protein+NEDD8+to+cullin-2+is+linked+to+von+Hippel-Lindau+tumor+suppressor+function&doi=10.1073%2Fpnas.96.10.5510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function</span></div><div class="casAuthors">Liakopoulos, Dimitris; Busgen, Tanja; Brychzy, Alexander; Jentsch, Stefan; Pause, Arnim</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5510-5515</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The von Hippel-Lindau tumor suppressor protein pVHL assembles with cullin-2 (hCUL-2) and elongin B/C forming a protein complex, CBCVHL, that resembles SKP1-CDC53-F-box protein ubiquitin ligases.  Here, we show that hCUL-2 is modified by the conserved ubiquitin-like protein NEDD8 and that NEDD8-hCUL-2 conjugates are part of CBCVHL complexes in vivo.  Remarkably, the formation of these conjugates is stimulated by the pVHL tumor suppressor.  A tumorigenic pVHL variant, however, is essentially deficient in this activity.  Thus, ligation of NEDD8 to hCUL-2 is linked to pVHL activity and may be important for pVHL tumor suppressor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp95mSK379KU7Vg90H21EOLACvtfcHk0lh74X6sp1XmRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtFCnsbk%253D&md5=216054cedff1a2ab3709dc4ad81bf7f4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.10.5510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.10.5510%26sid%3Dliteratum%253Aachs%26aulast%3DLiakopoulos%26aufirst%3DD.%26aulast%3DBusgen%26aufirst%3DT.%26aulast%3DBrychzy%26aufirst%3DA.%26aulast%3DJentsch%26aufirst%3DS.%26aulast%3DPause%26aufirst%3DA.%26atitle%3DConjugation%2520of%2520the%2520ubiquitin-like%2520protein%2520NEDD8%2520to%2520cullin-2%2520is%2520linked%2520to%2520von%2520Hippel-Lindau%2520tumor%2520suppressor%2520function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D1999%26volume%3D96%26spage%3D5510%26epage%3D5515%26doi%3D10.1073%2Fpnas.96.10.5510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">7130</span>– <span class="NLM_lpage">7139</span>, <span class="refDoi"> DOI: 10.1128/mcb.24.16.7130-7139.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1128%2FMCB.24.16.7130-7139.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=15282312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlOjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=7130-7139&author=A.+Kobayashiauthor=M.-I.+Kangauthor=H.+Okawaauthor=M.+Ohtsujiauthor=Y.+Zenkeauthor=T.+Chibaauthor=K.+Igarashiauthor=M.+Yamamoto&title=Oxidative+stress+sensor+Keap1+functions+as+an+adaptor+for+Cul3-based+E3+ligase+to+regulate+proteasomal+degradation+of+Nrf2&doi=10.1128%2Fmcb.24.16.7130-7139.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2</span></div><div class="casAuthors">Kobayashi, Akira; Kang, Moon-Il; Okawa, Hiromi; Ohtsuji, Makiko; Zenke, Yukari; Chiba, Tomoki; Igarashi, Kazuhiko; Yamamoto, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7130-7139</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Transcription factor Nrf2 is a major regulator of genes encoding phase 2 detoxifying enzymes and antioxidant stress proteins in response to electrophilic agents and oxidative stress.  In the absence of such stimuli, Nrf2 is inactive owing to its cytoplasmic retention by Keap1 and rapid degrdn. through the proteasome system.  We examd. the contribution of Keap1 to the rapid turnover of Nrf2 (half-life of less than 20 min) and found that a direct assocn. between Keap1 and Nrf2 is required for Nrf2 degrdn.  In a series of domain function analyses of Keap1, we found that both the BTB and intervening-region (IVR) domains are crucial for Nrf2 degrdn., implying that these two domains act to recruit ubiquitin-proteasome factors.  Indeed, Cullin 3 (Cul3), a subunit of the E3 ligase complex, was found to interact specifically with Keap1 in vivo.  Keap1 assocs. with the N-terminal region of Cul3 through the IVR domain and promotes the ubiquitination of Nrf2 in cooperation with the Cul3-Roc1 complex.  These results thus provide solid evidence that Keap1 functions as an adaptor of Cul3-based E3 ligase.  To our knowledge, Nrf2 and Keap1 are the first reported mammalian substrate and adaptor, resp., of the Cul3-based E3 ligase system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrut4YvhAuZKrVg90H21EOLACvtfcHk0liBZyWVcntM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlOjt7w%253D&md5=3d6e356865cd6f33c800bf9124d7c8da</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.16.7130-7139.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.16.7130-7139.2004%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DA.%26aulast%3DKang%26aufirst%3DM.-I.%26aulast%3DOkawa%26aufirst%3DH.%26aulast%3DOhtsuji%26aufirst%3DM.%26aulast%3DZenke%26aufirst%3DY.%26aulast%3DChiba%26aufirst%3DT.%26aulast%3DIgarashi%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DM.%26atitle%3DOxidative%2520stress%2520sensor%2520Keap1%2520functions%2520as%2520an%2520adaptor%2520for%2520Cul3-based%2520E3%2520ligase%2520to%2520regulate%2520proteasomal%2520degradation%2520of%2520Nrf2%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D7130%26epage%3D7139%26doi%3D10.1128%2Fmcb.24.16.7130-7139.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Read, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladysheva, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hottelet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coggins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podust, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span> <span> </span><span class="NLM_article-title">Nedd8 Modification of Cul-1 Activates SCFβ TrCP-Dependent Ubiquitination of IκBα</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2326</span>, <span class="refDoi"> DOI: 10.1128/mcb.20.7.2326-2333.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1128%2FMCB.20.7.2326-2333.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10713156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvFegtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=2326&author=M.+A.+Readauthor=J.+E.+Brownellauthor=T.+B.+Gladyshevaauthor=M.+Hotteletauthor=L.+A.+Parentauthor=M.+B.+Cogginsauthor=J.+W.+Pierceauthor=V.+N.+Podustauthor=R.-S.+Luoauthor=V.+Chauauthor=V.+J.+Palombella&title=Nedd8+Modification+of+Cul-1+Activates+SCF%CE%B2+TrCP-Dependent+Ubiquitination+of+I%CE%BAB%CE%B1&doi=10.1128%2Fmcb.20.7.2326-2333.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Nedd8 modification of Cul-1 activates SCFβTrCP-dependent ubiquitination of IκBα</span></div><div class="casAuthors">Read, Margaret A.; Brownell, James E.; Gladysheva, Tatiana B.; Hottelet, Maria; Parent, Lana A.; Coggins, Michael B.; Pierce, Jacqueline W.; Podust, Vladimir N.; Luo, Rong-Shu; Chau, Vincent; Palombella, Vito J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2326-2333</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Regulation of NF-κB occurs through phosphorylation-dependent ubiquitination of IκBα, which is degraded by the 26S proteasome.  Recent studies have shown that ubiquitination of IκBα is carried out by a ubiquitinligase enzyme complex called SCFβTrCP.  Here we show that Nedd8 modification of the Cul-1 component of SCFβTrCP is important for function of SCFβTrCP in ubiquitination of IκBα.  In cells, Nedd8-conjugated Cul-1 was complexed with two substrates of SCFβTrCP, phosphorylated IκBα and β-catenin, indicating that Nedd8-Cul-1 conjugates are part of SCFβTrCP in vivo.  Although only a minute fraction of total cellular Cul-1 is modified by Nedd8, the Cul-1 assocd. with ectopically expressed βTrCP was highly enriched for the Nedd8-conjugated form.  Moreover, optimal ubiquitination of IκBα required Nedd8 and the Nedd8-conjugating enzyme, Ubc12.  The site of Nedd8 ligation to Cul-1 is essential, as SCFβTrCP contg. a K720R mutant of Cul-1 only weakly supported IκBα ubiquitination compared to SCFβTrCP contg. WT Cul-1, suggesting that the Nedd8 ligation of Cul-1 affects the ubiquitination activity of SCFβTrCP.  These observations provide a functional link between the highly related ubiquitin and Nedd8 pathways of protein modification and show how they operate together to selectively target the signal-dependent degrdn. of IκBα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqju9vP-J9TFbVg90H21EOLACvtfcHk0liBZyWVcntM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvFegtbw%253D&md5=0c0448d6d1b25f9235c7e6d401cd9ab7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.7.2326-2333.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.7.2326-2333.2000%26sid%3Dliteratum%253Aachs%26aulast%3DRead%26aufirst%3DM.%2BA.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DGladysheva%26aufirst%3DT.%2BB.%26aulast%3DHottelet%26aufirst%3DM.%26aulast%3DParent%26aufirst%3DL.%2BA.%26aulast%3DCoggins%26aufirst%3DM.%2BB.%26aulast%3DPierce%26aufirst%3DJ.%2BW.%26aulast%3DPodust%26aufirst%3DV.%2BN.%26aulast%3DLuo%26aufirst%3DR.-S.%26aulast%3DChau%26aufirst%3DV.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26atitle%3DNedd8%2520Modification%2520of%2520Cul-1%2520Activates%2520SCF%25CE%25B2%2520TrCP-Dependent%2520Ubiquitination%2520of%2520I%25CE%25BAB%25CE%25B1%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D2326%26doi%3D10.1128%2Fmcb.20.7.2326-2333.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podust, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladysheva, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coggins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightcap, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, V.</span></span> <span> </span><span class="NLM_article-title">Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">4579</span>– <span class="NLM_lpage">4584</span>, <span class="refDoi"> DOI: 10.1073/pnas.090465597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1073%2Fpnas.090465597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10781063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFKjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=4579-4584&author=V.+N.+Podustauthor=J.+E.+Brownellauthor=T.+B.+Gladyshevaauthor=R.-S.+Luoauthor=C.+Wangauthor=M.+B.+Cogginsauthor=J.+W.+Pierceauthor=E.+S.+Lightcapauthor=V.+Chau&title=Nedd8+conjugation+pathway+is+essential+for+proteolytic+targeting+of+p27Kip1+by+ubiquitination&doi=10.1073%2Fpnas.090465597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination</span></div><div class="casAuthors">Podust, Vladimir N.; Brownell, James E.; Gladysheva, Tatiana B.; Luo, Rong-Shu; Wang, Chunhua; Coggins, Michael B.; Pierce, Jacqueline W.; Lightcap, Eric S.; Chau, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4579-4584</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Temporal control of p27Kip1 (p27) degrdn. imposes periodicity in its activity during cell cycle progression and its accumulation during cell cycle exit.  Degrdn. of p27 is initiated by phosphorylation of p27 at Thr-187, which marks the protein for ubiquitination by SCFSkp2 and subsequent proteolysis by the 26S proteasome.  Here we show that the p27 ubiquitination activity in cell exts. depends on the presence of the ubiquitin-like protein Nedd8 and enzymes that catalyze Nedd8 conjugation to proteins.  Moreover, we show that reconstitution of the p27 ubiquitination activity of recombinant SCFSkp2 also requires Nedd8 conjugation pathway components.  Inactivation of the Nedd8 conjugation pathway by a dominant neg. mutant of the Nedd8-conjugating enzyme Nce1/Ubc12 blocks the ubiquitination and degrdn. of p27 in cell exts.  Consistent with a role in cell-cycle progression, Nedd8 is expressed in proliferating cells and is itself down-regulated upon cellular differentiation.  These results suggest that the Nedd8 conjugation pathway may regulate the turnover of p27Kip1, independently of p27 phosphorylation, and further establishes the identity of protein components involved in p27 ubiquitination.  Finally, these findings provide a direct demonstration of a function for Nedd8 in a biol. process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHO24nRBBTpbVg90H21EOLACvtfcHk0liBZyWVcntM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFKjtr0%253D&md5=ebab54f5e34ee739ed00db716f331034</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.090465597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.090465597%26sid%3Dliteratum%253Aachs%26aulast%3DPodust%26aufirst%3DV.%2BN.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DGladysheva%26aufirst%3DT.%2BB.%26aulast%3DLuo%26aufirst%3DR.-S.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DCoggins%26aufirst%3DM.%2BB.%26aulast%3DPierce%26aufirst%3DJ.%2BW.%26aulast%3DLightcap%26aufirst%3DE.%2BS.%26aulast%3DChau%26aufirst%3DV.%26atitle%3DNedd8%2520conjugation%2520pathway%2520is%2520essential%2520for%2520proteolytic%2520targeting%2520of%2520p27Kip1%2520by%2520ubiquitination%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2000%26volume%3D97%26spage%3D4579%26epage%3D4584%26doi%3D10.1073%2Fpnas.090465597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin ligases: cell-cycle control and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1038/nrc1881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnrc1881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=16633365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD28XjslGitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=369-381&author=K.+I.+Nakayamaauthor=K.+Nakayama&title=Ubiquitin+ligases%3A+cell-cycle+control+and+cancer&doi=10.1038%2Fnrc1881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin ligases: cell-cycle control and cancer</span></div><div class="casAuthors">Nakayama, Keiichi I.; Nakayama, Keiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">369-381</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A driving force of the cell cycle is the activation of cyclin-dependent kinases (CDKs), the activities of which are controlled by the ubiquitin-mediated proteolysis of key regulators such as cyclins and CDK inhibitors.  Two ubiquitin ligases, the SKP1-CUL1-F-box-protein (SCF) complex and the anaphase-promoting complex/cyclosome (APC/C), are responsible for the specific ubiquitylation of many of these regulators.  Deregulation of the proteolytic system might result in uncontrolled proliferation, genomic instability and cancer.  Cumulative clin. evidence shows alterations in the ubiquitylation of cell-cycle regulators in the etiol. of many human malignancies.  A better understanding of the ubiquitylation machinery will provide new insights into the regulatory biol. of cell-cycle transitions and the development of anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeQVKJ7pAqq7Vg90H21EOLACvtfcHk0ljC76o-WOzasg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjslGitb4%253D&md5=23f2eff17be746153edf5be9e733bb21</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc1881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1881%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26aulast%3DNakayama%26aufirst%3DK.%26atitle%3DUbiquitin%2520ligases%253A%2520cell-cycle%2520control%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D369%26epage%3D381%26doi%3D10.1038%2Fnrc1881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsunematsu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2116</span>– <span class="NLM_lpage">2125</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7600217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fsj.emboj.7600217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=15103331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktVGjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=2116-2125&author=M.+Yadaauthor=S.+Hatakeyamaauthor=T.+Kamuraauthor=M.+Nishiyamaauthor=R.+Tsunematsuauthor=H.+Imakiauthor=N.+Ishidaauthor=F.+Okumuraauthor=K.+Nakayamaauthor=K.+I.+Nakayama&title=Phosphorylation-dependent+degradation+of+c-Myc+is+mediated+by+the+F-box+protein+Fbw7&doi=10.1038%2Fsj.emboj.7600217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7</span></div><div class="casAuthors">Yada, Masayoshi; Hatakeyama, Shigetsugu; Kamura, Takumi; Nishiyama, Masaaki; Tsunematsu, Ryosuke; Imaki, Hiroyuki; Ishida, Noriko; Okumura, Fumihiko; Nakayama, Keiko; Nakayama, Keiichi I.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2116-2125</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The F-box protein Skp2 mediates c-Myc ubiquitylation by binding to the MB2 domain.  However, the turnover of c-Myc is largely dependent on phosphorylation of threonine-58 and serine-62 in MB1, residues that are often mutated in cancer.  We now show that the F-box protein Fbw7 interacts with and thereby destabilizes c-Myc in a manner dependent on phosphorylation of MB1.  Whereas wild-type Fbw7 promoted c-Myc turnover in cells, an Fbw7 mutant lacking the F-box domain delayed it.  Furthermore, depletion of Fbw7 by RNA interference increased both the abundance and transactivation activity of c-Myc.  Accumulation of c-Myc was also apparent in mouse Fbw7-/- embryonic stem cells.  These observations suggest that two F-box proteins, Fbw7 and Skp2, differentially regulate c-Myc stability by targeting MB1 and MB2, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAzziISTkJnLVg90H21EOLACvtfcHk0ljC76o-WOzasg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktVGjtL0%253D&md5=30c2067e35099668b37a6ad7dcd591b1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600217%26sid%3Dliteratum%253Aachs%26aulast%3DYada%26aufirst%3DM.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DKamura%26aufirst%3DT.%26aulast%3DNishiyama%26aufirst%3DM.%26aulast%3DTsunematsu%26aufirst%3DR.%26aulast%3DImaki%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DN.%26aulast%3DOkumura%26aufirst%3DF.%26aulast%3DNakayama%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26atitle%3DPhosphorylation-dependent%2520degradation%2520of%2520c-Myc%2520is%2520mediated%2520by%2520the%2520F-box%2520protein%2520Fbw7%26jtitle%3DEMBO%2520J.%26date%3D2004%26volume%3D23%26spage%3D2116%26epage%3D2125%26doi%3D10.1038%2Fsj.emboj.7600217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Climent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DelRosario, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmain, A.</span></span> <span> </span><span class="NLM_article-title">FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1502</span>, <span class="refDoi"> DOI: 10.1126/science.1162981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1126%2Fscience.1162981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=18787170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2jsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2008&pages=1499-1502&author=J.-H.+Maoauthor=I.-J.+Kimauthor=D.+Wuauthor=J.+Climentauthor=H.+C.+Kangauthor=R.+DelRosarioauthor=A.+Balmain&title=FBXW7+targets+mTOR+for+degradation+and+cooperates+with+PTEN+in+tumor+suppression&doi=10.1126%2Fscience.1162981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">FBXW7 Targets mTOR for degradation and cooperates with PTEN in tumor suppression</span></div><div class="casAuthors">Mao, Jian-Hua; Kim, Il-Jin; Wu, Di; Climent, Joan; Kang, Hio Chung; DelRosario, Reyno; Balmain, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">5895</span>),
    <span class="NLM_cas:pages">1499-1502</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The enzyme mTOR (mammalian target of rapamycin) is a major target for therapeutic intervention to treat many human diseases, including cancer, but very little is known about the processes that control levels of mTOR protein.  Here, we show that mTOR is targeted for ubiquitination and consequent degrdn. by binding to the tumor suppressor protein FBXW7.  Human breast cancer cell lines and primary tumors showed a reciprocal relation between loss of FBXW7 and deletion or mutation of PTEN (phosphatase and tensin homolog), which also activates mTOR.  Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVmj3M3SluzLVg90H21EOLACvtfcHk0liPnSdTUywjhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2jsb7I&md5=d40961d1707d2d499a77a4e45e5db3cf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.1162981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1162981%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DI.-J.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DCliment%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DH.%2BC.%26aulast%3DDelRosario%26aufirst%3DR.%26aulast%3DBalmain%26aufirst%3DA.%26atitle%3DFBXW7%2520targets%2520mTOR%2520for%2520degradation%2520and%2520cooperates%2520with%2520PTEN%2520in%2520tumor%2520suppression%26jtitle%3DScience%26date%3D2008%26volume%3D321%26spage%3D1499%26epage%3D1502%26doi%3D10.1126%2Fscience.1162981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chairatvit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngamkitidechakul, C.</span></span> <span> </span><span class="NLM_article-title">Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1007/s11010-007-9566-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1007%2Fs11010-007-9566-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=17660949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyru7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2007&pages=163-169&author=K.+Chairatvitauthor=C.+Ngamkitidechakul&title=Control+of+cell+proliferation+via+elevated+NEDD8+conjugation+in+oral+squamous+cell+carcinoma&doi=10.1007%2Fs11010-007-9566-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma</span></div><div class="casAuthors">Chairatvit, Kongthawat; Ngamkitidechakul, Chatri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1&2</span>),
    <span class="NLM_cas:pages">163-169</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A prominent feature of all cancers including oral carcinoma is an abnormality in cellular proliferation.  Neural precursor cell-expressed developmentally down-regulated 8 (NEDD8) is a ubiquitin-like protein exerting its biol. function through covalent ligation to a family of cullin proteins, which act as a component of the Skp1, cullin, and F-box protein complex that plays a crit. role in the regulation of cell cycle.  Using Western blot anal., an increase in NEDD8 conjugation was obsd. in all highly proliferative cells, including immortalized normal oral keratinocyte (NOK), oral-derived carcinoma (KB, HSC4), and several types of human carcinoma cell lines as compared to normal human gingival fibroblast.  The level of NEDD8 conjugation was proportionally dependent on the concn. of serum in culture medium, which also affected proliferation status of oral squamous cell carcinoma.  NEDD8 conjugation was required for proliferation of the carcinoma cell since the transfection of dominant neg. Ubc12 (Ubc12C111S) could prolong the rate of proliferation.  Taken together, up-regulation of the NEDD8 conjugation is an essential requirement for the enhancement of proliferation of oral carcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroreuc9FDbo7Vg90H21EOLACvtfcHk0liPnSdTUywjhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyru7jK&md5=8bb3d0e4c580317f8ba6ecfe6970d2f8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs11010-007-9566-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-007-9566-7%26sid%3Dliteratum%253Aachs%26aulast%3DChairatvit%26aufirst%3DK.%26aulast%3DNgamkitidechakul%26aufirst%3DC.%26atitle%3DControl%2520of%2520cell%2520proliferation%2520via%2520elevated%2520NEDD8%2520conjugation%2520in%2520oral%2520squamous%2520cell%2520carcinoma%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2007%26volume%3D306%26spage%3D163%26epage%3D169%26doi%3D10.1007%2Fs11010-007-9566-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span> <span> </span><span class="NLM_article-title">Overactivated neddylation pathway as a therapeutic target in lung cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">dju083</span>, <span class="refDoi"> DOI: 10.1093/jnci/dju083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1093%2Fjnci%2Fdju083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=24853380" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=dju083&author=L.+Liauthor=M.+Wangauthor=G.+Yuauthor=P.+Chenauthor=H.+Liauthor=D.+Weiauthor=J.+Zhuauthor=L.+Xieauthor=H.+Jiaauthor=J.+Shiauthor=C.+Liauthor=W.+Yaoauthor=Y.+Wangauthor=Q.+Gaoauthor=L.+S.+Jeongauthor=H.+W.+Leeauthor=J.+Yuauthor=F.+Huauthor=J.+Meiauthor=P.+Wangauthor=Y.+Chuauthor=H.+Qiauthor=M.+Yangauthor=Z.+Dongauthor=Y.+Sunauthor=R.+M.+Hoffmanauthor=L.+Jia&title=Overactivated+neddylation+pathway+as+a+therapeutic+target+in+lung+cancer&doi=10.1093%2Fjnci%2Fdju083"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdju083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdju083%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DJia%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DF.%26aulast%3DMei%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHoffman%26aufirst%3DR.%2BM.%26aulast%3DJia%26aufirst%3DL.%26atitle%3DOveractivated%2520neddylation%2520pathway%2520as%2520a%2520therapeutic%2520target%2520in%2520lung%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2014%26volume%3D106%26spage%3Ddju083%26doi%3D10.1093%2Fjnci%2Fdju083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. Q.</span></span> <span> </span><span class="NLM_article-title">The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3733</span>, <span class="refDoi"> DOI: 10.1038/ncomms4733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fncomms4733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=24821572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVCjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3733&author=P.+Xieauthor=M.+H.+Zhangauthor=S.+Heauthor=K.+F.+Luauthor=Y.+C.+Chenauthor=G.+C.+Xingauthor=Y.+M.+Luauthor=P.+Liuauthor=Y.+Liauthor=S.+X.+Wangauthor=N.+Chaiauthor=J.+W.+Wuauthor=H.+T.+Dengauthor=H.+R.+Wangauthor=Y.+Caoauthor=F.+Zhaoauthor=Y.+Cuiauthor=J.+Wangauthor=F.+C.+Heauthor=L.+Q.+Zhang&title=The+covalent+modifier+Nedd8+is+critical+for+the+activation+of+Smurf1+ubiquitin+ligase+in+tumorigenesis&doi=10.1038%2Fncomms4733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis</span></div><div class="casAuthors">Xie, Ping; Zhang, Minghua; He, Shan; Lu, Kefeng; Chen, Yuhan; Xing, Guichun; Lu, Yiming; Liu, Ping; Li, Yang; Wang, Shaoxia; Chai, Nan; Wu, Jiawei; Deng, Haiteng; Wang, Hong-Rui; Cao, Yu; Zhao, Fei; Cui, Yu; Wang, Jian; He, Fuchu; Zhang, Lingqiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3733</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neddylation, the covalent attachment of ubiquitin-like protein Nedd8, of the Cullin-RING E3 ligase family regulates their ubiquitylation activity.  However, regulation of HECT ligases by neddylation has not been reported to date.  Here we show that the C2-WW-HECT ligase Smurf1 is activated by neddylation.  Smurf1 phys. interacts with Nedd8 and Ubc12, forms a Nedd8-thioester intermediate, and then catalyzes its own neddylation on multiple lysine residues.  Intriguingly, this autoneddylation needs an active site at C426 in the HECT N-lobe.  Neddylation of Smurf1 potently enhances ubiquitin E2 recruitment and augments the ubiquitin ligase activity of Smurf1.  The regulatory role of neddylation is conserved in human Smurf1 and yeast Rsp5.  Furthermore, in human colorectal cancers, the elevated expression of Smurf1, Nedd8, NAE1 and Ubc12 correlates with cancer progression and poor prognosis.  These findings provide evidence that neddylation is important in HECT ubiquitin ligase activation and shed new light on the tumor-promoting role of Smurf1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx6S-UZ8f-y7Vg90H21EOLACvtfcHk0liPnSdTUywjhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVCjsL0%253D&md5=a42d6c5b256fd17cc12eb2cb85b74c02</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fncomms4733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4733%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DM.%2BH.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DK.%2BF.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DXing%26aufirst%3DG.%2BC.%26aulast%3DLu%26aufirst%3DY.%2BM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%2BX.%26aulast%3DChai%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DJ.%2BW.%26aulast%3DDeng%26aufirst%3DH.%2BT.%26aulast%3DWang%26aufirst%3DH.%2BR.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DF.%2BC.%26aulast%3DZhang%26aufirst%3DL.%2BQ.%26atitle%3DThe%2520covalent%2520modifier%2520Nedd8%2520is%2520critical%2520for%2520the%2520activation%2520of%2520Smurf1%2520ubiquitin%2520ligase%2520in%2520tumorigenesis%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3733%26doi%3D10.1038%2Fncomms4733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lukkarila, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahani, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span> <span> </span><span class="NLM_article-title">Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1021/ml2000615</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml2000615" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlCku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=577-582&author=J.+L.+Lukkarilaauthor=S.+R.+da+Silvaauthor=M.+Aliauthor=V.+M.+Shahaniauthor=G.+W.+Xuauthor=J.+Bermanauthor=A.+Roughtonauthor=S.+Dhe-Paganonauthor=A.+D.+Schimmerauthor=P.+T.+Gunning&title=Identification+of+NAE+Inhibitors+Exhibiting+Potent+Activity+in+Leukemia+Cells%3A+Exploring+the+Structural+Determinants+of+NAE+Specificity&doi=10.1021%2Fml2000615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity</span></div><div class="casAuthors">Lukkarila, Julie L.; da Silva, Sara R.; Ali, Mohsin; Shahani, Vijay M.; Xu, G. Wei; Berman, Judd; Roughton, Andrew; Dhe-Paganon, Sirano; Schimmer, Aaron D.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">577-582</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MLN4924 is a selective inhibitor of the NEDD8-activating enzyme (NAE) and has advanced into clin. trials for the treatment of both solid and hematol. malignancies.  In contrast, the structurally similar compd. 1 (developed by Millennium: The Takeda Oncol. Company) is a pan inhibitor of the E1 enzymes NAE, ubiquitin activating enzyme (UAE), and SUMO-activating enzyme (SAE) and is currently viewed as unsuitable for clin. use given its broad spectrum of E1 inhibition.  Here, we sought to understand the determinants of NAE selectivity.  A series of compd. 1 analogs were synthesized through iterative functionalization of the purine C6 position and evaluated for NAE specificity.  Optimal NAE specificity was achieved through substitution with primary N-alkyl groups, while bulky or secondary N-alkyl substituents were poorly tolerated.  When assessed in vitro, inhibitors reduced the growth and viability of malignant K562 leukemia cells.  Through this study, we have successfully identified a series of sub-10 nM NAE-specific inhibitors and thereby highlighted the functionalities that promote NAE selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbNgZ42C7Y7Vg90H21EOLACvtfcHk0lidAEhSSvRoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlCku78%253D&md5=d522810186b43a4f45990f7cff9b1254</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml2000615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml2000615%26sid%3Dliteratum%253Aachs%26aulast%3DLukkarila%26aufirst%3DJ.%2BL.%26aulast%3Dda%2BSilva%26aufirst%3DS.%2BR.%26aulast%3DAli%26aufirst%3DM.%26aulast%3DShahani%26aufirst%3DV.%2BM.%26aulast%3DXu%26aufirst%3DG.%2BW.%26aulast%3DBerman%26aufirst%3DJ.%26aulast%3DRoughton%26aufirst%3DA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26atitle%3DIdentification%2520of%2520NAE%2520Inhibitors%2520Exhibiting%2520Potent%2520Activity%2520in%2520Leukemia%2520Cells%253A%2520Exploring%2520the%2520Structural%2520Determinants%2520of%2520NAE%2520Specificity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D577%26epage%3D582%26doi%3D10.1021%2Fml2000615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, P.-k.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel NEDD8 Activating Enzyme Inhibitor with Piperidin-4-amine Scaffold by Structure-Based Virtual Screening</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1901</span>– <span class="NLM_lpage">1907</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00159</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00159" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFKqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1901-1907&author=P.+Luauthor=X.+Liuauthor=X.+Yuanauthor=M.+Heauthor=Y.+Wangauthor=Q.+Zhangauthor=P.-k.+Ouyang&title=Discovery+of+a+novel+NEDD8+Activating+Enzyme+Inhibitor+with+Piperidin-4-amine+Scaffold+by+Structure-Based+Virtual+Screening&doi=10.1021%2Facschembio.6b00159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel NEDD8 Activating Enzyme Inhibitor with Piperidin-4-amine Scaffold by Structure-Based Virtual Screening</span></div><div class="casAuthors">Lu, Peng; Liu, Xiaoxin; Yuan, Xinrui; He, Minfang; Wang, Yubin; Zhang, Qi; Ouyang, Ping-kai</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1901-1907</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NEDD8 activating enzyme (NAE) plays an important role in regulating intracellular proteins with key parts in a broad array of cellular functions.  Here, we report a structure-based virtual screening of a compd. library contg. 50000 small mol. entities against the active site of NAE.  Computational docking and scoring followed by biochem. screening and target validation lead to the identification of 1-benzyl-N-(2,4-dichlorophenethyl) piperidin-4-amine (M22) as a selective NAE inhibitor.  M22 is reversible for NAE, inhibits multiple cancer cell lines with GI50 values in the low micromolar range, and induces apoptosis in A549 cells.  Furthermore, it produces tumor inhibition in AGS xenografts in nude mice and low acute toxicity in a zebrafish model.  M22, a novel NAE inhibitor, represents a promising lead structure for the development of new antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3wkfzasykYrVg90H21EOLACvtfcHk0lidAEhSSvRoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFKqurg%253D&md5=75b21e45e1698ccca8f4ac4a92a0a3b8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00159%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DOuyang%26aufirst%3DP.-k.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520NEDD8%2520Activating%2520Enzyme%2520Inhibitor%2520with%2520Piperidin-4-amine%2520Scaffold%2520by%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D1901%26epage%3D1907%26doi%3D10.1021%2Facschembio.6b00159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1027</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1016%2Fj.ejmech.2017.11.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=29232579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1021-1027&author=K.-J.+Wuauthor=H.-J.+Zhongauthor=G.+Liauthor=C.+Liuauthor=H.-M.+D.+Wangauthor=D.-L.+Maauthor=C.-H.+Leung&title=Structure-based+identification+of+a+NEDD8-activating+enzyme+inhibitor+via+drug+repurposing&doi=10.1016%2Fj.ejmech.2017.11.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</span></div><div class="casAuthors">Wu, Ke-Jia; Zhong, Hai-Jing; Li, Guodong; Liu, Chenfu; Wang, Hui-Min David; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1021-1027</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">NEDD8-activating enzyme (NAE) is an essential player of the NEDD8 conjugation pathway that regulates protein degrdn.  Meanwhile, drug repurposing is a cost-efficient strategy to identify new therapeutic uses for existing scaffolds.  In this report, mitoxantrone (1) was repurposed as an inhibitor of NAE by virtual screening of an FDA-approved drug database.  Compd. 1 inhibited NAE activity in cell-free and cell-based systems with high selectivity and was competitive with ATP.  Furthermore, compd. 1 induced apoptosis of colorectal adenocarcinoma cancer cells through inhibiting the degrdn. of the neddylation substrate p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUAq1axDoEP7Vg90H21EOLACvtfcHk0lidAEhSSvRoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3I&md5=c9d129e8a7887bcdc3e77cdc27e4fdbf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.101%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DK.-J.%26aulast%3DZhong%26aufirst%3DH.-J.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.-M.%2BD.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DStructure-based%2520identification%2520of%2520a%2520NEDD8-activating%2520enzyme%2520inhibitor%2520via%2520drug%2520repurposing%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1021%26epage%3D1027%26doi%3D10.1016%2Fj.ejmech.2017.11.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Targeting the DCN1-UBC12 Protein-Protein Interaction for Selective Modulation of Cullin Substrates</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1425</span>, <span class="refDoi"> DOI: 10.2174/156802661817181107151134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.2174%2F156802661817181107151134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=30497356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSgu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=1423-1425&author=Y.+Fangauthor=L.+Yuauthor=G.+Liaoauthor=B.+Yu&title=Targeting+the+DCN1-UBC12+Protein-Protein+Interaction+for+Selective+Modulation+of+Cullin+Substrates&doi=10.2174%2F156802661817181107151134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DCN1-UBC12 Protein-Protein Interaction for Selective Modulation of Cullin Substrates</span></div><div class="casAuthors">Fang, Yuan; Yu, Lei; Liao, Guochao; Yu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1423-1425</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review discussing about the targeting of the DCN1-UBC12 protein-protein interaction (PPI) for selective modulation of Cullin substrates.  The findings in this review suggested that the DCN1-UBC12 PPI plays crucial roles in modulating neddylation of specific downstream Cul3/1 substrates, and targeting this PPI may have applications in CUL3 dysregulated diseases.  The development of inhibitors targeting DCN1-UBC12 interaction ares currently undergoing worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7vtIBLyRf4bVg90H21EOLACvtfcHk0lgojGJ1lh0BoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSgu7jL&md5=236bb62a84c26179302b7385960791b3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F156802661817181107151134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661817181107151134%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DB.%26atitle%3DTargeting%2520the%2520DCN1-UBC12%2520Protein-Protein%2520Interaction%2520for%2520Selective%2520Modulation%2520of%2520Cullin%2520Substrates%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D18%26spage%3D1423%26epage%3D1425%26doi%3D10.2174%2F156802661817181107151134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span> <span> </span><span class="NLM_article-title">Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5382</span>– <span class="NLM_lpage">5403</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOntrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5382-5403&author=W.+Zhouauthor=L.+Maauthor=L.+Dingauthor=Q.+Guoauthor=Z.+Heauthor=J.+Yangauthor=H.+Qiaoauthor=L.+Liauthor=J.+Yangauthor=S.+Yuauthor=L.+Zhaoauthor=S.+Wangauthor=H.-M.+Liuauthor=Z.+Suoauthor=W.+Zhao&title=Potent+5-Cyano-6-phenyl-pyrimidin-Based+Derivatives+Targeting+DCN1-UBE2M+Interaction&doi=10.1021%2Facs.jmedchem.9b00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction</span></div><div class="casAuthors">Zhou, Wenjuan; Ma, Liying; Ding, Lina; Guo, Qian; He, Zhangxu; Yang, Jing; Qiao, Hui; Li, Lingyu; Yang, Jie; Yu, Shimin; Zhao, Lili; Wang, Shaomeng; Liu, Hong-Min; Suo, Zhenhe; Zhao, Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5382-5403</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neddylation of the Cullin-RING E3 ligases (CRLs) regulates the homeostasis of approx. 20% of cellular proteins.  Defective in cullin neddylation 1 (DCN1), as a co-E3 ligase, interacts with UBE2M to enhance the activation of CRLs, and this interaction is emerging as a therapeutic target for human diseases.  Here, we present a series of pyrimidin-based small mol. inhibitors targeting DCN1-UBE2M interaction.  After finding a novel inhibitor DC-1 with IC50 = 1.2 μM, we performed a series of chem. optimizations, which finally led to the discovery of a potent thiazole contg. 5-cyano-6-phenylpyrimidin-based inhibitor DC-2 (IC50 = 15 nM).  Next, using protein and cellular thermal shift assays, coimmunopptn., mol. docking, and site-specific mutation expts., we further proved that DC-2 specifically inhibited the interaction of UBE2M and DCN1 at mol. and cellular levels, resulting in the decrease of cullin3 neddylation and accumulation of its substrate, NRF2.  Our findings indicate that DC-2 may serve as a novel lead compd. for specific derivs. targeting DCN1-UBE2M interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqFJ-HvcKxn7Vg90H21EOLACvtfcHk0lgojGJ1lh0BoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOntrzI&md5=b0b7b00a80e377905d1532b4e2c5992b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00003%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DH.-M.%26aulast%3DSuo%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DW.%26atitle%3DPotent%25205-Cyano-6-phenyl-pyrimidin-Based%2520Derivatives%2520Targeting%2520DCN1-UBE2M%2520Interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5382%26epage%3D5403%26doi%3D10.1021%2Facs.jmedchem.9b00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraj, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spelman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sells, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visiers, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2009.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1016%2Fj.molcel.2009.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=20129059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFKgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=102-111&author=J.+E.+Brownellauthor=M.+D.+Sintchakauthor=J.+M.+Gavinauthor=H.+Liaoauthor=F.+J.+Bruzzeseauthor=N.+J.+Bumpauthor=T.+A.+Soucyauthor=M.+A.+Milhollenauthor=X.+Yangauthor=A.+L.+Burkhardtauthor=J.+Maauthor=H.-K.+Lokeauthor=T.+Lingarajauthor=D.+Wuauthor=K.+B.+Hammanauthor=J.+J.+Spelmanauthor=C.+A.+Cullisauthor=S.+P.+Langstonauthor=S.+Vyskocilauthor=T.+B.+Sellsauthor=W.+D.+Mallenderauthor=I.+Visiersauthor=P.+Liauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=L.+R.+Dick&title=Substrate-assisted+inhibition+of+ubiquitin-like+protein-activating+enzymes%3A+the+NEDD8+E1+inhibitor+MLN4924+forms+a+NEDD8-AMP+mimetic+in+situ&doi=10.1016%2Fj.molcel.2009.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ</span></div><div class="casAuthors">Brownell, James E.; Sintchak, Michael D.; Gavin, James M.; Liao, Hua; Bruzzese, Frank J.; Bump, Nancy J.; Soucy, Teresa A.; Milhollen, Michael A.; Yang, Xiaofeng; Burkhardt, Anne L.; Ma, Jingya; Loke, Huay-Keng; Lingaraj, Trupti; Wu, Dongyun; Hamman, Kristin B.; Spelman, James J.; Cullis, Courtney A.; Langston, Steven P.; Vyskocil, Stepan; Sells, Todd B.; Mallender, William D.; Visiers, Irache; Li, Ping; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The NEDD8-activating enzyme (NAE) initiates a protein homeostatic pathway essential for cancer cell growth and survival.  MLN4924 is a selective inhibitor of NAE currently in clin. trials for the treatment of cancer.  Here, we show that MLN4924 is a mechanism-based inhibitor of NAE and creates a covalent NEDD8-MLN4924 adduct catalyzed by the enzyme.  The NEDD8-MLN4924 adduct resembles NEDD8 adenylate, the first intermediate in the NAE reaction cycle, but cannot be further utilized in subsequent intraenzyme reactions.  The stability of the NEDD8-MLN4924 adduct within the NAE active site blocks enzyme activity, thereby accounting for the potent inhibition of the NEDD8 pathway by MLN4924.  Importantly, we have detd. that compds. resembling MLN4924 demonstrate the ability to form analogous adducts with other ubiquitin-like proteins (UBLs) catalyzed by their cognate-activating enzymes.  These findings reveal insights into the mechanism of E1s and suggest a general strategy for selective inhibition of UBL conjugation pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrGGYI7bTPerVg90H21EOLACvtfcHk0lgLV9iBYjqmwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFKgsbw%253D&md5=b080f6ec40864164ab2252f629975456</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2009.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2009.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DLiao%26aufirst%3DH.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBurkhardt%26aufirst%3DA.%2BL.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.-K.%26aulast%3DLingaraj%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DHamman%26aufirst%3DK.%2BB.%26aulast%3DSpelman%26aufirst%3DJ.%2BJ.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DSells%26aufirst%3DT.%2BB.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DVisiers%26aufirst%3DI.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DSubstrate-assisted%2520inhibition%2520of%2520ubiquitin-like%2520protein-activating%2520enzymes%253A%2520the%2520NEDD8%2520E1%2520inhibitor%2520MLN4924%2520forms%2520a%2520NEDD8-AMP%2520mimetic%2520in%2520situ%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D37%26spage%3D102%26epage%3D111%26doi%3D10.1016%2Fj.molcel.2009.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talreja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span> <span> </span><span class="NLM_article-title">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>458</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1038/nature07884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnature07884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=19360080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=732-736&author=T.+A.+Soucyauthor=P.+G.+Smithauthor=M.+A.+Milhollenauthor=A.+J.+Bergerauthor=J.+M.+Gavinauthor=S.+Adhikariauthor=J.+E.+Brownellauthor=K.+E.+Burkeauthor=D.+P.+Cardinauthor=S.+Critchleyauthor=C.+A.+Cullisauthor=A.+Doucetteauthor=J.+J.+Garnseyauthor=J.+L.+Gaulinauthor=R.+E.+Gershmanauthor=A.+R.+Lublinskyauthor=A.+McDonaldauthor=H.+Mizutaniauthor=U.+Narayananauthor=E.+J.+Olhavaauthor=S.+Pelusoauthor=M.+Rezaeiauthor=M.+D.+Sintchakauthor=T.+Talrejaauthor=M.+P.+Thomasauthor=T.+Traoreauthor=S.+Vyskocilauthor=G.+S.+Weatherheadauthor=J.+Yuauthor=J.+Zhangauthor=L.+R.+Dickauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=S.+P.+Langston&title=An+inhibitor+of+NEDD8-activating+enzyme+as+a+new+approach+to+treat+cancer&doi=10.1038%2Fnature07884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span></div><div class="casAuthors">Soucy, Teresa A.; Smith, Peter G.; Milhollen, Michael A.; Berger, Allison J.; Gavin, James M.; Adhikari, Sharmila; Brownell, James E.; Burke, Kristine E.; Cardin, David P.; Critchley, Stephen; Cullis, Courtney A.; Doucette, Amanda; Garnsey, James J.; Gaulin, Jeffrey L.; Gershman, Rachel E.; Lublinsky, Anna R.; McDonald, Alice; Mizutani, Hirotake; Narayanan, Usha; Olhava, Edward J.; Peluso, Stephane; Rezaei, Mansoureh; Sintchak, Michael D.; Talreja, Tina; Thomas, Michael P.; Traore, Tary; Vyskocil, Stepan; Weatherhead, Gabriel S.; Yu, Jie; Zhang, Julie; Dick, Lawrence R.; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Langston, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7239</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. development of an inhibitor of cellular proteasome function suggests that compds. targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies.  NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome.  Substrates of cullin-RING ligases have important roles in cellular processes assocd. with cancer cell growth and survival pathways.  Here we describe MLN4924, a potent and selective inhibitor of NAE.  MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumor cells by a new mechanism of action, the deregulation of S-phase DNA synthesis.  MLN4924 suppressed the growth of human tumor xenografts in mice at compd. exposures that were well tolerated.  Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8fx7OnZtYjbVg90H21EOLACvtfcHk0lgLV9iBYjqmwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D&md5=365d4b4feac3994849050e00f1aae5e0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnature07884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07884%26sid%3Dliteratum%253Aachs%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DK.%2BE.%26aulast%3DCardin%26aufirst%3DD.%2BP.%26aulast%3DCritchley%26aufirst%3DS.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DDoucette%26aufirst%3DA.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DGaulin%26aufirst%3DJ.%2BL.%26aulast%3DGershman%26aufirst%3DR.%2BE.%26aulast%3DLublinsky%26aufirst%3DA.%2BR.%26aulast%3DMcDonald%26aufirst%3DA.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DPeluso%26aufirst%3DS.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DTalreja%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26atitle%3DAn%2520inhibitor%2520of%2520NEDD8-activating%2520enzyme%2520as%2520a%2520new%2520approach%2520to%2520treat%2520cancer%26jtitle%3DNature%26date%3D2009%26volume%3D458%26spage%3D732%26epage%3D736%26doi%3D10.1038%2Fnature07884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">40867</span>– <span class="NLM_lpage">40877</span>, <span class="refDoi"> DOI: 10.1074/jbc.m111.279984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1074%2Fjbc.M111.279984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=21969368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=40867-40877&author=J.+J.+Chenauthor=C.+A.+Tsuauthor=J.+M.+Gavinauthor=M.+A.+Milhollenauthor=F.+J.+Bruzzeseauthor=W.+D.+Mallenderauthor=M.+D.+Sintchakauthor=N.+J.+Bumpauthor=X.+Yangauthor=J.+Maauthor=H.-K.+Lokeauthor=Q.+Xuauthor=P.+Liauthor=N.+F.+Benceauthor=J.+E.+Brownellauthor=L.+R.+Dick&title=Mechanistic+studies+of+substrate-assisted+inhibition+of+ubiquitin-activating+enzyme+by+adenosine+sulfamate+analogues&doi=10.1074%2Fjbc.m111.279984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues</span></div><div class="casAuthors">Chen, Jesse J.; Tsu, Christopher A.; Gavin, James M.; Milhollen, Michael A.; Bruzzese, Frank J.; Mallender, William D.; Sintchak, Michael D.; Bump, Nancy J.; Yang, Xiaofeng; Ma, Jingya; Loke, Huay-Keng; Xu, Qing; Li, Ping; Bence, Neil F.; Brownell, James E.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">40867-40877</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ubiquitin-activating enzyme (UAE or E1) activates ubiquitin via an adenylate intermediate and catalyzes its transfer to a ubiquitin-conjugating enzyme (E2).  MLN4924 is an adenosine sulfamate analog that was identified as a selective, mechanism-based inhibitor of NEDD8-activating enzyme (NAE), another E1 enzyme, by forming a NEDD8-MLN4924 adduct that tightly binds at the active site of NAE, a novel mechanism termed substrate-assisted inhibition.  In the present study, substrate-assisted inhibition of human UAE (Ube1) by another adenosine sulfamate analog, 5'-O-sulfamoyl-N6-[(1S)-2,3-dihydro-1H-inden-1-yl]-adenosine (Compd. I), a nonselective E1 inhibitor, was characterized.  Compd. I inhibited UAE-dependent ATP-PPi exchange activity, caused loss of UAE thioester, and inhibited E1-E2 transthiolation in a dose-dependent manner.  Mechanistic studies on Compd. I and its purified ubiquitin adduct demonstrate that the proposed substrate-assisted inhibition via covalent adduct formation is entirely consistent with the three-step ubiquitin activation process and that the adduct is formed via nucleophilic attack of UAE thioester by the sulfamate group of Compd. I after completion of step 2.  Kinetic and affinity anal. of Compd. I, MLN4924, and their purified ubiquitin adducts suggest that both the rate of adduct formation and the affinity between the adduct and E1 contribute to the overall potency.  Because all E1s are thought to use a similar mechanism to activate their cognate ubiquitin-like proteins, the substrate-assisted inhibition by adenosine sulfamate analogs represents a promising strategy to develop potent and selective E1 inhibitors that can modulate diverse biol. pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiclhUT_b-7Vg90H21EOLACvtfcHk0lgLV9iBYjqmwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE&md5=2362ac83bb8acf0de63162bac731c6e7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.279984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.279984%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DTsu%26aufirst%3DC.%2BA.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.-K.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBence%26aufirst%3DN.%2BF.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DMechanistic%2520studies%2520of%2520substrate-assisted%2520inhibition%2520of%2520ubiquitin-activating%2520enzyme%2520by%2520adenosine%2520sulfamate%2520analogues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D40867%26epage%3D40877%26doi%3D10.1074%2Fjbc.m111.279984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiiwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazuno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span> <span> </span><span class="NLM_article-title">TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-18-0644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F1535-7163.MCT-18-0644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=31092565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1205-1216&author=C.+Yoshimuraauthor=H.+Muraokaauthor=H.+Ochiiwaauthor=S.+Tsujiauthor=A.+Hashimotoauthor=H.+Kazunoauthor=F.+Nakagawaauthor=Y.+Komiyaauthor=S.+Suzukiauthor=T.+Takenakaauthor=M.+Kumazakiauthor=N.+Fujitaauthor=T.+Mizutaniauthor=S.+Ohkubo&title=TAS4464%2C+A+Highly+Potent+and+Selective+Inhibitor+of+NEDD8-Activating+Enzyme%2C+Suppresses+Neddylation+and+Shows+Antitumor+Activity+in+Diverse+Cancer+Models&doi=10.1158%2F1535-7163.mct-18-0644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">TAS4464, a highly potent and selective inhibitor of NEDD8-activating enzyme, suppresses neddylation and shows antitumor activity in diverse cancer models</span></div><div class="casAuthors">Yoshimura, Chihoko; Muraoka, Hiromi; Ochiiwa, Hiroaki; Tsuji, Shingo; Hashimoto, Akihiro; Kazuno, Hiromi; Nakagawa, Fumio; Komiya, Yu; Suzuki, Satoshi; Takenaka, Toru; Kumazaki, Masafumi; Fujita, Naoya; Mizutani, Takashi; Ohkubo, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1205-1216</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In this study, we describe the preclin. profile of a novel, highly potent, and selective NAE inhibitor, TAS4464.  TAS4464 selectively inhibited NAE relative to the other E1s UAE and SAE.  TAS4464 treatment inhibited cullin neddylation and subsequently induced the accumulation of CRL substrates such as CDT1, p27, and phosphorylated IkBa in human cancer cell lines.  TAS4464 showed greater inhibitory effects than those of the known NAE inhibitor MLN4924 both in enzyme assay and in cells.  Cytotoxicity profiling revealed that TAS4464 is highly potent with widespread antiproliferative activity not only for cancer cell lines, but also patient-derived tumor cells.  TAS4464 showed prolonged target inhibition in human tumor xenograft mouse models; weekly or twice a week TAS4464 administration led to prominent antitumor activity in multiple human tumor xenograft mouse models including both hematol. and solid tumors without marked wt. loss.  As a conclusion, TAS4464 is the most potent and highly selective NAE inhibitor reported to date, showing superior antitumor activity with prolonged target inhibition.  It is, therefore, a promising agent for the treatment of a variety of tumors including both hematol. and solid tumors.  These results support the clin. evaluation of TAS4464 in hematol. and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLvsFtDEsV3rVg90H21EOLACvtfcHk0liwY3MktBqnww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsLfL&md5=39762fcc9437ca90e5160ab0be09f6b6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0644%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DOchiiwa%26aufirst%3DH.%26aulast%3DTsuji%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DKazuno%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DF.%26aulast%3DKomiya%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DTakenaka%26aufirst%3DT.%26aulast%3DKumazaki%26aufirst%3DM.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DOhkubo%26aufirst%3DS.%26atitle%3DTAS4464%252C%2520A%2520Highly%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520NEDD8-Activating%2520Enzyme%252C%2520Suppresses%2520Neddylation%2520and%2520Shows%2520Antitumor%2520Activity%2520in%2520Diverse%2520Cancer%2520Models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26spage%3D1205%26epage%3D1216%26doi%3D10.1158%2F1535-7163.mct-18-0644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocki, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carew, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3800</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-11-254862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1182%2Fblood-2009-11-254862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=20203261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1ensrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3796-3800&author=R.+T.+Swordsauthor=K.+R.+Kellyauthor=P.+G.+Smithauthor=J.+J.+Garnseyauthor=D.+Mahalingamauthor=E.+Medinaauthor=K.+Oberheuauthor=S.+Padmanabhanauthor=M.+O%E2%80%99Dwyerauthor=S.+T.+Nawrockiauthor=F.+J.+Gilesauthor=J.+S.+Carew&title=Inhibition+of+NEDD8-activating+enzyme%3A+a+novel+approach+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1182%2Fblood-2009-11-254862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Swords, Ronan T.; Kelly, Kevin R.; Smith, Peter G.; Garnsey, James J.; Mahalingam, Devalingam; Medina, Ernest; Oberheu, Kelli; Padmanabhan, Swaminathan; O'Dwyer, Michael; Nawrocki, Steffan T.; Giles, Francis J.; Carew, Jennifer S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3796-3800</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">NEDD8 activating enzyme (NAE) has been identified as an essential regulator of the NEDD8 conjugation pathway, which controls the degrdn. of many proteins with important roles in cell-cycle progression, DNA damage, and stress responses.  Here we report that MLN4924, a novel inhibitor of NAE, has potent activity in acute myeloid leukemia (AML) models.  MLN4924 induced cell death in AML cell lines and primary patient specimens independent of Fms-like tyrosine kinase 3 expression and stromal-mediated survival signaling and led to the stabilization of key NAE targets, inhibition of nuclear factor-κB activity, DNA damage, and reactive oxygen species generation.  Disruption of cellular redox status was shown to be a key event in MLN4924-induced apoptosis.  Administration of MLN4924 to mice bearing AML xenografts led to stable disease regression and inhibition of NEDDy-lated cullins.  Our findings indicate that MLN4924 is a highly promising novel agent that has advanced into clin. trials for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfgbcmAqI5mbVg90H21EOLACvtfcHk0liwY3MktBqnww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1ensrw%253D&md5=081233e7c0651a42ddb52979c200b60d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-11-254862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-11-254862%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DMahalingam%26aufirst%3DD.%26aulast%3DMedina%26aufirst%3DE.%26aulast%3DOberheu%26aufirst%3DK.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DM.%26aulast%3DNawrocki%26aufirst%3DS.%2BT.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCarew%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520NEDD8-activating%2520enzyme%253A%2520a%2520novel%2520approach%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3796%26epage%3D3800%26doi%3D10.1182%2Fblood-2009-11-254862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMillin, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmore, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monrose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span> <span> </span><span class="NLM_article-title">Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F1535-7163.MCT-11-0563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=22246439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=942-951&author=D.+W.+McMillinauthor=H.+M.+Jacobsauthor=J.+E.+Delmoreauthor=L.+Buonauthor=Z.+R.+Hunterauthor=V.+Monroseauthor=J.+Yuauthor=P.+G.+Smithauthor=P.+G.+Richardsonauthor=K.+C.+Andersonauthor=S.+P.+Treonauthor=A.+L.+Kungauthor=C.+S.+Mitsiades&title=Molecular+and+cellular+effects+of+NEDD8-activating+enzyme+inhibition+in+myeloma&doi=10.1158%2F1535-7163.mct-11-0563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma</span></div><div class="casAuthors">McMillin, Douglas W.; Jacobs, Hannah M.; Delmore, Jake E.; Buon, Leutz; Hunter, Zachary R.; Monrose, Val; Yu, Jie; Smith, Peter G.; Richardson, Paul G.; Anderson, Kenneth C.; Treon, Steven P.; Kung, Andrew L.; Mitsiades, Constantine S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">942-951</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The NEDD8-activating enzyme is upstream of the 20S proteasome in the ubiquitin/proteasome pathway and catalyzes the first step in the neddylation pathway.  NEDD8 modification of cullins is required for ubiquitination of cullin-ring ligases that regulate degrdn. of a distinct subset of proteins.  The more targeted impact of NEDD8-activating enzyme on protein degrdn. prompted us to study MLN4924, an investigational NEDD8-activating enzyme inhibitor, in preclin. multiple myeloma models.  In vitro treatment with MLN4924 led to dose-dependent decrease of viability (EC50 = 25-150 nmol/L) in a panel of human multiple myeloma cell lines.  MLN4924 was similarly active against a bortezomib-resistant ANBL-6 subline and its bortezomib-sensitive parental cells.  MLN4924 had submicromolar activity (EC50 values <500 nmol/L) against primary CD138+ multiple myeloma patient cells and exhibited at least additive effect when combined with dexamethasone, doxorubicin, and bortezomib against MM.1S cells.  The bortezomib-induced compensatory upregulation of transcripts for ubiquitin/proteasome was not obsd. with MLN4924 treatment, suggesting distinct functional roles of NEDD8-activating enzyme vs. 20S proteasome.  MLN4924 was well tolerated at doses up to 60 mg/kg 2x daily and significantly reduced tumor burden in both a s.c. and an orthotopic mouse model of multiple myeloma.  These studies provide the framework for the clin. investigation of MLN4924 in multiple myeloma.  Mol Cancer Ther; 11(4); 942-51.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocMb3UagwGorVg90H21EOLACvtfcHk0liwY3MktBqnww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2nur8%253D&md5=e3a5f1f8f5334296e5c289674d6f3e02</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0563%26sid%3Dliteratum%253Aachs%26aulast%3DMcMillin%26aufirst%3DD.%2BW.%26aulast%3DJacobs%26aufirst%3DH.%2BM.%26aulast%3DDelmore%26aufirst%3DJ.%2BE.%26aulast%3DBuon%26aufirst%3DL.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DMonrose%26aufirst%3DV.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26atitle%3DMolecular%2520and%2520cellular%2520effects%2520of%2520NEDD8-activating%2520enzyme%2520inhibition%2520in%2520myeloma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D942%26epage%3D951%26doi%3D10.1158%2F1535-7163.mct-11-0563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams-Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span> <span> </span><span class="NLM_article-title">MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-03-272567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1182%2Fblood-2010-03-272567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=20525923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2qsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=1515-1523&author=M.+A.+Milhollenauthor=T.+Traoreauthor=J.+Adams-Duffyauthor=M.+P.+Thomasauthor=A.+J.+Bergerauthor=L.+Dangauthor=L.+R.+Dickauthor=J.+J.+Garnseyauthor=E.+Koenigauthor=S.+P.+Langstonauthor=M.+Manfrediauthor=U.+Narayananauthor=M.+Rolfeauthor=L.+M.+Staudtauthor=T.+A.+Soucyauthor=J.+Yuauthor=J.+Zhangauthor=J.+B.+Bolenauthor=P.+G.+Smith&title=MLN4924%2C+a+NEDD8-activating+enzyme+inhibitor%2C+is+active+in+diffuse+large+B-cell+lymphoma+models%3A+rationale+for+treatment+of+NF-%7Bkappa%7DB-dependent+lymphoma&doi=10.1182%2Fblood-2010-03-272567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma</span></div><div class="casAuthors">Milhollen, Michael A.; Traore, Tary; Adams-Duffy, Jennifer; Thomas, Michael P.; Berger, Allison J.; Dang, Lenny; Dick, Lawrence R.; Gamsey, James J.; Koenig, Erik; Langston, Steven P.; Manfredi, Mark; Narayanan, Usha; Rolfe, Mark; Staudt, Louis M.; Soucy, Teresa A.; Yu, Jie; Zhang, Julie; Bolen, Joseph B.; Smith, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1515-1523</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">MLN4924 is a potent and selective small mol. NEDD8-activating enzyme (NAE) inhibitor.  In most cancer cells tested, inhibition of NAE leads to induction of DNA rereplication, resulting in DNA damage and cell death.  However, in preclin. models of activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), we show that MLN4924 induces an alternative mechanism of action.  Treatment of ABC DLBCL cells with MLN4924 resulted in rapid accumulation of pIκBα, decrease in nuclear p65 content, redn. of nuclear factor-κB (NF-κB) transcriptional activity, and G1 arrest, ultimately resulting in apoptosis induction, events consistent with potent NF-κB pathway inhibition.  Treatment of germinal-center B cell-like (GCB) DLBCL cells resulted in an increase in cellular Cdt-1 and accumulation of cells in S-phase, consistent with cells undergoing DNA rereplication.  In vivo administration of MLN4924 to mice bearing human xenograft tumors of ABC- and GCB-DLBCL blocked NAE pathway biomarkers and resulted in complete tumor growth inhibition.  In primary human tumor models of ABC-DLBCL, MLN4924 treatment resulted in NF-κB pathway inhibition accompanied by tumor regressions.  This work describes a novel mechanism of targeted NF-κB pathway modulation in DLBCL and provides strong rationale for clin. development of MLN4924 against NF-κB-dependent lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Ez4BtgNx0LVg90H21EOLACvtfcHk0livJ387s90vjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2qsbzO&md5=6100194d48b30325e94b3b0cdb77fae0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-272567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-272567%26sid%3Dliteratum%253Aachs%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DAdams-Duffy%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DKoenig%26aufirst%3DE.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26atitle%3DMLN4924%252C%2520a%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520is%2520active%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%2520models%253A%2520rationale%2520for%2520treatment%2520of%2520NF-%257Bkappa%257DB-dependent%2520lymphoma%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D1515%26epage%3D1523%26doi%3D10.1182%2Fblood-2010-03-272567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span> <span> </span><span class="NLM_article-title">The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3360</span>– <span class="NLM_lpage">3371</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-12-0388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F0008-5472.CAN-12-0388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=22562464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3360-3371&author=Z.+Luoauthor=G.+Yuauthor=H.+W.+Leeauthor=L.+Liauthor=L.+Wangauthor=D.+Yangauthor=Y.+Panauthor=C.+Dingauthor=J.+Qianauthor=L.+Wuauthor=Y.+Chuauthor=J.+Yiauthor=X.+Wangauthor=Y.+Sunauthor=L.+S.+Jeongauthor=J.+Liuauthor=L.+Jia&title=The+Nedd8-activating+enzyme+inhibitor+MLN4924+induces+autophagy+and+apoptosis+to+suppress+liver+cancer+cell+growth&doi=10.1158%2F0008-5472.can-12-0388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth</span></div><div class="casAuthors">Luo, Zhongguang; Yu, Guangyang; Lee, Hyuk Woo; Li, Lihui; Wang, Lingyan; Yang, Dongqin; Pan, Yongfu; Ding, Chan; Qian, Jing; Wu, Lijun; Chu, Yiwei; Yi, Jing; Wang, Xiangdong; Sun, Yi; Jeong, Lak Shin; Liu, Jie; Jia, Lijun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3360-3371</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings offer preclin. evidence for therapeutic efficacy of a first-in-class neddylation inhibitor to treat liver cancer and provide a mechanistic rationale for its combination with an autophagy inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0YYRMtkc5JLVg90H21EOLACvtfcHk0livJ387s90vjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKrsr8%253D&md5=174581252b4b0b165279ab719c794bd9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-0388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-0388%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DYi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DL.%26atitle%3DThe%2520Nedd8-activating%2520enzyme%2520inhibitor%2520MLN4924%2520induces%2520autophagy%2520and%2520apoptosis%2520to%2520suppress%2520liver%2520cancer%2520cell%2520growth%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3360%26epage%3D3371%26doi%3D10.1158%2F0008-5472.can-12-0388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span> <span> </span><span class="NLM_article-title">Targeting the neddylation pathway to suppress the growth of prostate cancer cells: therapeutic implication for the men’s cancer</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">974309</span>, <span class="refDoi"> DOI: 10.1155/2014/974309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1155%2F2014%2F974309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=25093192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A280%3ADC%252BC2cbptVyktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=974309&author=X.+Wangauthor=L.+Liauthor=Y.+Liangauthor=C.+Liauthor=H.+Zhaoauthor=D.+Yeauthor=M.+Sunauthor=L.+S.+Jeongauthor=Y.+Fengauthor=S.+Fuauthor=L.+Jiaauthor=X.+Guo&title=Targeting+the+neddylation+pathway+to+suppress+the+growth+of+prostate+cancer+cells%3A+therapeutic+implication+for+the+men%E2%80%99s+cancer&doi=10.1155%2F2014%2F974309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the neddylation pathway to suppress the growth of prostate cancer cells: therapeutic implication for the men's cancer</span></div><div class="casAuthors">Wang Xiaofang; Li Lihui; Liang Yupei; Li Chunjie; Jia Lijun; Zhao Hu; Ye Dingwei; Sun Menghong; Jeong Lak Shin; Feng Yan; Fu Shen; Guo Xiaomao</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">974309</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The neddylation pathway has been recognized as an attractive anticancer target in several malignancies, and its selective inhibitor, MLN4924, has recently advanced to clinical development.  However, the anticancer effect of this compound against prostate cancer has not been well investigated.  In this study, we demonstrated that the neddylation pathway was functional and targetable in prostate cancer cells.  Specific inhibition of this pathway with MLN4924 suppressed the proliferation and clonogenic survival of prostate cancer cells.  Mechanistically, MLN4924 treatment inhibited cullin neddylation, inactivated Cullin-RING E3 ligases (CRLs), and led to accumulation of tumor-suppressive CRLs substrates, including cell cycle inhibitors (p21, p27, and WEE1), NF-κB signaling inhibitor IκBα, and DNA replication licensing proteins (CDT1 and ORC1).  As a result, MLN4924 triggered DNA damage, G2 phase cell cycle arrest, and apoptosis.  Taken together, our results demonstrate the effectiveness of targeting the neddylation pathway with MLN4924 in suppressing the growth of prostate cancer cells, implicating a potentially new therapeutic approach for the men's cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTRSSZ-9zT-MULxIEhxUjPfW6udTcc2eYF1XWncs-gKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbptVyktA%253D%253D&md5=29fc252ddf8c28018bd954563ddc52fe</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1155%2F2014%2F974309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F974309%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DX.%26atitle%3DTargeting%2520the%2520neddylation%2520pathway%2520to%2520suppress%2520the%2520growth%2520of%2520prostate%2520cancer%2520cells%253A%2520therapeutic%2520implication%2520for%2520the%2520men%25E2%2580%2599s%2520cancer%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2014%26volume%3D2014%26spage%3D974309%26doi%3D10.1155%2F2014%2F974309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.-Y.</span></span> <span> </span><span class="NLM_article-title">The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2415</span>– <span class="NLM_lpage">2425</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-11-0401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1158%2F1535-7163.MCT-11-0401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=21914854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2415-2425&author=L.+Zhaoauthor=P.+Yueauthor=S.+Lonialauthor=F.+R.+Khuriauthor=S.-Y.+Sun&title=The+NEDD8-activating+enzyme+inhibitor%2C+MLN4924%2C+cooperates+with+TRAIL+to+augment+apoptosis+through+facilitating+c-FLIP+degradation+in+head+and+neck+cancer+cells&doi=10.1158%2F1535-7163.mct-11-0401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells</span></div><div class="casAuthors">Zhao, Liqun; Yue, Ping; Lonial, Sagar; Khuri, Fadlo R.; Sun, Shi-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2415-2425</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">TNF-related apoptosis-inducing ligand (TRAIL) is a tumor-selective cytokine with potential anticancer activity and is currently under clin. testing.  Head and neck squamous cell carcinoma (HNSCC), like other cancer types, exhibits varied sensitivity to TRAIL.  MLN4924 is a newly developed investigational small mol. inhibitor of NEDD8-activating enzyme with potent anticancer activity.  This study reveals a novel function of MLN4924 in synergizing with TRAIL to induce apoptosis in HNSCC cells.  MLN4924 alone effectively inhibited the growth of HNSCC cells and induced apoptosis.  When combined with TRAIL, synergistic effects on decreasing the survival and inducing apoptosis of HNSCC cells occurred.  MLN4924 decreased c-FLIP levels without modulating death receptor 4 and death receptor 5 expression.  Enforced expression of c-FLIP substantially attenuated MLN4924/TRAIL-induced apoptosis.  Thus c-FLIP redn. plays an important role in mediating MLN4924/TRAIL-induced apoptosis.  Moreover, MLN4924 decreased c-FLIP stability, increased c-FLIP ubiquitination, and facilitated c-FLIP degrdn., suggesting that MLN4924 decreases c-FLIP levels through promoting its degrdn.  MLN4924 activated c-jun-NH2-kinase (JNK) signaling, evidenced by increased levels of phospho-c-Jun in MLN4924-treated cells.  Chem. inhibition of JNK activation not only prevented MLN4924-induced c-FLIP redn., but also inhibited MLN4924/TRAIL-induced apoptosis, suggesting that JNK activation mediates c-FLIP downregulation and subsequent enhancement of TRAIL-induced apoptosis by MLN4924.  Because knockdown of NEDD8 failed to activate JNK signaling and downregulate c-FLIP, it is likely that MLN4924 reduces c-FLIP levels and enhances TRAIL-induced apoptosis independent of NEDD8 inhibition.  Mol Cancer Ther; 10(12); 2415-25.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRM_UK5KRWp7Vg90H21EOLACvtfcHk0li9ilT28QQY2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfI&md5=132fc8fcb08e34d4592b325e2aaf98d5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0401%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DSun%26aufirst%3DS.-Y.%26atitle%3DThe%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520MLN4924%252C%2520cooperates%2520with%2520TRAIL%2520to%2520augment%2520apoptosis%2520through%2520facilitating%2520c-FLIP%2520degradation%2520in%2520head%2520and%2520neck%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2415%26epage%3D2425%26doi%3D10.1158%2F1535-7163.mct-11-0401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.-Y.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">29680</span>– <span class="NLM_lpage">29691</span>, <span class="refDoi"> DOI: 10.1074/jbc.m113.495069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1074%2Fjbc.M113.495069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=23995842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ShsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=29680-29691&author=W.-W.+Panauthor=J.-J.+Zhouauthor=C.+Yuauthor=Y.+Xuauthor=L.-J.+Guoauthor=H.-Y.+Zhangauthor=D.+Zhouauthor=F.-Z.+Songauthor=H.-Y.+Fan&title=Ubiquitin+E3+ligase+CRL4%28CDT2%2FDCAF2%29+as+a+potential+chemotherapeutic+target+for+ovarian+surface+epithelial+cancer&doi=10.1074%2Fjbc.m113.495069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin E3 ligase CRL4CDT2/DCAF2 as a potential chemotherapeutic target for ovarian surface epithelial cancer</span></div><div class="casAuthors">Pan, Wei-Wei; Zhou, Jian-Jie; Yu, Chao; Xu, Ying; Guo, Lian-Jun; Zhang, Hai-Yi; Zhou, Dawang; Song, Fang-Zhou; Fan, Heng-Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">29680-29691</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cullin-RING ubiquitin ligases (CRLs) are the largest family of E3 ligases and require cullin neddylation for their activation.  The NEDD8-activating enzyme inhibitor MLN4924 reportedly blocked cullin neddylation and inactivated CRLs, which resulted in apoptosis induction and tumor suppression.  However, CRL roles in ovarian cancer cell survival and the ovarian tumor repressing effects of MLN4924 are unknown.  We show here that CRL4 components are highly expressed in human epithelial ovarian cancer tissues.  MLN4924-induced DNA damage, cell cycle arrest, and apoptosis in ovarian cancer cells in a time- and dose-dependent manner.  In addn., MLN4924 sensitized ovarian cancer cells to other chemotherapeutic drug treatments.  Depletion of CRL4 components Roc1/2, Cul4a, and DDB1 had inhibitory effects on ovarian cancer cells similar to MLN4924 treatment, which suggested that CRL4 inhibition contributed to the chemotherapeutic effect of MLN4924 in ovarian cancers.  We also investigated for key CRL4 substrate adaptors required for ovarian cancer cells.  Depleting Vprbp/Dcaf1 did not significantly affect ovarian cancer cell growth, even though it was expressed by ovarian cancer tissues.  However, depleting Cdt2/Dcaf2 mimicked the pharmacol. effects of MLN4924 and caused the accumulation of its substrate, CDT1, both in vitro and in vivo.  MLN4924-induced DNA damage and apoptosis were partially rescued by Cdt1 depletion, suggesting that CRL4CDT2 repression and CDT1 accumulation were key biochem. events contributing to the genotoxic effects of MLN4924 in ovarian cancer cells.  Taken together, these results indicate that CRL4CDT2 is a potential drug target in ovarian cancers and that MLN4924 may be an effective anticancer agent for targeted ovarian cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8_uVQfMphY7Vg90H21EOLACvtfcHk0li9ilT28QQY2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ShsrbN&md5=048dec2acd31a0805f9287dd72c73424</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.495069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.495069%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DW.-W.%26aulast%3DZhou%26aufirst%3DJ.-J.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DL.-J.%26aulast%3DZhang%26aufirst%3DH.-Y.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DF.-Z.%26aulast%3DFan%26aufirst%3DH.-Y.%26atitle%3DUbiquitin%2520E3%2520ligase%2520CRL4%2528CDT2%252FDCAF2%2529%2520as%2520a%2520potential%2520chemotherapeutic%2520target%2520for%2520ovarian%2520surface%2520epithelial%2520cancer%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D29680%26epage%3D29691%26doi%3D10.1074%2Fjbc.m113.495069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faessel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedarati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span> <span> </span><span class="NLM_article-title">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1111/bjh.13323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1111%2Fbjh.13323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=25733005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2015&pages=534-543&author=R.+T.+Swordsauthor=H.+P.+Erbaauthor=D.+J.+DeAngeloauthor=D.+L.+Bixbyauthor=J.+K.+Altmanauthor=M.+Marisauthor=Z.+Huaauthor=S.+J.+Blakemoreauthor=H.+Faesselauthor=F.+Sedaratiauthor=B.+J.+Dezubeauthor=F.+J.+Gilesauthor=B.+C.+Medeiros&title=Pevonedistat+%28MLN4924%29%2C+a+First-in-Class+NEDD8-activating+enzyme+inhibitor%2C+in+patients+with+acute+myeloid+leukaemia+and+myelodysplastic+syndromes%3A+a+phase+1+study&doi=10.1111%2Fbjh.13323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</span></div><div class="casAuthors">Swords, Ronan T.; Erba, Harry P.; DeAngelo, Daniel J.; Bixby, Dale L.; Altman, Jessica K.; Maris, Michael; Hua, Zhaowei; Blakemore, Stephen J.; Faessel, Helene; Sedarati, Farhad; Dezube, Bruce J.; Giles, Francis J.; Medeiros, Bruno C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">534-543</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : This trial was conducted to det. the dose-limiting toxicities (DLTs) and max. tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).  Pevonedistat was administered via a 60-min i.v. infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days.  Dose escalation proceeded using a std. '3 + 3' design.  Responses were assessed according to published guidelines.  The MTD for schedules A and B were 59 and 83 mg/m2, resp.  On schedule A, hepatotoxicity was dose limiting.  Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concns. peaked after infusion followed by elimination in a biphasic pattern.  Pharmacodynamic studies of biol. correlates of NAE inhibition demonstrated target-specific activity of pevonedistat.  In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clin. activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKvj57_N1VFrVg90H21EOLACvtfcHk0li7R09rI4qDCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOntLY%253D&md5=435529c5ec061a767d00a3feb6589bb1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13323%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DMaris%26aufirst%3DM.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DBlakemore%26aufirst%3DS.%2BJ.%26aulast%3DFaessel%26aufirst%3DH.%26aulast%3DSedarati%26aufirst%3DF.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26atitle%3DPevonedistat%2520%2528MLN4924%2529%252C%2520a%2520First-in-Class%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukaemia%2520and%2520myelodysplastic%2520syndromes%253A%2520a%2520phase%25201%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D169%26spage%3D534%26epage%3D543%26doi%3D10.1111%2Fbjh.13323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidner, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardhanabhuti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlikowska-Dobler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faessel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedarati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savona, M. R.</span></span> <span> </span><span class="NLM_article-title">Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-09-805895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1182%2Fblood-2017-09-805895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=29348128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVemtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=1415-1424&author=R.+T.+Swordsauthor=S.+Coutreauthor=M.+B.+Marisauthor=J.+F.+Zeidnerauthor=J.+M.+Foranauthor=J.+Cruzauthor=H.+P.+Erbaauthor=J.+G.+Berdejaauthor=W.+Tamauthor=S.+Vardhanabhutiauthor=I.+Pawlikowska-Doblerauthor=H.+M.+Faesselauthor=A.+B.+Dashauthor=F.+Sedaratiauthor=B.+J.+Dezubeauthor=D.+V.+Fallerauthor=M.+R.+Savona&title=Pevonedistat%2C+a+first-in-class+NEDD8-activating+enzyme+inhibitor%2C+combined+with+azacitidine+in+patients+with+AML&doi=10.1182%2Fblood-2017-09-805895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML</span></div><div class="casAuthors">Swords, Ronan T.; Coutre, Steven; Maris, Michael B.; Zeidner, Joshua F.; Foran, James M.; Cruz, Jose; Erba, Harry P.; Berdeja, Jesus G.; Tam, Wayne; Vardhanabhuti, Saran; Pawlikowska-Dobler, Iwona; Faessel, Helene M.; Dash, Ajeeta B.; Sedarati, Farhad; Dezube, Bruce J.; Faller, Douglas V.; Savona, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1415-1424</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme (NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia (AML).  We performed a phase 1b study of pevonedistat (PEV) with azacitidine (AZA) based on synergistic activity seen preclinically.  Primary objectives included safety and tolerability, and secondary objectives included pharmacokinetics (PK) and disease response.  Patients ≥60 years with treatment-naive AML (unfit for std. induction therapy) received PEV 20 or 30 mg/m2 IV on days 1, 3, and 5 combined with fixed-dose AZA (75 mg/m2 IV/ s.c.) on days 1 to 5, 8, and 9, every 28 days.  The most common treatmentemergent adverse events were constipation (48%), nausea (42%), fatigue (42%), and anemia (39%).  In total, 11 deaths were obsd. and considered unrelated to study therapy by the investigators.  Transient elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were dose limiting.  The recommended phase 2 dose (RP2D) of PEV in this combination is 20 mg/m2.  PEV PK was not altered by the addn. of AZA.  Overall response rate (ORR) based on an intent-to-treat anal. was 50% (20 complete remissions [CRs], 5 complete remission with incomplete peripheral count recovery, 7 partial remissions [PRs]), with an 8.3-mo median duration of remission.  In patients receiving =6 cycles of therapy (n 5 23, 44%), ORR was 83%.  In patients with TP53 mutations, the composite CR/PR rate was 80% (4/5).  Two of these patients stayed on study for >10 cycles.  Baseline bone marrow blast percentage or cytogenetic/mol. risk did not influence ORR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWP3dayPgwy7Vg90H21EOLACvtfcHk0li7R09rI4qDCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVemtr%252FL&md5=7890ca924d46b4bb1a5e039f5d137fd7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-09-805895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-09-805895%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DMaris%26aufirst%3DM.%2BB.%26aulast%3DZeidner%26aufirst%3DJ.%2BF.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DCruz%26aufirst%3DJ.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DTam%26aufirst%3DW.%26aulast%3DVardhanabhuti%26aufirst%3DS.%26aulast%3DPawlikowska-Dobler%26aufirst%3DI.%26aulast%3DFaessel%26aufirst%3DH.%2BM.%26aulast%3DDash%26aufirst%3DA.%2BB.%26aulast%3DSedarati%26aufirst%3DF.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DFaller%26aufirst%3DD.%2BV.%26aulast%3DSavona%26aufirst%3DM.%2BR.%26atitle%3DPevonedistat%252C%2520a%2520first-in-class%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520combined%2520with%2520azacitidine%2520in%2520patients%2520with%2520AML%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D1415%26epage%3D1424%26doi%3D10.1182%2Fblood-2017-09-805895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekeres, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radinoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangerman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerrano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidner, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campelo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liesveld, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selleslag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzvetkov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fram, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ades, L.</span></span> <span> </span><span class="NLM_article-title">Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1038/s41375-021-01125-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fs41375-021-01125-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2021&pages=1&author=M.+A.+Sekeresauthor=J.+Wattsauthor=A.+Radinoffauthor=M.+A.+Sangermanauthor=M.+Cerranoauthor=P.+F.+Lopezauthor=J.+F.+Zeidnerauthor=M.+D.+Campeloauthor=C.+Grauxauthor=J.+Liesveldauthor=D.+Selleslagauthor=N.+Tzvetkovauthor=R.+J.+Framauthor=D.+Zhaoauthor=J.+Bellauthor=S.+Friedlanderauthor=D.+V.+Fallerauthor=L.+Ades&title=Randomized+phase+2+trial+of+pevonedistat+plus+azacitidine+versus+azacitidine+for+higher-risk+MDS%2FCMML+or+low-blast+AML&doi=10.1038%2Fs41375-021-01125-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fs41375-021-01125-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-021-01125-4%26sid%3Dliteratum%253Aachs%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DRadinoff%26aufirst%3DA.%26aulast%3DSangerman%26aufirst%3DM.%2BA.%26aulast%3DCerrano%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DP.%2BF.%26aulast%3DZeidner%26aufirst%3DJ.%2BF.%26aulast%3DCampelo%26aufirst%3DM.%2BD.%26aulast%3DGraux%26aufirst%3DC.%26aulast%3DLiesveld%26aufirst%3DJ.%26aulast%3DSelleslag%26aufirst%3DD.%26aulast%3DTzvetkov%26aufirst%3DN.%26aulast%3DFram%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DBell%26aufirst%3DJ.%26aulast%3DFriedlander%26aufirst%3DS.%26aulast%3DFaller%26aufirst%3DD.%2BV.%26aulast%3DAdes%26aufirst%3DL.%26atitle%3DRandomized%2520phase%25202%2520trial%2520of%2520pevonedistat%2520plus%2520azacitidine%2520versus%2520azacitidine%2520for%2520higher-risk%2520MDS%252FCMML%2520or%2520low-blast%2520AML%26jtitle%3DLeukemia%26date%3D2021%26volume%3D18%26spage%3D1%26doi%3D10.1038%2Fs41375-021-01125-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0li7R09rI4qDCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armitage, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubbin, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span> <span> </span><span class="NLM_article-title">Process Development and GMP Production of a Potent NAE Inhibitor Pevonedistat</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1299</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.5b00209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlehu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1299-1307&author=I.+Armitageauthor=E.+L.+Elliottauthor=F.+Hicksauthor=M.+Langstonauthor=A.+McCarronauthor=Q.+J.+McCubbinauthor=E.+O%E2%80%99Brienauthor=M.+Stirlingauthor=L.+Zhu&title=Process+Development+and+GMP+Production+of+a+Potent+NAE+Inhibitor+Pevonedistat&doi=10.1021%2Facs.oprd.5b00209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development and GMP Production of a Potent NAE Inhibitor Pevonedistat</span></div><div class="casAuthors">Armitage, Ian; Elliott, Eric L.; Hicks, Frederick; Langston, Marianne; McCarron, Ashley; McCubbin, Quentin J.; O'Brien, Erin; Stirling, Matt; Zhu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1299-1307</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical synthesis of a novel NEDD8-activating enzyme (NAE) inhibitor pevonedistat (MLN4924) is described.  Key steps include an enantioselective synthesis of an amino-diol cyclopentane intermediate contg. three chiral centers and a novel, regioselective sulfamoylation using N-(tert-butoxycarbonyl)-N-[(triethylenediammonium)sulfonyl]azanide.  The linear process, involving six solid isolations, has been carried out in multiple cGMP productions on 15-30 kg scale to produce pevonedistat in 98% (a/a) chem. purity and 25% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroYA4DtDY5BrVg90H21EOLACvtfcHk0lgLxe0ajygcHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlehu77N&md5=0551462cca51b7a2cdde0eb21cc0acdc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00209%26sid%3Dliteratum%253Aachs%26aulast%3DArmitage%26aufirst%3DI.%26aulast%3DElliott%26aufirst%3DE.%2BL.%26aulast%3DHicks%26aufirst%3DF.%26aulast%3DLangston%26aufirst%3DM.%26aulast%3DMcCarron%26aufirst%3DA.%26aulast%3DMcCubbin%26aufirst%3DQ.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DE.%26aulast%3DStirling%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DL.%26atitle%3DProcess%2520Development%2520and%2520GMP%2520Production%2520of%2520a%2520Potent%2520NAE%2520Inhibitor%2520Pevonedistat%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D1299%26epage%3D1307%26doi%3D10.1021%2Facs.oprd.5b00209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarron, A. S.</span>; <span class="NLM_string-name">Sells, T. B.</span>; <span class="NLM_string-name">Stirling, M.</span>; <span class="NLM_string-name">Stroud, S. G.</span></span> <span> </span><span class="NLM_article-title">Preparation of chloromethoxydihydroindenylaminopyrimidinyloxyhydroxycyclopentylmethyl sulfamate as Nedd8-activating enzyme inhibitors for treatment of cancer</span>. <span class="NLM_patent">WO 2013028832 A2</span>, Feb 28, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+S.+McCarron&author=T.+B.+Sells&author=M.+Stirling&author=S.+G.+Stroud&title=Preparation+of+chloromethoxydihydroindenylaminopyrimidinyloxyhydroxycyclopentylmethyl+sulfamate+as+Nedd8-activating+enzyme+inhibitors+for+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarron%26aufirst%3DA.%2BS.%26atitle%3DPreparation%2520of%2520chloromethoxydihydroindenylaminopyrimidinyloxyhydroxycyclopentylmethyl%2520sulfamate%2520as%2520Nedd8-activating%2520enzyme%2520inhibitors%2520for%2520treatment%2520of%2520cancer%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makings, L. R.</span>; <span class="NLM_string-name">Garcia-Guzman, B. M.</span>; <span class="NLM_string-name">Hurley, D. J.</span>; <span class="NLM_string-name">Drutu, I.</span>; <span class="NLM_string-name">Raffai, G.</span>; <span class="NLM_string-name">Bergeron, D. J.</span>; <span class="NLM_string-name">Nakatani, A.</span>; <span class="NLM_string-name">Termin, A. P.</span>; <span class="NLM_string-name">Silinas, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of spiro-fused piperidines as as modulators of muscarinic receptors</span>. <span class="NLM_patent">WO 2006023852 A2</span>, Mar 2, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=L.+R.+Makings&author=B.+M.+Garcia-Guzman&author=D.+J.+Hurley&author=I.+Drutu&author=G.+Raffai&author=D.+J.+Bergeron&author=A.+Nakatani&author=A.+P.+Termin&author=A.+Silinas&title=Preparation+of+spiro-fused+piperidines+as+as+modulators+of+muscarinic+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMakings%26aufirst%3DL.%2BR.%26atitle%3DPreparation%2520of%2520spiro-fused%2520piperidines%2520as%2520as%2520modulators%2520of%2520muscarinic%2520receptors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span> <span> </span><span class="NLM_article-title">Stereoselective synthesis of MLN4924, an inhibitor of NEDD8-activating enzyme</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3557</span>– <span class="NLM_lpage">3561</span>, <span class="refDoi"> DOI: 10.1021/jo2001897</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo2001897" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFKntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=3557-3561&author=H.+W.+Leeauthor=S.+K.+Namauthor=W.+J.+Choiauthor=H.+O.+Kimauthor=L.+S.+Jeong&title=Stereoselective+synthesis+of+MLN4924%2C+an+inhibitor+of+NEDD8-activating+enzyme&doi=10.1021%2Fjo2001897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective Synthesis of MLN4924, an Inhibitor of NEDD8-Activating Enzyme</span></div><div class="casAuthors">Lee, Hyuk Woo; Nam, Soo Kyung; Choi, Won Jun; Kim, Hea Ok; Jeong, Lak Shin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3557-3561</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carbocyclic nucleoside MLN4924 I, which is in clin. trials as an anticancer agent, was stereoselectively synthesized from D-ribose via a route involving stereoselective redn., regioselective cleavage of an isopropylidene moiety, and selective displacement of a cyclic sulfate moiety as key steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppbnZAsQWf57Vg90H21EOLACvtfcHk0lgLxe0ajygcHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFKntLo%253D&md5=0526e0d5d7b9ece1c7cd1f3d44da7657</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjo2001897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo2001897%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DNam%26aufirst%3DS.%2BK.%26aulast%3DChoi%26aufirst%3DW.%2BJ.%26aulast%3DKim%26aufirst%3DH.%2BO.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26atitle%3DStereoselective%2520synthesis%2520of%2520MLN4924%252C%2520an%2520inhibitor%2520of%2520NEDD8-activating%2520enzyme%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D3557%26epage%3D3561%26doi%3D10.1021%2Fjo2001897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciavarri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/nm.4474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1038%2Fnm.4474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=29334375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=186-193&author=M.+L.+Hyerauthor=M.+A.+Milhollenauthor=J.+Ciavarriauthor=P.+Flemingauthor=T.+Traoreauthor=D.+Sappalauthor=J.+Huckauthor=J.+Shiauthor=J.+Gavinauthor=J.+Brownellauthor=Y.+Yangauthor=B.+Stringerauthor=R.+Griffinauthor=F.+Bruzzeseauthor=T.+Soucyauthor=J.+Duffyauthor=C.+Rabinoauthor=J.+Ricebergauthor=K.+Hoarauthor=A.+Lublinskyauthor=S.+Menonauthor=M.+Sintchakauthor=N.+Bumpauthor=S.+M.+Pulukuriauthor=S.+Langstonauthor=S.+Tirrellauthor=M.+Kurandaauthor=P.+Veibyauthor=J.+Newcombauthor=P.+Liauthor=J.+T.+Wuauthor=J.+Poweauthor=L.+R.+Dickauthor=P.+Greenspanauthor=K.+Galvinauthor=M.+Manfrediauthor=C.+Claiborneauthor=B.+S.+Amidonauthor=N.+F.+Bence&title=A+small-molecule+inhibitor+of+the+ubiquitin+activating+enzyme+for+cancer+treatment&doi=10.1038%2Fnm.4474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span></div><div class="casAuthors">Hyer, Marc L.; Milhollen, Michael A.; Ciavarri, Jeff; Fleming, Paul; Traore, Tary; Sappal, Darshan; Huck, Jessica; Shi, Judy; Gavin, James; Brownell, Jim; Yang, Yu; Stringer, Bradley; Griffin, Robert; Bruzzese, Frank; Soucy, Teresa; Duffy, Jennifer; Rabino, Claudia; Riceberg, Jessica; Hoar, Kara; Lublinsky, Anya; Menon, Saurabh; Sintchak, Michael; Bump, Nancy; Pulukuri, Sai M.; Langston, Steve; Tirrell, Stephen; Kuranda, Mike; Veiby, Petter; Newcomb, John; Li, Ping; Wu, Jing Tao; Powe, Josh; Dick, Lawrence R.; Greenspan, Paul; Galvin, Katherine; Manfredi, Mark; Claiborne, Chris; Amidon, Benjamin S.; Bence, Neil F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-193</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis.  The therapeutic potential of this pathway has been validated by the clin. successes of a no. of UPS modulators, including proteasome inhibitors and immunomodulatory imide drugs (IMiDs).  Here we identified TAK-243 (formerly known as MLN7243) as a potent, mechanism-based small-mol. inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade.  TAK-243 treatment caused depletion of cellular ubiquitin conjugates, resulting in disruption of signaling events, induction of proteotoxic stress, and impairment of cell cycle progression and DNA damage repair pathways.  TAK-243 treatment caused death of cancer cells and, in primary human xenograft studies, demonstrated antitumor activity at tolerated doses.  Due to its specificity and potency, TAK-243 allows for interrogation of ubiquitin biol. and for assessment of UAE inhibition as a new approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GCsna-MdUrVg90H21EOLACvtfcHk0lir1cgrqX-3WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D&md5=06010b7eb1cc59cf3687b9c52844eb96</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnm.4474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4474%26sid%3Dliteratum%253Aachs%26aulast%3DHyer%26aufirst%3DM.%2BL.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DCiavarri%26aufirst%3DJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DSappal%26aufirst%3DD.%26aulast%3DHuck%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DGavin%26aufirst%3DJ.%26aulast%3DBrownell%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DStringer%26aufirst%3DB.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DSoucy%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DRabino%26aufirst%3DC.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DHoar%26aufirst%3DK.%26aulast%3DLublinsky%26aufirst%3DA.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DTirrell%26aufirst%3DS.%26aulast%3DKuranda%26aufirst%3DM.%26aulast%3DVeiby%26aufirst%3DP.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%2BT.%26aulast%3DPowe%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGreenspan%26aufirst%3DP.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DClaiborne%26aufirst%3DC.%26aulast%3DAmidon%26aufirst%3DB.%2BS.%26aulast%3DBence%26aufirst%3DN.%2BF.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520the%2520ubiquitin%2520activating%2520enzyme%2520for%2520cancer%2520treatment%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D186%26epage%3D193%26doi%3D10.1038%2Fnm.4474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.-H.</span></span> <span> </span><span class="NLM_article-title">Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials</span>. <i>Canc. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=10.1016%2Fj.canlet.2016.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=27847302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOgsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2017&pages=47-56&author=B.+Yuanauthor=N.+Yeauthor=S.-S.+Songauthor=Y.-T.+Wangauthor=Z.+Songauthor=H.-D.+Chenauthor=C.-H.+Chenauthor=X.-J.+Huanauthor=Y.-Q.+Wangauthor=Y.+Suauthor=Y.-Y.+Shenauthor=Y.-M.+Sunauthor=X.-Y.+Yangauthor=Y.+Chenauthor=S.-Y.+Guoauthor=Y.+Ganauthor=Z.-W.+Gaoauthor=X.-Y.+Chenauthor=J.+Dingauthor=J.-X.+Heauthor=A.+Zhangauthor=Z.-H.+Miao&title=Poly%28ADP-ribose%29polymerase+%28PARP%29+inhibition+and+anticancer+activity+of+simmiparib%2C+a+new+inhibitor+undergoing+clinical+trials&doi=10.1016%2Fj.canlet.2016.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials</span></div><div class="casAuthors">Yuan, Bo; Ye, Na; Song, Shan-Shan; Wang, Yu-Ting; Song, Zilan; Chen, Hua-Dong; Chen, Chuan-Huizi; Huan, Xia-Juan; Wang, Ying-Qing; Su, Yi; Shen, Yan-Yan; Sun, Yi-Ming; Yang, Xin-Ying; Chen, Yi; Guo, Shi-Yan; Gan, Yong; Gao, Zhi-Wei; Chen, Xiao-Yan; Ding, Jian; He, Jin-Xue; Zhang, Ao; Miao, Ze-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Poly(ADP-ribose)polymerase (PARP)1/2 inhibitors have been proved to be clin. effective anticancer drugs.  Here we report a new PARP1/2 inhibitor, simmiparib, displaying apparently improved preclin. anticancer activities relative to the first approved inhibitor olaparib.  Simmiparib inhibited PARP1/2 approx. 2-fold more potently than olaparib, with more than 90-fold selectivity over the other tested PARP family members.  Simmiparib and olaparib caused similar cellular PARP1-DNA trapping.  Simmiparib selectively induced the accumulation of DNA double-strand breaks, G2/M arrest and apoptosis in homologous recombination repair (HR)-deficient cells.  Consistently, simmiparib showed 26- to 235-fold selectivity in its antiproliferative activity against HR-deficient cells over the corresponding isogenic HR-proficient cells.  Notably, its antiproliferative activity was 43.8-fold more potent than that of olaparib in 11 HR-deficient cancer cell lines.  Simmiparib also potentiated the proliferative inhibition of several conventional anticancer drugs.  Simmiparib reduced the poly(ADP-ribose) formation in HR-deficient cancer cells and xenografts.  When orally administered to nude mice bearing xenografts, simmiparib revealed excellent pharmacokinetic properties.  Simmiparib caused approx. 10-fold greater growth inhibition than olaparib against HR-deficient human cancer cell- or tissue-derived xenografts in nude mice.  Collectively, these findings support the undergoing clin. trials of simmiparib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxJ6byH62sDrVg90H21EOLACvtfcHk0lir1cgrqX-3WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOgsbrK&md5=d9d0bab15554c03d964ced3448d6f9d7</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DS.-S.%26aulast%3DWang%26aufirst%3DY.-T.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DH.-D.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DHuan%26aufirst%3DX.-J.%26aulast%3DWang%26aufirst%3DY.-Q.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.-Y.%26aulast%3DSun%26aufirst%3DY.-M.%26aulast%3DYang%26aufirst%3DX.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DS.-Y.%26aulast%3DGan%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DZ.-W.%26aulast%3DChen%26aufirst%3DX.-Y.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DJ.-X.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DMiao%26aufirst%3DZ.-H.%26atitle%3DPoly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%2520inhibition%2520and%2520anticancer%2520activity%2520of%2520simmiparib%252C%2520a%2520new%2520inhibitor%2520undergoing%2520clinical%2520trials%26jtitle%3DCanc.%2520Lett.%26date%3D2017%26volume%3D386%26spage%3D47%26epage%3D56%26doi%3D10.1016%2Fj.canlet.2016.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GZN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GZN','PDB','3GZN'); return false;">PDB: 3GZN</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i68"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00242">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_03871"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00242?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00242</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H and <sup>13</sup>C spectra of all new compounds, HPLC of representative compounds, X-ray crystallographic data for analogues of compound <b>26</b>, and KINOMEscan kinase selectivity profile for compounds <b>1</b> and <b>26</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_001.pdf">jm1c00242_si_001.pdf (8.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00242/suppl_file/jm1c00242_si_002.csv">jm1c00242_si_002.csv (3.76 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00242&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-9%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00242%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00242" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a02d77f333cdc","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
